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ABSTRACT
This thesis describes design, construction and evaluation in a BALB/c mouse
model, for five novel Brucella specific DNA vaccines.
Brucellosis is worldwide zoonosis of economic significance that poses a
significant threat to both animal and human health. Vaccination of livestock can
be valuable for reducing transmission and facilitating control. Development of
an efficacious non-living vaccine is therefore a valuable goal in brucellosis
research.
Five candidate antigens were identified within the Brucella melitensis 16M
genome. In silico selection was supported by confirming transcription of the
selected genes from cultured Brucella, and evidence of candidate protein
immunogenicity in Brucella infected sheep. Eukaryotic and prokaryotic
expression plasmids were constructed for each candidate antigen. The
protective efficacy of six DNA vaccine constructs was evaluated in a BALB/c
model of brucellosis. From this evaluation, two protective antigens were
identified for further study: Invasion protein B and the 25 kDa outer membrane
protein. The DNA vaccines p-omp25 and p-ialB were shown to have equivalent
protective efficacy in the mouse model to that achieved through vaccination with
the live vaccine strain Rev.1. DNA vaccine mediated protection was associated
with production of specific antibodies and priming of both CD4+ and CD8+ IFN-y
secreting cells. High numbers of CD8+ cells were observed for the p-omp25
vaccine, whereas CD4+ cells and antibodies were more prevalent following p-
ialB vaccination. The vaccines were found to be most effective when three
homologous booster vaccinations were used. Single dose vaccination afforded
only modest levels of protection. Attempts to improve delivery of DNA vaccines
through adsorption of DNA to cationic liposomes was partially successful in that
there was a notable increase in specific humoral immune responses. However,
these increases were not associated with increased cell mediated immunity or
protective efficacy.
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Chapter 1: INTRODUCTION
1. 1 Brucella melitensis and brucellosis
Brucellosis is a worldwide zoonosis of considerable social and economic
importance. It is considered by the Food and Agriculture Organisation (FAO)
and World Health Organisation (WHO) to be the most widespread zoonoses in
the world, and is on the Office International des Epizooties (OlE) List B,
denoting diseases of significant socia-economic, public health and international
trade importance. The causative agents of the disease are facultative
intracellular bacteria of the monospecific genus Brucella melitensis. Despite
extensive genetic homogeneity amongst strains, historical classification defines
six separate species, B. melitensis, B. abortus, B. suis, B. ovis, B. canis and B.
neotomae, and a multitude of phenotypically defined sub-species or biovars.
For review, see Verger et aI, (1987). This nomenclature remains common
practice amongst researchers in the field, and has epidemiological and clinical
relevance. Brucella infections can be found in a wide range of animal hosts. The
six species display distinct animal host preferences and have variable virulence
in man. B. abortus infections are mostly associated with the disease in cattle, B.
melitensis with small ruminants and camelids, B. suis with pigs, hares, rodents
and rangifers (depending on biovar), B. ovis with sheep and B. canis with dogs.
B. neotomae, has only ever been reported in desert wood rats. Recently, strains
of Brucella not belonging to the currently recognised species have been isolated
from marine mammals (Jahans et aI, 1997).
The history of brucellosis
Brucellosis was first described in the late 1800's and early 1900's. The earliest
recorded work on brucellosis is largely attributed to the physician Sir David
Bruce, after whom the genus was eventually named. Brucellosis was brought to
the attention of the British Army Medical Corps when British soldiers stationed
on the island of Malta became sick with a debilitating and severe undulant fever.
Bruce was commissioned to head the Mediterranean Fever Commission
19
charged with investigating the disease. Bruce isolated the bacterium from the
blood of a patient and named it Micrococcus melitensis. A local Maltese
scientist, Theomisticles Zammit is credited with establishing the link between
the undulant fevers in man and the drinking of unpasturised goats milk. Zammit
was the first to isolate the bacterium from the milk of the goats. The 1904 report
of the Mediterranean Fever Commission recommended a ban on the
consumption of raw local goat milk and that sterilisation of the milk was required
in order to protect the army.
The isolation of Brucella abortus came some years later, with the description of
Bangs disease in humans associated with contagious abortion in cattle. The
causative organism was originally termed Bacillus abortus (Bang, 1897). The
discovery of similarities between the various abortifacient diseases and their
causative organisms is attributed to Alice Evans (1918), and as these
relationships became apparent the nomenclature was adapted to reflect the
knowledge and the genus named in honour of Sir David Bruce (Meyer and
Shaw, 1920). Brucella suis was first isolated by Traum in 1914, and identified by
Huddleson in 1929. Subsequent isolates of other Brucellae; B. canis
(Carmichael and Brunner, 1968), B. ovis (Buddie and Boyes, 1956) and B.
neotomae (Stoener and Lackman, 1957), were named according to this pattern.
The bacteria of the Brucella genus are coccobacilliary in morphology. Under low
power light microscopic examination the colonial morphology is smooth and
refractory to light, giving a characteristic rainbow effect. As with other Gram-
negative bacteria phase dissociation can occur and 'rough' variants or strains
do occur. Rough colonies lack the refractive appearance of their smooth
relatives. Both rough and smooth strains display characteristic Gram-negative
cell wall properties and are relatively fastidious in laboratory culture. B.
melitensis is most commonly isolated as smooth type morphology, and although
rough strains of this species have been described, these are generally viewed
as avirulent or attenuated.
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1.2 Global epidemiology and impact of brucellosis
The principal economic and social impact of brucellosis is in the agricultural
sector, where infections in cattle, pigs, sheep and goats cause enormous
economic losses due to effects on animal health, and international trade in
animals and their products. Zoonotic transmission of the disease means that it
also poses a significant public health issue. Human brucellosis is most
frequently associated with occupational exposure to the organism. Thus,
farmers, veterinarians, laboratory workers, abattoir workers, and dairy industry
technicians are the most at risk. In B. melitensis and B. abortus endemic areas
the consumption of unpasteurised dairy products is the most common source of
non-occupational exposure. Furthermore, B. melitensis, B. abortus and B. suis
are listed as biological warfare or bioterrorism threat agents, indicating a further
possibility for human infection following a deliberately orchestrated release of
weaponised pathogen.
B. melitensis remains the most significant species in terms of zoonotic
transmission and pathology in the human host, and the incidence of infection in
endemic areas is reported to be rising. The most recent FAO report on
brucellosis indicates the distribution of small ruminant (sheep and goat) disease
to be widespread. Up to date epidemiological data regarding prevalence and
incidence of the disease is obtainable from the FAO Global Livestock
Production and Health Atlas (GLiPHA). Data for the period 1999-2003 is
summarised in figure 1.1.
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Figure 1.1: The global distribution and incidence of Ovine and Caprine
brucellosis (excluding B. avis) between 1999 and 2003.
Map legend Number of outbreaks of caprine or ovine
brucellosis reported between 1999 and 2003
Total # outbreaks (by country)Livestock health cases
~ 7,600
1,110 -7,600
400 - 1,110
100- 400
s 100
No information avail
Italy 12,436
Portugal 7,754
Mexico 6,870
Algeria 2,718
Mongolia 1,624
FYR Macedonia 999
Greece 888
Saudi Arabia 712
Cyprus 340
Turkey 331
Yemen 203
Tajikistan 193
France 174
Serbia and Montenegro 141
Syrian Arab Republic 78
Kazakhstan 63
Lebanon 53
Israel 49
Brazil 46
Russian Federation 39
Data obtained from http://www.fao.org/aglagalg/ipha pertaining to the incidence of caprine and
ovine brucellosis due to smooth strains of Brucella (Not including B. ovis infections).
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Unfortunately, human infection remains the best sentinel for the prevalence of
animal disease (http://www.who.intlinf-fs/en/fact173.html), and cases occur
wherever the disease is endemic in livestock. High seroprevalence rates have
been recorded worldwide in populations that are occupationally exposed to
infected livestock. The actual incidence of human infection is likely to be much
higher than any officially reported figures as the non-specific symptoms of
clinical illness in the human host mean disease is often misdiagnosed or
reported as 'fevers of unknown origin'. Accurate diagnosis relies upon
serological tests and isolation of the organism and therefore the problem of
diagnosis is more acute in the developing world where resources are scarce.
Infection with B. melitensis remains the most significant form of brucellosis in
humans worldwide, although B. abortus and B. suis infections are also reported
and the incidence of each disease reflects the predominant livestock systems
and disease situation. For example, in Mexico an average of 3,500 cases per
year were recorded between 1990 and 2001 of which 98% are identified as B.
melitensis from either caprine (93%) or bovine (5%) sources. In the same period
for livestock up to 17% of cattle herds and 64% of goat herds were seropositive
(Eduardo Luna-Martinez et aI, 2002). In contrast, in Argentina where livestock
agriculture is dominated by cattle farming, B. abortus is the most frequently
reported human infection (Samartino et aI, 2002). In the Near and Middle East
regions B. melitensis biovar 3 is the most frequently reported human Brucella
infection, but recently there has been a rise in the number of cases of human
brucellosis associated with Brucella strains of bovine origin (B. abortus) (Refai
et aI, 2002). The reporting of both livestock and human brucellosis varies across
continents, countries and regions making accurate comparisons of prevalence
impossible. However, the incidence and impact of both human and animal
brucellosis is also expected to be high in Sub-Saharan Africa (McDermott et aI,
2002), the Indian SUb-Continent (Renukaradhyra et aI, 2002., Bandara et aI,
2002), and China (Oequi et aI, 2002). Within the member states of the
European Union many are now officially brucellosis free (OBF) for livestock.
However, 2,857 cases of human brucellosis were recorded in 2002, the majority
of which have acquired infection from ingestion of non-pasteurised dairy
products whilst travelling in endemic areas (Godfroid and Kasbohrer, 2002).
The prevalence and incidence of brucellosis is greater in some of the newest
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member states of the European Union. In particular, B. melitensis infection
remains a significant problem in the sheep and goat populations of the Balkan
region (Taleski et ai, 2002)
1.3Brucellosis in livestock
In livestock, the principal symptom of infection with Brucella is abortion, and
reduction or loss of fertility. Infections are acquired via contact, through
ingestion, inhalation and direct sexual contact or artificial insemination. The risk
of transmission within animal populations and to humans is greatest where
abortion has occurred, as huge numbers of viable Brucella are shed when the
foetus is expelled from the host. Ruminant brucellosis caused by the smooth
strain varieties of B. melitensis (mainly in sheep and goats) and B. abortus
(mainly in cattle), is characterised by late gestation abortion. Sheep are also
affected by infection with the naturally rough species B. ovis, which mainly
causes fertility problems in rams and is characterised by orchitis and
epididymitis.
Establishing infection
Infection is acquired through direct contact. Potential hosts are exposed to the
pathogen when it is shed in massive quantities with the secretions and tissues
during an abortive episode. Brucella organisms can be ingested or inhaled,
contaminate wounds or directly infiltrate mucus membranes. The pathogen
crosses mucus membranes of the naso-pharynx, conjunctiva, vagina, etc., and
is quickly engulfed by wandering phagocytic cells of the innate immune system.
The mechanism by which Brucella spp., are able to penetrate the mucosa
remains undefined. A local acute inflammatory reaction is elicited at the site of
epithelial penetration, with the infiltration of a variety of cells to the area
promoting phagocytosis of the Brucella (Enright, 1990). The process of
phagocytosis is designed to lead to the destruction of the pathogen following
fusion of the endosome with lysosomal vesicles containing destructive
enzymes. However, as with other intracellular pathogens, it is estimated that up
to 30% of virulent Brucella phagocytosed by na'ive host cells manage to escape
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destruction within the phagolysosome and survive to replicate within the
parasitised host cell (Gorvel et ai, 2002).
Survival, dissemination and persistence within the host
Intramacrophagic Brucella are distributed via lymphatic drainage to the local
lymph nodes and subsequently throughout the body. In experimental infections
the local lymph node draining the site of inoculation harbours greater numbers
of Brucella for longer times than any other site in the body. In addition,
experimental infection indicates a dose dependent dissemination of infection,
with greater chances of finding Brucella in lymph nodes and tissues distal to the
inoculation site when high dose inoculations are given. Infected lymph nodes
become enlarged due to the infiltration of inflammatory cells (For review see
Enright, 1990).
In the absence of protective immunity a failure to contain Brucella within the
draining lymph nodes allows dissemination of infection throughout the host via
haematogenous spread. In Brucella abortus experimental infection of cattle,
infection via the conjunctival route (a mucosal surface) results in parotid lymph
node colonisation between 2 - 4 days post inoculation (P.I.), splenic infection as
early as 15 days P.I., and colonisation of distal lymph nodes, mammary tissue
and the pregnant uterus at 22 - 29 days P.1. (Payne, 1959). A similar pattern of
infection progression is antlclpated for all ruminant hosts and strains of smooth
Brucella, although the exact kinetics will vary depending upon host species and
immune status and Brucella strain and infectious dose.
Brucella organisms are able to colonise many organs and tissues in the infected
host but preferentially localise in the tissues of the reproductive tract and the
lymph nodes. The Brucella tropism for the ruminant uterus and placental
trophoblast cells in particular, is the ultimate cause of the abortive pathology in
livestock.
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The pathology of brucellosis in livestock
The principal symptom of brucellosis in ruminant livestock is abortion, but the
mechanism of Brucella induced abortion remains poorly understood.
Descriptions of clinical disease indicate that placentitis may ultimately cause a
disruption in the homeostasis of the foetus, and endocrine imbalance in the
mother leading to a failure of pregnancy. Damage to the placenta may result in
an impaired ability to manufacture progesterone which is essential for the
maintenance of pregnancy. Furthermore, infected trophoblasts have been
shown to generate cortisol, which is normally only produced at parturition and
may trigger premature delivery or abortion. There appears to be only a limited
relationship between the severity of the placentitis and the abortive effect. The
severity of placentitis in an individual Brucella infected ruminant host is highly
variable, ranging from widespread destruction of the placenta and extending to
foetal membranes, to small localised foci of damage. These observations
suggest that in some cases placental disruption alone can account for the
abortion, but for others placental damage is so slight it would not be expected to
result in abortion or foetal distress. Therefore, additional factors may be
involved in triggering the abortion.
Direct foetal infection may also play a role in initiating abortion. Experimental
infection of the foetus results in increased levels of cortisol, associated with
adrenocortical hyperplasia. The increase begins as early as 24 hours post
infection, and the foetus is usually delivered dead between 5 - 7 days post
infection. Exogenous administration of cortisol to the dam results in premature
delivery within the same time frame, suggesting that the infection causes a
stress response from the foetus and the elevated steroids are associated with
the abortion. Ruminant foetuses are very susceptible to Brucella infection.
Studies with sheep indicate widespread inflammatory lesions as early as 4 days
P.I., and the presence of Brucella specific antibody by day 10 P.1. Neutrophil
and macrophage numbers are increased, and these cell changes coincide with
the elevation of foetal cortisol levels (Gorham 1983, cited by Enright 1990).
There is evidence to suggest that whilst some attenuated strains are capable of
infecting the foetus, they do not result in premature delivery or abortion. The
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outcome of brucellosis in the pregnant host is therefore dependent upon the
virulence of the infecting organism and the pathology of the infection in both the
placental tissue and the foetus.
In male animals acute clinical symptoms of Brucella infection are limited to
orchitis and epididymitis. Often clinical symptoms are not apparent. Male sheep
and goats are reputedly less susceptible to B. melitensis infection than females,
and there is limited effect on reproductive ability in terms of male fertility. In
contrast, B. avis is largely considered an infection of male animals. B. ovis
infections result in considerably reduced fertility of rams but are less frequently
associated with abortions (For review see Blasco, 1990 or Stack et aI, 2005).
1.4 Brucellosis in humans
From a veterinary perspective brucellosis is primarily associated with
reproductive disorders. The abortive pathology of the infection in animals
facilitates the spread of the disease, and association with infected animals
facilitates the zoonotic acquisition of the disease. The most serious human
cases of brucellosis are the result of infection with B. melitensis, B. suis or B.
abortus respectively. B. canis infections have been recorded in humans (Bigler
et aI, 1977) but are uncommon. B. neotomae infection in humans has not been
recorded and B. ovis is considered non pathogenic to man (Corbel, 1997.,
Madkour, 2001). Human brucellosis is predominantly characterised by a
debilitating undulant fever, and described as a 'flu-like illness'. Symptoms such
as depression, anorexia, and general malaise are also frequently cited.
Evidence for abortion in infected humans is limited and circumstantial. Human
to human transmission is uncommon.
The pathology of human brucellosis
Febrile episodes are characteristic of acute human brucellosis. As with other
febrile illnesses, the physical effect on the body is considerable in terms of
dehydration and general weakness and psychologically disturbing symptoms of
confusion and hallucinations are also experienced. Chronic brucellosis is a
more insidious disease. The list of Brucella induced conditions, from mild joint
27
pain to severe osteoarthritis, mild depression to complex psychoneuroses,
indicates the long-term persistence of the pathogen to have serious effects on
the general health and welfare of the infected individual (Corbel, 1990).
Fortunately, brucellosis is considered treatable and chronic infections can be
prevented, or at least limited, by the use of appropriate antibiotics.
Combinational therapy with doxycycline and rifampin is the current
recommended treatment regimen. Effective treatment requires immediate and
long-term treatment and subsequent monitoring for relapse. Treatment is an
expensive option, and in situations where disease is endemic the health care
systems have limited resources for either accurate diagnosis or effective
treatment. At present there is no vaccine suitable for brucellosis prophylaxis in
humans.
1.5 Brucella intracellular infection
The placental trophoblasts are the cells most frequently associated with
Brucella infection in the pregnant ruminant. In non-pregnant animals the
organism is generally isolated from the lymph nodes, indicating that in the
absence of stimuli from the gravid uterus the natural home of Brucella is within
the macrophages of the host.
The mechanisms of Brucella invasion or internalisation have been extensively
studied (Gorvel et aI, 2002). It has been apparent for many years that there are
differences in the initial host-pathogen interaction between smooth and rough
strain Brucella. Smooth Brucella O-polysaccharide (OPS) is considered a major
virulence factor (Moreno et aI, 1981., Parte et aI, 2003), although the naturally
rough species B. canis and B. ovis which lack externally expressed OPS are
also pathogenic. Notably, OPS defective smooth strain mutants and phase
variants are attenuated in vivo (Alien et aI, 1998., Ugalde et aI, 2000), but this
attenuation is not always apparent in macrophage survival studies in vitro and
may be linked to the fact that smooth Brucella are generally more resistant to
complement mediated lysis (Corbeil et aI, 1988). The OPS of the smooth
Brucella does not activate the alternative pathway for complement deposition
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(Hoffman et ai, 1983) and thus the triggering of the initial complement response
is restricted to classical and lectin pathway activation.
Opsonised Brucella appear to gain entry to professional phagocytes via Fc
receptor ligation, whereas non-opsonised organisms bind via fibronectin or
lectin receptors (Ackermann et ai, 1998., Campbell et ai, 1994., Harmon et ai,
1988). In macrophages the fate of the invading bacteria is linked to the mode of
internalisation, with Brucella entry via Fc receptors resulting in more effective
bacterial killing by the invaded macrophages (Gross et aI, 2000). For non-
professional phagocyte invasion there is indirect evidence for Brucella specific
ligands and host receptor interactions in that not all cells in a monolayer
epithelial cell culture are reported to be permissive to infection. Although
Brucella specific putative adhesion and invasion associated genes have been
identified in the B. melitensis 16M genome (DelVecchio et aI, 2002), the
expression of these protein effectors has not yet been confirmed. Furthermore,
the BvrR/BvrS two-component system, which is involved in the generation of
and integrity of the outer-membrane, affects the internalisation of Brucella,
suggesting that membrane proteins and structures play an important role in
internalisation. BvrRlBvrS null mutants, which are defective in the production of
several outer-membrane proteins (amps) and the LPS, appear to be incapable
of internalisation and remains bound the host cell surface (Sola-Landa et ai,
1998., Lopez-Goni et ai, 2001). In addition to the previously identified effects on
the expression of known Omps, it is possible that the BvrR/BvrS mutants are
defective in the production of molecules directly associated with the invasion
process. Recently, it has been shown that Brucella transiently interact with the
host cell cholesterol-rich-microdomains called lipid rafts (Waterai et aI, 2002.,
Kim et al 2002), and that these may be Significant in subsequent trafficking to
the replicative niche.
Following internalisation, the majority of Brucella that are ingested by
professional phagocytes are rapidly destroyed within phagolysomes. Whilst
trophoblast cells are able to phagocytose Brucella, they are less effective at
destruction of invading cells. Consequently, in contrast to the phagocytic cells of
the immune system that always contain a relatively small number of Brucella,
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infected trophoblasts contain vast numbers of viable bacteria. In both cell types
bacterial replication occurs in a membrane bound compartment. The
intracellular trafficking of virulent Brucella in both macrophages and
trophoblasts is diverted to avoid lysosomal fusion and establish a replicative
niche in a membranous compartment resembling the endoplasmic reticulum
(Pizzaro-Cerda et ai, 1998, Gorvel et ai, 2002). The benefits of localisation
within an endoplasmic reticulum (ER) type compartment and the reasons for
preferential replication of Brucella within placental trophoblasts are not yet
completely understood. It has been postulated that the ER location affords
access to complex nutrients required for bacterial replication (Kohler et ai,
2002b) since phagosomes of macrophages are understood to be nutrient poor.
Similarly, the preferential replication of Brucella within trophoblasts may be
related to the ability of these infected cells to produce growth factors for the
bacteria. Trophoblast cells are metabolically highly active, secreting a variety of
proteins including hormones, and at least some of these products are known to
stimulate the growth of Brucella in vitro (Meyer et aI, 1976).
Many studies have been conducted to evaluate the mechanisms by which
bacteria are able to create and maintain a stable replicative niche within host
cells (Duclos et ai, 2000). There is a clear correlation with the virulence of a
Brucella strain and it's ability to resist intramacrophagic destruction. The specific
mechanism allowing delay or inhibition of phagolysosomal fusion is not yet
understood, but the initial association with surface receptors and lipid rafts is
considered significant (Waterai et ai, 2002 and 2004). Furthermore, there is
some evidence for the involvement of a Brucella secreted soluble mediator
(Frenchick et ai, 1985), and mutations in the VirB type IV secretion system of
virulent Brucella have been shown to have a detrimental effect on the ability of
the organism to reach the replicative niche and persist intracellularly
(O'Callaghan et ai, 1999., Comerci et ai, 2001). The effector molecule that is
secreted by the virB system and mediates intracellular trafficking has yet to be
identified.
Stationary phase physiology plays an important role in the ability of the Brucella
to survive within the hostile intramacrophagic environment. This is most
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effectively demonstrated through deletion of the hfq gene. Hfq disruption
prevents the production of essential c factors resulting in reduced expression of
a number of genes associated with defence against acid and oxidative stress
(hdeA, sodC and ahpC), and stationary phase maintenance metabolism,
resulting in observed attenuation in vivo and in vitro (Roop et ai, 2003).
Moreover, purine biosynthesis mutants and amino acid auxotrophs are highly
attenuated in cultured macrophages and exhibit reduced persistence in vivo
(Crawford et aI, 1996., Foulongne et aI, 2001). Tn5 insertional mutagenesis
studies further indicate the importance of nutrient acquisition, also revealing
attenuation of strains which are mutated in the genes associated with purine,
pyrimidine and amino acid biosynthesis (Kohler et aI, 2002). In addition to
genes associated with survival in a nutrient poor environment mutagenesis
studies most frequently reveal genes associated with the virB operon and the
synthesis of the OPS as essential for the establishment and maintenance of
intracellular infection (Alien et ai, 1998., O'Caliaghan et aI, 1999). The recent
sequencing of the B. melitensis genome has failed to reveal any further
immediately obvious virulence determinants that could account for the
Brucella's ability to persist with the host. Moreover, the Brucella genome lacks
the major classical virulence determinants observed for other intracellular
pathogens such as Salmonella (DelVecchio et aI, 2002., Moriyon et aI, 2002).
Such observations have lead to the use of descriptors such as enigmatic and
stealthy to describe Brucella (Letesson et ai, 2002).
1.6 Control of brucellosis
Control of and prevention of brucellosis can be achieved through instigating
rigorous standards of farm hygiene concurrent to the implementation of sanitary
measures for the eradication of infected animals, and, or, medical interventions
such as vaccination to prevent infection.
1.6.1 Sanitary control measures
Extensive and expensive control policies implemented by a number of
developed countries have significantly reduced the incidence of B. abortus
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disease in cattle. Great Britain (GB) was declared Officially Brucellosis Free
(OBF) in 1985 (European Commission Decision 93/52), following a
comprehensive eradication campaign, involving comprehensive surveillance
and a test, slaughter and compensation programme. Reduced control measures
still exist in order to monitor and protect this OBF status, involving regular
compulsory testing and the imposition of movement restrictions and ultimately
compulsory slaughter orders upon identified B. abortus reactor herds. The
procedures were originally instigated under the 'Notifiable Diseases: Brucella
melitensis Order of 1940, and later amended to the Specified Diseases Order
(http://www.defra.gov.uk) and EC directive 91/88. Other EC nations have
adopted similar strategies for control of bovine disease, and consequently
northern continental Europe is now largely free of cattle brucellosis. Import and
export regulations throughout the EC exist to prevent trade and movement of
potentially infected livestock. Outside Europe, Australia and New Zealand are
OBF. Whilst the USA and Canada claim to be largely free of bovine brucellosis
in domestic cattle herds, sporadic outbreaks as a result of transmission from
wildlife reservoir hosts have been recorded (Godfroid, 2002). Brucella infection
of livestock other than cattle, is economically and historically a less significant
problem. In the UK sporadic (non-endemic) occurance of B. suis infection in
pigs has been controlled by application of similar measures to those used with
cattle, and B. avis and B. melitensis infection have never been recorded in the
UK livestock population.
Whilst test and slaughter policies have been successful at eliminating or
reducing the disease from developed countries, they are not universally
applicable or effective in all situations. In regions where brucellosis has been
effectively eradicated, obligatory animal testing and compulsory slaughter of
reactors has been overseen by a comprehensive, well-resourced and centrally
coordinated veterinary service with the ability to track and restrict animal
movements and epidemiologically monitor disease outbreaks. Limited
resources in the developing world, where brucellosis remains endemic, mean
that this approach is not always feasible or suitable. Furthermore, certain animal
husbandry practices including extensive shared grazing and transhumance can
facilitate inter-herd spread and create difficulties for animal identification and
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tracing. In addition to these problems the effectiveness of test and slaughter
procedures is only optimal under conditionswhere the prevalence of disease is
relatively low (:5 1% of the herds) (Garin-Bastuji, 1995).
1.6.2 Vaccination and protective immunity
Following natural infection and abortion animals will either clear infection or
become latent carriers depending upon the effectiveness of the adaptive
immune response. It is commonly observed that previously infected animals are
resistant to reinfection. Moreover, if subsequently exposed to the pathogen they
are better able to control Brucella replication to prevent placentitis, abortion, and
foetal infection, thus providing anecdotal evidence for the development of
protective immunity.
The majority of information regarding protective immunity against brucellosis
comes from studies with small animal models. In the mouse model of
brucellosis the principal site of pathology is the spleen and the outcome of
protective immunity or infection can be defined in terms of the number of
Brucella in this organ. Mice are readily infected with Brucella but do not
succumb to disease, and eventually clear the infection. There is ample evidence
for a role for Th 1 responses, and particularly IFN-y, in promoting this bacterial
elimination. A number of studies have demonstrated the in vitro effects of IFN-y
depletion or supplementation on Brucella growth in macrophage cultures. For
example IFN-y activation of mouse macrophages directly inhibits the growth of
B. melitensis 16M (Eze et aI, 2000), whilst others have shown that
supplementation of Brucella macrophage cultures (from murine, human or
bovine hosts) with IFN-y increases the ability of the macrophage to control
Brucella replication at around 48 hours post-phagocytosis (Stevens et aI, 1992.,
Jones and Winter 1992., Baldwin and Winter 1993., Jiang and Baldwin 1993). In
the latter studies the effect of IFN-y does not appear to be through the
enhanced macrophage activation as it is known that even unactivated
macrophages effectively kill up to 95% of invading Brucella, but rather the effect
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is hypothesised to be due to an as yet undefined interference with
establishment of a replicative niche within the phagocyte.
In vivo evidence of a role for IFN-y in Brucella control has been shown in many
studies. Neutralisation of murine IFN-y through administration of monoclonal
antibodies has been shown to result in increased splenic load of Brucella in
BALB/c, CBA and C57BU6 mouse strains (Zhan and Cheers, 1993., Fernandes
et aI, 1996), whereas administration of recombinant IFN-y to infected BALB/c
mice results in a reduction of the splenic load (Stevens et aI, 1992).
Furthermore, Murphy et al (2001a and b) showed that infection of virulent B.
abortus 2308 in wild type BALB/c mice resulted in the characteristic chronic
infection, but IFN-y knock out (KO) BALB/c mice (genetically impaired in their
ability to produce IFN-y) were unable to control infection ultimately leading to
death at 10.5 weeks post-infection. Thus, indicating that generation of IFN-y is
crucial to the control of infection in the BALB/c mouse.
Despite its essential role in Brucella control, IFN-y is not thought to be solely
responsible for anti-Brucella immunity, and this is especially evident in the
BALB/c mouse. The BALB/c mouse strain is often cited as Brucella susceptible
whilst C57BLl6 mice are referred to as relatively resistant (Monteraz and
Winter, 1996). Studies by Murphy et al (2001b) indicated that infection of
BALB/c and C57BU6 results in different kinetics for IFN-y production during the
course of infection. Indeed, there was a "hiatus" of IFN-y generation observed in
the BALB/c mouse commencing after the initial replication phase and lasting
through the plateau phase of the infection. Production of IFN-y resumed at a
time when bacterial clearance was beginning. Initially, these data were thought
to explain the observed differences in Brucella susceptibility, with the innate
deficiencies in BALB/c IFN-y production facilitating bacterial persistence in this
mouse strain. Incongruously, in their studies with IFN-y KO strains Murphy et 81
(2001b) showed that BALB/c IFN-y .,. mice outlived the C57BU6 IFN-y .,. mice,
and were comparatively more able to control Brucella replication. The authors
speculated that the BALB/c mice may be using some additional form of control
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in the absence of IFN-y. Obvious contenders for this role are other Th 1 type
cytokines, such as TNF-a and IL-12.
Both IL-12 and TNF-a have been detected in assays involving specific antigen
stimulation of splenocytes from infected BALB/c mice, but their contribution to
brucellosis control in this model or in target species is complex and not
completely understood. In particular their role in Brucella control during the IFN-
y hiatus is not clearly defined. The generation of IL-12 in response to Brucella
infection has been largely attributed to innate mechanisms including the
interaction of Brucella LPS with TLR-2 on macrophages and dendritic cells.
Endogenous bioactive IL-12 (the p70 heterodimer) has been demonstrated in
vivo as early as three days post-infectionwith both the vaccine strain B. abortus
S19 (Zhan and Cheers, 1995) and virulent strain B. abortus 2308 (Fernandez-
Lago et aI, 1999). The overall effects of IL-12 appear to be similar to those
described for IFN-y. In vivo depletion of IL-12 in the Brucella infected BALB/c
mouse results in an increased splenic load (Zhan and Cheers, 1995), whereas
in vivo administration of IL-12 improves the control of bacterial replication
(Sathiyaseelan et aI, 2005). Despite this, direct evidence for enhanced
production of IL-12 p40 or p70 during the IFN-y hiatus is not seen in the BALB/c
mouse infection model (Murphy et aI, 2001b). In the Sathiyaseelan study the
ability of IL-12 to reduce Brucella CFU in the infected BALB/c spleen was
partially abrogated by treatment with anti-IFN-y antibodies, indicating that the
effects of these two cytokines are linked and possibly dependent upon one
another.
TNF-a also plays a role in control of Brucella. In vitro studies showed that TNF-
a presence in macrophage cultures enhanced the controlling effect of IFN-y on
Brucella growth and that in the absence of IFN-y mediated activation, TNF-a
was essential to promote the brucellacidal activities of macrophages (Jiang et
aI, 1993). Conversely, the in vivo inhibition of TNF-a using monoclonal
antibodies causes an exacerbation of splenic infection of BALB/c mice (Murphy
et aI, 2001a). Furthermore, the work of Zhan et al (1993) supports the notion of
an in vivo role for TNF-a through illustration that mice lacking TNF receptors
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(TNF-R'-) also had increased numbers of Brucella in their spleens, and a
marked deficit of IL-12 production. Despite the fact that all of these data indicate
a role for TNF-a in control of brucellosis, TNF-a is not detected at elevated
levels during the IFN-y hiatus (Murphy et aI, 2001b). Notably, in all of these
studies the effects of TNF-a depletion or supplementation are only significant in
the early stages of infection. Overall, research to date indicates that cytokine
responses to Brucella infection are dominated by IFN-y, and the action of this
critical cytokine is influenced and augmented through IL-12 and TNF-a
production.
Analysis of the relative contributions of CD4+ and CD8+ cells to protective
immunity in the Brucella infected mouse has revealed conflicting results. Whilst
there are plenty of studies indicatingan essential role for CD8+ T cells in control
of Brucella (Pavlov et aI, 1982., Mielke et aI, 1991., Splitter et ai, 1996., Oliveira
et aI, 1998), the effect appears dependant upon the virulence of the infecting
strain and the time post-challengewhen the effect was observed. For example:
CD8+ T cells contribute to the control of virulent B. abortus 2308 infectionsearly
on in infection but not at later times (Murphy et ai, 2001), but they appear to be
important in all stages of B. abortus strain 19 control. It is possible that
undefined virulence factors expressed by B. abortus 2308, but absent in strain
19, permit this strain to avoid CD8+ T cell priming and thus do not trigger
effective cytotoxic responses important for the elimination of infected cells. It is
therefore proposed that CD8+ T cells are important in the early stages of
infection, but CD4+ T cells are important for control of infection in the long term
(Baldwin and Gorenka, 2004). Similar observations have been made with
another abortifacient zoonosis: Chlamydia. Buendia et al (1999) described the
rapid generation of CD8+ T cells by the vaccine strain of Chlamydia pscittaci
and the preferential priming of CD4+ T cells from the virulent wild type strain
during primary infection. This mirrors the observations of Baldwin et aI,
regarding Brucella infection. Importantly, adoptive transfer studies have
revealed that polyclonal Chlamydia specific CD4+ cells are more important in
protection against challenge than CD8+ cells and that CD8+ T cells do not play
a role in protective adaptive immunity (For review see Morrison et ai, 2003).
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Although the majority of this information has been obtained from studies in
mice, similar mechanisms of Brucella control are expected to be active in
livestock and man (Wyckoff et ai, 2002., Domand et ai, 2002).
A number of vaccines are currently licensed for use in livestock against the
various important pathogenic species of Brucella, all of which are live
attenuated strains of the organism. B. abortus S19, and B. abortus RB51 (For
review see Cheville (2000)) vaccines, have been used for the protection of
cattle against brucellosis. S19 was developed through laboratory culture and
selection of altered phenotypic characteristics when compared to the parent
strain B. abortus 544 (Buck, 1930). RB51 was similarly selected as a stable
'rough' mutant of B. abortus 2308 (Schurig et ai, 1991). B. suis S2, a naturally
occurring avirulent isolate of B. suis biovar 1, has been used extensively for the
vaccination of pigs in China, where success rates are reportedly high (Xie et ai,
1986). However, evaluation of this vaccine in other locations has resulted in
extremely variable efficacy and its use has not been widely adopted (Bosseray
et ai, 1990). The vaccine B. melitensis Rev. 1 has been established as
recommended for the protection of sheep and goats against B. melitensis (Alton
1987., Garin-Bastuji et ai, 1998) and is intermittently used as part of the control
strategy in affected Mediterranean countries. Rev. 1 was derived from a
streptomycin dependant field isolate of B. melitensis following selection of
altered phenotypic characteristics: loss of streptomycin dependency and
becoming sensitive to penicillin (Elberg, 1957). There are no Brucella vaccines
available for the prophylaxis of human infection.
The use of a live attenuated vaccine strain essentially involves the deliberate
infection of the naive animal with attenuated Brucella such that protective
immune responses are elicited without concurrent pathology. The genetic
mechanism underlying the attenuation of each of the vaccine strains is not fully
understood. Phenotypically RB51 is distinct as the only rough strain licenced
vaccine. The principal defect in this strain in OPS biosynthesis is contributed by
a mutation in the wboA gene (Vermulapalli et ai, 1999 and 2001). Whilst the
lack of OPS undoubtedly contributes to the reduced virulence of this strain, a
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simple disruption or deletion of wboA from Brucella spp, does not confer the
levels of attenuation observed in RB51 (Winter et aI, 1996). Furthermore, not all
rough phase Brucella are avirulent (Moriyon et aI, 2004), thus indicating that
other mutations contribute to the attenuation of RB51.
The specific mechanism by which virulent Brucella causes abortion is unknown,
and as such information regarding the loss or attenuation of abortogenic
properties in vaccine strains is also limited. In the case of B. abortus 819, a
gene deletion in the ery locus influencing the ability of the organism to
metabolise erythritol is involved in, or at least linked to, the attenuation in
ruminant systems. Erythritol is found in the ruminant placenta and a loss of
ability to metabolise or detoxify this sugar reduces the capability of Brucella to
colonise the placenta, thereby reducinq its' potential to cause abortion in
ruminant hosts (8angari et aI, 1994, 1996, 1998). However, 819 retains
characteristics of reduced persistence in the BALB/c mouse model, where
erythritol and abortive potential are not associated with pathology. Thus
suggesting that this is not the sole facet of the 819 attenuation.
There have been few reported genomic differences between Rev.1 and virulent
B. melitensis biovar 1, although proteomic analysis hints toward inefficient iron
metabolism as a mechanism underlying Rev.1 attenuation (Eschenbrenner et
aI, 2002). Notably, Rev.1 is the only licensed vaccine providing appropriate
levels of protective efficacy against B. melitensis in ruminants (Blasco et aI,
2005., Garin-Bastuji et aI, 2005).
In all cases the effective vaccine strains are disabled in either their ability to
replicate within the host macrophages and establish chronic disease, or through
being less able to evade the host attempts to clear infection. The 819, RB51,
Rev.1 and 82 vaccines all exhibit reduced persistence compared to the
respective parent strains during infection of the natural host and or reduced
survival abilities in macrophage culture. This reduced persistence is also
demonstrable in vivo using mouse models.
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Although there have been attempts to produce non-living vaccines, these have
not been as widely accepted or successful as the live strains. One of the most
widely studied non-living vaccines was the B. abortus 45/20 vaccine. Various
preparations of this vaccine existed ranging from simple heat killed bacterin
preparations to semi-fractionated preparations formulated with incomplete
Freunds adjuvant. Strain 45/20 was originally isolated from a cow and serially
passaged through Guinea Pigs (20 passages) resulting in a naturally rough
phase B. abortus strain. It was originally used as a live vaccine but there were
problems associated with reversion to smooth morphology and virulence
(McEwen, 1940). The adjuvanted bacterin vaccine was reported to be protective
in cattle and did not directly cause abortion. However, yearly boosters were
required to maintain immunity, and local reactogenicity at the inoculation site
was found to be a considerable problem. Furthermore, insufficient
standardisation in the production and evaluation methods for the killed
preparations resulted in unacceptable levels of variability in efficacy between
batches. Ultimately the use of the 45/20-adjuvant vaccine was abandoned in
favour of the more consistent and longer-lived immunising properties of the live
vaccines such as S19. Numerous other attempts to generate non-living Brucella
vaccines, either using simple bacterins or fractionated antigen preparations,
have concluded that these preparations are poorly immunogenic (Montaraz and
Winter 1986., Nicoletti, 1990., Schurig et aI, 2002).
Similarly, a number of recombinant protein based vaccines have been assessed
but in each case these have been unable to promote comparable protective
immunity to the live vaccines. A variety of delivery strategies have been
employed for these recombinant antigens ranging from simple direct inoculation
of the protein to formulation with adjuvants such as CpG ODN or delivery via
vaccinia or E.coli. Table 1.1 lists some of the Brucella antigens that have been
evaluated as recombinant vaccines.
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Table 1.1:Brucella antigens studied as potential recombinant vaccines
Antigen Details Reference
Brucella a-chain LPS
B. abortus HSP601GroEL
B. abortus Cu/Zn
Superoxide Dismutase
Brucella spp. outer
membrane proteins
B. abortus P39
Purified a-chain LPS
Stress response proteins. e.g.: HSPs are
immunodominant antigens in natural
Brucella infections.
Recombinant proteins evoke strong
specific immune responses.
Vaccinia expressing GroEL provide
limited protection in the mouse model.
Vaccination with live E.coli expressing
the Brucella Cu/Zn SOD antigen has
been shown to protect mice against
challenge with virulent B. abortus
Recombinant amps used directly as
vaccines are protective. The efficacy of
vaccination is not consistent between
different studies or different amps.
Passive transfer studies have shown that
monoclonal antibodies raised against
certain amps are protective against
challenge with rough strains in the
mouse model.
P39 protein delivered with CpG adjuvant
has a modest protective effect
Cherwonogrodsky.
1993
Teixeira-Gomes et
a/.2000
Bagolu et al. 2000
Lin et aI, 1996
Onate et aI, 1999
Brooks-Worrell et aI,
1992
Bowden et aI, 1995.
1998.2000
Guilloteau et aI,
1999
Cloeckaert et aI,
1991.1995,1996
Estein et aI, 2003
AI-Mariri et aI, 2001
Recently a novel non-living vaccine based upon antigenic extracts of rough
strain B. ovis has been described (Murillo et aI, 2001). The vaccine consists of
hot saline extracted membrane antigens microencapsulated within poIY-E-
caprolactone particles, and is able to protect rams against infection with B. ovis.
However, at this present time there are not any non-living vaccines that are
licensed for use against brucellosis, and none with reported efficacy against
smooth strain Brucella.
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1.6.3 Problems with currently licensed live vaccines for
brucellosis
An effective live vaccine promotes the development of pathogen specific
adaptive immune responses without the risks of pathology associated with the
virulent strain. Ultimately, this procedure introduces immunological barriers that
prevent either the introduction of infection to susceptible groups of animals, or
prevents transmission within the group. Although the live vaccines for
brucellosis are presently the most effective option for prophylaxis, there are a
number of problems associated with the use of such vaccines. The problems
are largely linked to the persistence of the vaccine strain within the host.
Residual virulence
All live Brucella vaccines persist within the host for a limited period. Persistence
has long been associated with the ability to generate lasting protective
immunity, but it remains a source of concern over possibilities for reversion to
virulence and release into the environment.
With each of the vaccines the timing of vaccination is of paramount importance
to ensure safe and efficacious use. B. melitensis Rev. 1 when used optimally in
the intended host species (sheep and goats) confers adequate protection
against virulent B. melitensis challenge. However, the vaccine retains
abortogenic qualities, and the presence of persisting viable Rev. 1 organisms in
female animals when they become pregnant, can result in abortion (Alton, 1975
and 1988., Blasco et aI, 1985 and 1988). Similarly, B. abortus S19 and RB51
vaccines have been associated with abortion (Mingle et aI, 1942., Palmer et et,
1996). Consequently, vaccination must be timed such that the Brucella will be
eliminated from the host before pregnancy is initiated. Vaccine associated
abortion can result in the shedding of large numbers of Brucellae, and can
therefore transmit vaccine strain infections to other susceptible animals in the
flock or herd, and contaminant the environment. A less frequently reported
complication of vaccination is the development of immune-complex mediated
arthropathies (Bracewell and Corbel 1980).
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Reported pathogenicity of vaccine strains in alternate hosts
S19, RB51, S2 and Rev. 1, when use optimally in the preferred host, confer
adequate protection against challenge with homologous species. However,
despite the high levels of genetic homogeneity of the Brucella genus, no single
brucellosis vaccine is capable of protection against challenge with all species of
Brucella, or conferring protection against homologous challenge in all possible
animal hosts. Moreover, administration of vaccines to inappropriate hosts can
have devastating consequences. Clearly, more research into the host specifics
of Brucella strain pathogenesis is required before accurate extrapolation of
protective efficacy and immunogenicity between potential hosts can be made.
Significantly none of the currently available brucellosis vaccines are suitable for
use in man, and indeed may remain virulent and lead to disease in the human
host. From a public health perspective, one of the greatest issues surrounding
the use of live Brucella in vaccination is that the organisms retain virulence and
can be fully pathogenic to humans. Occupational exposure to Rev. 1 vaccine is
a problem and isolated epidemics of human Rev. 1 infection have been
documented (Blasco, 1993). Ironically, the Rev.1 vaccine was originally
developed as a candidate vaccine for use in humans. Although the vaccine
afforded good protection it was ultimately considered too virulent and it lead to
active brucellosis when administered to human volunteers. The attempted use
of the S19 B. abortus vaccine in humans was also reported to have caused
unacceptable levels of active disease (Hoover et aI, 2004). Recently, the first
case of human RB51 associated brucellosis has been reported (Ashford et aI,
2004).
Differential diagnosis of vaccinated and infected animals
Serodiagnosis of brucellosis is largely based upon the detection of an antibody
response to the immunodominant LPS of the Brucella organism. Differentiation
of animals producing antibodies in response to LPS from vaccine strains or
virulent strains is not possible using these assays, resulting in vaccinated
animals presenting as 'Brucella positive' in serodiagnostic tests. The practical
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virulence. Therefore, alternatives to live vaccines must be sought. The use of
non-living antigen for vaccination eliminates the risk of vaccine acquired
infection, and knowledge of the antigenic components of the vaccine may
permit differential diagnosis. Additionally, sub-unit vaccines have practical
advantages such as reproducibility and stability.
One of the major impediments to the development of sub-unit vaccines has
been the paucity of information identifying potentially protective Brucella
antigens. The knowledge of Brucella genomes was limited until recently.
Allardet-Servent (1991) produced the first physical map of the B. melitensis 16M
genome, indicating two chromosomes. Michaux-Charcharon (1997) completed
mapping of the main type strains of Brucella showing similar genomic structure
between Brucella species. Notably, Brucella spp. are highly genetically
homogenous. Jumas-Bilak (1998), Michaux-Chacharon (1997) and Boschiroli
(2001) proposed that the separate species originated from a single clonal
ancestor following isolation in the favoured host (1993). Genomic differences
that can be exploited for diagnosis and molecular epidemiology are limited. A
transposable (Vermulapalli et ai, 1999) insertion sequence (IS711 I IS6501)
(Hailing et ai, 1993, Ouahrani et ai, 1993) is found in variable copy number in all
Brucella spp., and shorter intergenic repeats also occur (Halling and Bricker
1994). None of the Brucella contain plasmids, although broad range plasmids
can be maintained in Brucella (Verger 1991). Recently the genome sequences
of the three most important Brucella pathogens: B. melitensis 16M (DelVecchio
et ai, 2001), B. abortus 544 (Sanchez et ai, 2000, Hailing et ai, 2005) and B.
suis 1330 (Paulsen et al 2002), have been completed. Comparison reveals
considerable gene synteny between Brucella species (Hailing et ai, 2004), and
related members of the a2-Proteobacteriacae (Paulsen et ai, 2002). Notably,
classical virulence factors were not identified, and the small differences in
predicted gene content between species is not sufficient to account for the
observed differences in pathogenicity and host preference. Post genomic
analysis is expected to greatly assist the rational selection of potentially
protective antigens for vaccine development. Furthermore, such information
may be useful in identifying antigens that are difficult to characterise in vivo. For
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instance the identification of specific host cell binding proteins, invasion
associated proteins, and potential secreted antigens, which are practically
difficult to investigate, may be facilitated by the availability of genomic,
transcriptomic and proteomic data.
The lack of success so far seen with sub-unit vaccines is not just related to the
selection of an appropriate antigen. A significant hurdle in vaccine development
for any pathogen is the effective targeting of antigens to generate and sustain a
protective immune response (Kauffman, 1999., Gurunathan, 1998). Much of the
information pertaining to antigen presentation and effectors in Brucella
protective immunity come from studies in small animal models. Immunity
against brucellosis in all species appears to involve antigen specific T cell
activation, CD4+ and CD8+ T cells, activation of macrophages by IFN-y, and
specific humoral responses. In particular, IFN-y production and the presence of
CD8+ cytotoxic T cells are considered essential to the clearance of virulent
Brucella from the host (Murphy et ai, 2001a & b., Splitter et ai, 1997). The
protective response is therefore described as essentially a Th1 style immune
response. Hence, in order to develop an effective sub-unit vaccine an antigen
evoking Th 1 style immune responses must be used. Additionally, the delivery
route of the sub-unit vaccine is associated with effective presentation to the host
immune system and is of paramount importance in generation of appropriate
responses (Feltquate, 1998., Pachuk et ai, 2000). The development of
successful sub-unit vaccines requires both the selection of appropriate
candidate antigens and the delivery of these antigens in a manner that will
induce an appropriate and lasting protective response.
1.8 The potential of DNA based vaccination
Recent developments in vaccinology provide renewed promise for the
development of effective sub-unit vaccines against intracellular pathogens.
Genetic or DNA vaccines are plasmid-based DNA constructs engineered to
enable expression of a chosen gene in a eukaryotic host. Vaccination with the
plasmid construct results in the in vivo transfection of the host and the
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expression of the gene of interest from the construct within the host cell. The
immune response is directed against the expressed product of the gene of
interest. The simplicity of the approach, ease of development and production of
the constructs, and the potential for a prolonged delivery of antigen has ensured
that DNA vaccination has received much attention.
DNA vaccination was born with the demonstration that intramuscular delivery of
plasmid resulted in the in vivo production of the antigen within myocytes (Wolff
et aI, 1990), and that in vivo production of the encoding antigen could induce an
immune response (Tang et aI, 1992). Further work indicated that an influenza
DNA vaccine was able to promote protective immunity against a virulent viral
challenge in a mouse model (Ulmer et aI, 1993).
One of the major advantages of DNA vaccination is the ability to prime cytotoxic
T cells essential in the clearance of intracellular infections. This is largely
achieved as a result of the endogenous production of the antigen within the
transfected host cell, which results in antigen processing via MHC class I and
subsequent presentation to CD8+ T cells. Antigen presentation following DNA
vaccination has been the subject of much debate. Most DNA vaccine studies
use the intramuscular route of inoculation where DNA is presumed to be directly
transfected into the somatic cells such as myocytes and keratinocytes, or the
professional antigen presenting cells (APCs) such as dendritic cells (Des).
Studies have shown that very little protein antigen (pg amounts) is produced in
the host, and thus it is inferred that the CpG based adjuvant effect of the DNA
vector itself, and the mechanism of antigen presentation contribute significantly
to the development of the immune response. Direct transfection of professional
APCs allows direct priming of CD8+ cells following endogenous processing and
presentation of the antigen via MHC class I (Corr et aI, 1996). Secreted antigen
is taken up by phagocytosis and presented in the context of MHC class II to
prime CD4+ T cells. However, direct transfection of APCs is not thought to be
particularly efficient following ilm inoculation of naked plasmid DNA, and most of
the detectable antigen expression occurs within the myocytes (Casares,S.,
1997). Interestingly, myocytes are not efficient APCs. They are capable of
presenting antigen in the context of MHC class I molecules but lack the
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necessary co-stimulatory molecules that allow for effective T cell priming.
Considering that DNA vaccination is an effective strategy for priming CD8+ T
cells, and the effects of direct priming from the myocytes are limited, it is likely
that the immune response is heavily dependent upon involvement of
professional APCs. In addition to direct priming from either DC or myocytes it
has been shown that antigen can be prepared and secreted from the
transfected cell and taken up by professional APCs and presented as peptides
to T cells in the context of MHC class I and class II. Peptides from exogenous
sources do not normally access the MHC I presentation pathway, but
generation of primed CD8+ cells has been demonstrated following uptake of
antigen secreted from transfected cells or phagocytosis of transfected apoptotic
or necrotic transfected cells (Albert et aI, 1998., Fu et aI, 1997). This route of
CD8+ priming is termed cross-priming. There remains considerable uncertainty
as to the relative contributions of direct and cross-presentation in the immune
response to DNA vaccines. Some researchers propose that cross-presentation
is the principal mechanism for CD8+ induction (Cho et aI, 2001), but others
consider that direct uptake and endogenous production of the protein within the
APC providing direct access to the MHC class I presentation pathway is the
main mechanism of CD8+ priming (Porgador et aI, 1998).
In addition to the appropriate generation of CD4+ and CD8+ effector cells, DNA
vaccines also have the advantage of sustained delivery of antigen. Theoretically
the plasmid DNA may persist within the host cell for the life of that cell. In this
respect the plasmids are similar to live viral or intracellular bacteria where
persistence can be postulated to deliver antigen over a sustained period. The
prolonged stimulation with antigen is a factor considered beneficial for the
optimal development of memory immunity. Furthermore, the DNA vaccine
approach is highly advantageous when linked with genome data permitting the
selection and investigation of putative antigens without the need for culture,
characterisation and genetic manipulation of the live bacteria.
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1.8.1 DNA vaccines for intracellular pathogens
A large number of viral, bacterial and protozoan antigens have been assessed
for protective efficacy against a variety of important pathogens. In addition to
demonstrating direct protective efficacy these studies have also been valuable
in identifying protective antigens from a number of organisms. Moreover, the
results demonstrating variation due to vaccination schedule, dose, delivery
route, or challenge dose and route, has generated important information
regarding the development of protective immune responses (Bohrn et ai, 1998.,
Mor, 1998., Feigner, 1998., Gurunathan et ai, 2000., Mollenkopf, 2001). DNA
vaccination for protection against a complex intracellular bacterial pathogen was
first described by Lowrie et ai, (1994) using the Mycobacterium leprae 65 kDa
heat shock protein, to provide protection against M. tuberculosis challenge.
Examples of DNA vaccines developed for protection against complex
intracellular pathogens (bacterial, mycoplasma and protozoan) are provided in
table 1.2.
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Table 1.2: DNA vaccines against bacteria and parasites
Pathogen and study details
BACTERIAL DISEASES
Reference
Tuberculosis
Ag85 complex, as a DNA vaccine, is immunogenic and provides Lozes et aI, (1997)
significant protection against virulent H27rV challenge in the guinea pig
and mouse model.
MPT64, ESAT-6, evoke appropriate immune responses and provide
limited protection against challenge both individually and in combination
formulations.
TB DNA vaccine antigens co-delivered with murine GM-CSF have
enhanced cellular immune responses but limited protective efficacy.
Mycobacterium bovis specific antigens MPB70 and MPB83, as DNA
vaccines are immunogenic and protective in the BALB/c mouse model,
and elicit strong cellular responses from immunised cattle.
The use of TB specific antigens in a DNA vaccine, demonstrated to
have therapeutic value during active TB infection.
Leprosy
The immunodominant 35 kDa protein as a DNA vaccine is protective.
(Demonstrating protection achievable through a response to a single
antigen).
Chlamydiosis
Chlamydophila abortus Dna-K antigen evokes specific immune
responses and provides partial protection against challenge in the
pregnant mouse model. Immune responses vary between pregnant and
non-pregnant models and protection is predicted to be due to non-
specific effects of the CpG motifs in the construct backbone.
Listeriosis
DNA vaccine encoding Lysteriolysin-O is protective in mice.
Meningitis
Generation of meninococcal group B vaccine candidates, through
reverse vaccinology and DNA vaccination.
Mycoplasma diseases
Use of the entire genome randomly fragmented and expressed in DNA
vaccine plasm ids protects against challenge (Expression library
immunisation (ELI). The identity of the protective antigens or mediators
of the protective effect remain unknown.
Morris et aI, (2000)
Kamath et aI,
(1999)
Chambers et aI,
(2000)
Lowrie et aI, (1999)
Martin et aI, (2001)
Hechard et aI,
(2004)
Cornell et aI,
(1999)
Rappuoli et aI,
(2001)
Barry et aI, (1995)
Continued ...
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...... continued
Table 1.2 continued ....
INTRACELLULAR PROTOZOAL PARASITES
Leishmaniasis
Protection against L. donovani through DNA vaccine encoding the
A2 virulence is enhanced through inhibition of the host P53
response.
Ghosh et aI,
(2001)
DNA vaccine encoding LA CK Ag protects mice against L. major
challenge.
cDNA based ELI provides limited protective effect against L. major
challenge in the mouse model.
Gurunathan et
aI, (1997)
Piedrafita et aI,
(1999)
Malaria
DNA vaccines based upon merozoite surface protein 1, protects
mice against P. yoe/ii sporozoite challenge.
Becker et aI,
(1998)
DNA vaccines against malaria for humans now in phase 3 clinical
trials.
Doolan et aI,
(1997)
1.8.2 DNA vaccines for brucellosis
DNA vaccination has been investigated for Brucella. It was first reported in 1997
(Kurar et aI, 1997), using the B. abortus ribosomal L7/L9 sub-unit as the
expressed antigen in a simple pCMV based plasmid. The results of this first
Brucella DNA vaccine, demonstrated development of a specific and appropriate
immune response, but no significant protection against challenge. Brucella
specific DNA vaccines have since been reported for B. abortus GroEL (LeClerq
et aI, 2001), B. abortus P39 and Bfr (AI-Mariri et aI, 2001, 2002), B. abortus
Lumazine synthetase (Velikovsky et aI, 2002) and B. abortus glyceraldehyde-3-
phosphate-dehydrogenase (Rosinha et aI, 2002). Assessment of a B. suis
hsp62 based vaccine (A homologue of the candidate investigated by LeClerq et
a/ 2002) for immunogenicity and preliminary efficacy in the BALB/c mouse
model (Mansour, 2003) indicated a modest protective effect observed early
Post-challenge. In all reported investigations so far, DNA vaccines have evoked
appropriate Th 1 biased immune responses against the specific antigens, and in
some cases eVidence of protection in a mouse model.
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1.8.3 The future for DNA vaccines
The transfer of DNA vaccines from the laboratory setting to clinical and
veterinary investigations has proven disappointing in a large number of studies,
prompting a backlash of negative reactions regarding the overall concept of
such vaccines. Nevertheless, in 2005, the first commercially available veterinary
use DNA vaccine was approved by the United States regulatory authorities. The
vaccine "West Nile Innovator DNA" manufactured by Fort Dodge Animal Health
has recently been granted marketing authority for use in horses in the USA for
protection against West Nile Virus, and is expected to be available to veterinary
practices from 2006. Regulatory approval of the West Nile Virus vaccine sets an
important precedent in the commercialisation of DNA based vaccines, and also
in combat of the popular perception that these vaccines are ineffective in large
animals. Significantly, a second DNA vaccine "Apex IHN" (Aqua Health,
Novartis, Canada) to prevent infectious haematopoietic necrosis in farm raised
Atlantic Salmon, has also passed the first stages of the regulatory process
(Anon, 2005), signalling that the application of these vaccines for use in food
animals is not unfeasible. These recent events signal the advancement of DNA
vaccines from a theory, through the clinic, and now into the field. Undoubtedly,
further DNA vaccines will follow.
1.9 The aims of this investigation
Brucellosis in livestock remains a considerable problem in many areas of the
world, and thus remains a threat to public health. Previously, vaccination has
proved to be a useful strategy for reducing the prevalence of diseases in
livestock in endemic areas and consequently lowering the incidence of human
disease. Currently available live vaccines used for protection of livestock
against pathogenic Brucella infections have a number of undesirable
characteristiCS, including problems associated with efficacy, interference with
current statutory diagnostic assays, and residual pathogenicity. Furthermore
none of these vaccines are applicable for use in humans, and accidental
inoculation may lead to disease. Novel or improved, rationally designed
vaccines are necessary in order to address these issues.
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Chapter 1: Introduction
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Chapter 1: Introduction
An efficacious sub-unit or non-living Brucella vaccine has the advantage of
being non-infectious to man or animals, and with careful selection of the
antigenic components it can be created to produce immune responses that are
distinguishable from those evoked by virulent infection. DNA vaccination
technology, the recent availability of genome data for B. melitensis 16M and an
increasing immunological knowledge relating to effective vaccine antigen
delivery and presentation, and Brucella specific immunity, provide a unique
opportunity for the rational investigation of new sub-unit DNA vaccine
formulation for the protection of livestock against brucellosis, and the
subsequent protection of humans handling livestock.
The aim of the research presented in this thesis was to develop and evaluate
novel DNA vaccines to protect livestock and humans against brucellosis.
It is hypothesised that DNA vaccination using constructs encoding proteins
involved in the establishment of infection will provide protection through priming
adaptive immune responses that act to inhibit Brucella invasion or reduce their
ability to persist within host macrophages. The research makes timely use of
the Brucella genome sequencing project and allied post genomic technologies.
Genome data will be used to identify novel candidate antigens for which DNA
vaccines will be produced and evaluated for protective effect in the BALB/c
mouse model. Immunological correlates of protective immunity will be
measured. Furthermore, since naked DNA vaccines are reported to be poor
immunogens in livestock mechanisms to improve the immune response will also
be investigated. The overall plan for this investigation is summarised in Figure
1.2.
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ChaRter 1: Introduction
Figure 1.2:A flow chart summarising the investigations discussed in this
thesis
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Chapter 2: MATERIALS AND METHODS
Detailed method descriptions are provided in this chapter. The brief materials
and methods sections in subsequent chapters refer to the techniques described
herein, and provides the context for these methods. Reagent sources and
suppliers are listed in appendix 3.
2.1: Bacterial culture techniques and containment issues
A list of all bacterial strains used or created in these studies is given in the
following table.
Tab/e 2.1: Details of all bacteria/ strains used or created in this study
E. coli strains used in enetic modification rocedures
E. coli JM109 recA1, endA1, gyrA96, thi, hsdR17, (rK-mK+), re/A1, supE44, fl(/ac-
proAB) [F', traD36, proAB,Iac1QZflM15]
Strain of E. coli common I used for lasmid maintenance
E. coli TOP10F' F' <t>80dlacZflM15 fl(/acZYA-argF)U169 deoR recA1 endA1
hsdR17(rK-, mic') phoA supE44 ")..-thi-1 gyrA96 re/A1
Strain of E. coli commonly used for plasmid maintenance
E. coli TOP10 F- mcrA fl(m"-hsdRMS-mcrBC) <t>80d/acZflM15 fllacX74 deoR recA1
araD139 (flara-leu)7697 ga/U ga/K rpsL (str") endA 1 nupG
E. coli BL21(DE3) F- ompT hsdSB (rB-mB-)gal dcm rne131 (DE3) pLysS (CamR)
pLys Strain of E. coli commonly used for the expression of recombinant
proteins
Brucella strains used
B. melitensis 16M B. melitensis biovar 1 type strain (ATCC: 23456), maintained at VLA
(Weybridge) WHO/FAO/ OlE reference laboratory. (1955)
B. melitensis B115 B. melitensis naturally occurring rough strain, maintained at VLA
(Weybridge) WHO/FAO/ OlE reference laboratory.
B. melitensis Rev.1 B. melitensis biovar 1 vaccine strain, from seed stocks maintained by
(Vetoquinol,) the Vaccine production facility at Vetoquinol©, France.
Continued .
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Table 2.1 continued ...
p-fliG TOP1OF'
JM109 E. coli transformed with the pTargeT plasmid with omp25 gene
insertion.
p-omp25 (1) TOP10F'
TOP10F' E. coli transformed with the pCR3.1 plasmid with omp25 gene
insertion.
p-omp25 (2) JM109
p-ia/BTOP10F'
TOP10F' E. coli transformed with the pCR3.1 plasmid with ia/S gene
insertion.
p-frpS TOP1OF'
TOP10F' E. coli transformed with the pCR3.1 plasmid with frpS gene
insertion.
TOP10F' E. coli transformed with the pCR3.1 plasmid with fliG gene
insertion.
p-acvB TOP1OF'
TOP10F' E. coli transformed with the pCR3.1 plasmid with acvS gene
insertion
(b) Prokaryotic expression
pRSET-fliC BL21
TOP10 E. coli transformed with the pGEX-6P plasmid containing the omp25
gene insertion. Plasmid production Imaintenance strain. GST fusion protein.
pGEX-Omp25 TOP10
pGEX-Omp25 BL21 BL21 E. coli transformed with the pGEX-6P plasmid containing the omp25
gene insertion. Recombinant protein production strain. GST fusion protein.
pGEX-iaiB TOP10 TOP10 E. coli transformed with the pGEX-6P plasmid containing the ialB
gene insertion. Plasmid production Imaintenance strain. GST fusion protein.
pGEX-laIB BL21 BL21 E. coli transformed with the pGEX-6P plasmid containing the i81B gene
insertion. Recombinant protein production strain. GST fusion protein.
pGEX- acvB TOP10 TOP10 E. coli transformed with the pGEX-6P plasmid containing the acvB
gene insertion. Plasmid production Imaintenance strain. GST fusion protein.
pGEX-acvB BL21 BL21 E. coli transformed with the pGEX-6P plasmid containing the omp25
gene insertion. Recombinant protein production strain. GST fusion protein.
pRSET- frpB TOP10 TOP10 E. coli transformed with the pRSET plasmid containing the frpS gene
insertion. Plasmid production Imaintenance strain. Histidine tagged fusion
protein.
pRSET-frpS BL21 BL21 E. coli transformed with the pRSET plasmid containing the frpB gene
insertion. Recombinant protein production strain. Histidine tagged fusion
protein.
pRSET-fliC TOP10 TOP10 E. coli transformed with the pRSET plasmid containing the fliG gene
insertion. Plasmid production Imaintenance strain. Histidine tagged fusion
protein.
BL21 E. coli transformed with the pRSET plasmid containing the fliG gene
insertion. Recombinant protein production strain. Histidine tagged fusion
protein.
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Contained use of Brucella spp.
Brucella melitensis 16M and all related strains are ACDP category III zoonotic
pathogens, and as such can only be handled within designated appropriate
containment laboratories. Containment of the pathogen is also required under
the Specified Animal Pathogens Order (SAPO) 1998. For this project all culture
and manipulation of live Brucella spp., was performed within SAPO licensed
containment level III laboratories at VLA Weybridge.
Brucella melitensis strains 16M, Rev.1 and B115 were used in this study for
provision of antigens and inocula for in vivo and in vitro work. B. melitensis 16M
lyophilised aliquots are maintained at the VLA Brucellosis reference centre.
These stocks were generated in 1958 from the original 16M isolate listed as the
B. melitensis biovar 1 type strain (ATCC 23456). Rev.1 seedlot strain was
provided by Vetoquinol, courtesy of Dr Ariane Van Der Moer and Dr Thierry
Masse. B115 was obtained from the lyophilised stocks in the VLA reference
collection.
Culture of Brucella melitensis 16M on solid agar media for isolation
of total RNA
B. melitensis 16M was resurrected from lyophilised stocks into a minimal
volume of sterile water, and transferred immediately to serum dextrose agar
(SDA) + 10% horse serum media. Plates were incubated at 37°C in a 10% C02
atmosphere incubator for 4 days. Bacterial growth was harvested directly into
Tri-ReagentTMby adding 1 ml of Tri-reagentTMto each plate surface and gently
scraping the bacterial lawn into the solution using a sterile bacterial loop. The
suspension was transferred to a sterile 50 ml FalconTMstyle centrifuge tube,
vortexed for 10 minutes and frozen immediately at :-80°C to facilitate cell lysis.
The suspension was subjected to three cycles of freezing and thawing, before
proceeding with RNA isolation.
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Culture of Brucella melitensis 16M in Albimi broth for isolation of
total RNA
B. melitensis 16M was resurrected from lyophilised stock and seeded to SDA
+10% horse serum as described above, except that cultures were plated to
provide single colonies. After 4 days growth on agar, a single colony was
selected and transferred to a 1 ml aliquot of Albimi Broth Culture. The sample
was thoroughly vortexed and then incubated for 24 hours at 37°C in 10% C02
atmosphere. The 1 ml suspension culture was then added to 9 ml of fresh
Albimi solution in a sterile Falcon style tube, and incubated for a further 18 -24
hours under the same conditions. For bacterial harvest, the tubes were
centrifuged at 4000 rcf for 15 minutes. Supernatant was discarded. The pellet
was immediately resuspended into 1 ml of Tri-Reaqentl'", and subjected to
freeze thaw cycles as described above.
Maintenance and culture of B. melitensis 16M, for use as the
challenge strain in protective efficacy studies
Each time B. melitensis 16M was required as inocula for use in vivo in
challenge studies, individual lyophilised stocks were reconstituted in a minimal
volume of sterile water and plated on SDA as described above for culture of B.
melitensis 16M for RNA isolation. Cultures were incubated at 37°C for 4 days in
a 10% C02 supplemented atmosphere. Cultures were visually inspected on a
daily basis for the presence of extraneous agents, or indications of phase
dissociation. Cultures not observed to be 100% smooth phase Brucella were
not used in inocula preparation. At the time of inocula preparation a
representative sample of heat-killed inocula was analysed by 16S rRNA
bacterial sequencing to confirm Brucella spp., identity.
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Maintenance and culture of B. melitensis Rev. 1, for use as live
vaccine controls in protective efficacy studies
B. melitensis Rev.1 was used as a positive control for successful vaccination
throughout these studies . The strain was propagated on the recommended
Brucella blood agar in order to generate lyophilised stocks. Enough aliquots
were produced to last for the duration of the project. When required, a freeze-
dried aliquot was reconstituted in a minimal volume of sterile water and seeded
onto agar. Following four days growth at 37°C growth was visually assessed for
purity and evidence of phase dissociation. As indicated for B. melitensis 16M
cultures, only pure smooth strain cultures were used to prepare the inocula.
Preparation of viable Brucella suspensions for vaccine and
challenge inocula used in protective efficacy studies
A standard procedure was followed in order to prepare a known CFU inocula of
the vaccine control strain Rev.1 or the challenge strain 16M. Brucella were
cultivated as described above and then harvested from the plate into 0.1M PBS.
The opacity of the suspension was determined using the nephelometer device.
The suspension was altered until a transmission value of 42 - 46 % was
obtained. This value is known to equate to a Brucella concentration of
approximately 1 X 1010 CFU / ml. Serial dilution from this stock solution was
then used to generate a solution with an appropriate expected concentration,
which was inoculated into mice as soon as possible after preparation in order to
limit time during which there could be a natural decrease in viability.
For retrospective enumeration of the actual inoculation dose, remaining Brucella
suspension was returned to the laboratory immediately after inoculation of mice
was completed. The sample was further serially diluted to the anticipated
dilution limit. Each of the dilutions, including the 'neat' suspension were plated
onto SDA plates (100 J.LIper plate, in triplicate). Plates were incubated at 3rC
for 7 days and CFU counted.
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Recovery of Brucella from infected mouse tissues for bacterial
enumeration in protective efficacy studies
Mice were sacrificed by cervical dislocation. Spleens were aseptically removed
and immediately placed in 3 ml of 0.1 M PBS. Spleens were prepared in PBS
using sterile scissors to disrupt the membranes and the barrel of a sterile 5 ml
syringe to macerate the spleen by passing the material through a 100 flM mesh
cell sieve. Sieving permitted Brucella and splenocytes to be separated from
fibrous connective tissue. For enumeration of the Brucella the sieved material
was serially diluted to 1 in 10,000 dilution. Each dilution was plated in 100 III
aliquots in triplicate onto SDA plates. Samples isolated from animals that had
received Rev.1 vaccination were also plated onto both trypticase soya agar
(TSA), and TSA + 5 I,U.lml penicillin. Plates were incubated at 37°C for 5 - 7
days. CFU were counted on all plates, and used to determine the number of
Brucella recovered from the spleen of each mouse. Comparison of CFU
recovered on TSA and TSA + penicillin was used to determine the relative
percentage of Rev.1 from the total recovered Brucella.
Recovery and culture of Brucella melitensis 16M from infected
mouse splenocytes for isolation of total RNA
Mice were sacrificed by cervical dislocation. Spleens were aseptically removed
and processed to generate free suspension splenocytes as described above,
except that suspensions were produced in DMEM media (Invitrogen Life
Technologies, Paisley, UK) rather than PBS. DMEM media without antibiotics
was used as streptomycin can inhibit the growth of 16M. Cultures were
incubated overnight at 3rC, 5% CO2, in a humid atmosphere incubator.
Following the 24-hour incubation plates were centrifuged at 200 rcf to sediment
the bacteria and the cells. Supernatant was discarded and the bacteria / cell
suspension was resuspended into 0.5 ml of Tri-reagenFM per well. Suspensions
were transferred to sterile Eppendorf tubes and subjected to freeze thaw cycles
as described previously.
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Sterility assessment of samples prepared in Tri-Reagent
Sterility validation exercises were performed to show that following suspension
in Tri-Reaqent'" and freeze thawing there were no remaining viable Brucella in
the suspension. In order to determine that samples did not contain viable
Brucella, an aliquot of each sample (not less that 10% of the total sample
volume) was assessed. The sample was centrifuged to sediment bacteria and
bacterial debris and the supernatant discarded. The pellet was washed twice by
centrifugation at 4000 rcf for 10 minutes in 0.1 M PBS, in order to remove
residual traces of the Tri-Reagent solution from the preparation. The sample
was resuspended in 400 ~I of 0.1 M PBS and plated in 100 ~I volumes in
triplicate onto SDA plates. Plates were incubated at 37°C, 10% C02 for 7 - 10
days, and assessed daily for the presence of viable bacteria. Samples, which
were demonstrated to be sterile, were then classed as non-infectious and could
be dealt with at containment level II rather than III. This was necessary because
RNA isolation procedures at containment level III proved to be impractical, as
the need for rapid and dexterous sample manipulation could not be
accommodated under the strict containment conditions. Thus sterility of the
sample was a prerequisite for this procedure.
Detection of any bacterial growth, including non-Brucella contaminants, resulted
in the entire sample being discarded.
Culture and maintenance of E. coli strains.
E. coli host organisms were used for the maintenance of DNA vaccine
plasmids, and for production of recombinant proteins from prokaryotic fusion-
protein expression constructs. Plasmid maintenance strains were classified as
Class I genetically modified microorganisms (GMMs) under the genetic
modification contained use regulations (2001) Expression strains were
designated as class II GMMs. All work with live E. coli strains (both
maintenance and expression) was performed within designated containment
60
level II laboratories, and work with live bacteria was restricted to a class II safety
cabinet to maintain isolation of the organisms.
The E. coli strains used and created in this project were maintained as frozen
seed stocks at -80°C. Broth cultures for each strain were produced as
described below for the isolation of plasm ids. E. coli was harvested from broth
by centrifugation (4000 rcf, for 10 minutes, at 4°C (Heraeus MegaFuge 1.0R))
and resuspended in a minimal volume of Brain-Hearth Infusion Broth (BHIB) +
10% Glycerol. This suspension was transferred to sterile eppendorf tubes in 1
ml aliquots and frozen immediately at -80°C. At least 10 aliquots of each E. coli
strain were produced.
Culture of E. coli for the isolation of plasm ids
GMM E. coli containing the DNA vaccine plasm ids were grown on LB agar and
in Luria-Bertani (LB) broth containing ampicillin (at 100 J.!g/ml).
For solid agar cultures E. coli were seeded onto LB-Agar (100 J.!g/ml ampicillin),
to generate single colonies. A single vial of frozen seed stock was removed
from storage at -80°C, but not allowed to defrost completely. A sterile bacterial
loop was used to scrape a sample of the cell stock from the frozen surface,
which was streaked onto the agar plate. Plates were incubated overnight at
3rC.
For broth cultures, a 30 J.!Ibacterial loop of frozen cell stock or a single colony
from a plate culture was inoculated into 10 ml of cold LB Broth (100 J.!g/ml
ampicillin). This culture was incubated at 37°C in a shaker incubator (225 rpm),
for 12 - 16 hours. If larger volumes were required this culture was then
transferred directly into a larger vessel containing the appropriate volume of
pre-warmed LB broth plus ampicillin, and incubated for a further 24 hours.
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Culture of E. coli for the expression of recombinant proteins
Culture of expression clones was essentially the same as for plasmid isolation,
except that liquid culture used LB broth without antibiotic. Optimal expression
conditions varied between individual E. coli strains. Generally for each
procedure, the frozen seed stock of the GMM E. coli was plated to provide
single colonies on LB agar containing selective antibiotic (either ampicillin at
100 ~g/ml or kanamycin at 40 ~g/ml). After 24 hours a single colony was
transferred to a minimal volume (approximately 5 - 10 ml) of LB broth without
antibiotics. After 24 hours the suspension culture was passaged by transfer of
an aliquot to a larger volume of pre-warmed LB broth, generally a ratio (v/v) of
1: 10, culture : LB broth was used. Bacterial growth in suspension was
monitored using a spectrophotometer in terms of the optical density of the
suspension at 600 nm until the culture was determined to be ready for
induction. Expression of the recombinant protein was induced through the
addition of IPTG to the media. Culture supernatant or cell paste was harvested
after optimal incubation and the presence of protein confirmed in the
appropriate fraction through SDS-PAGE and western blotting procedures.
Large scale protein production (for Omp25-GST and lalB proteins) was sub-
contracted to a commercial company. Protein details are provided in appendix
2.
Maintenance of Cos 7 cell cultures
Cos7 cells were routinely cultured in 75 ml Nunc tissue culture flasks in OMEM,
supplemented with 200 mM L-Glutamine (Glutamax™), 100 ~g/ml Antibiotic
antimycotic solution, and 10% Foetal Bovine Serum. Cultures were incubated at
3rC in a 5% C02 atmosphere. Cells were passaged on a weekly basis. For
transfection studies cells were cultured in 12 well Nunc tissue culture plates
containing with sterile glass coverslips (18 mm diameter, no.2, BOH Lab
supplies). Twenty-four hours prior to the transfection procedure the cells were
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passaged and seeded to sterile 12 well plates at 1 X 105 cells/m!. Growth under
standard incubation conditions resulted in cells at between 40 - 80%
confluence at the time of transfection.
2.2 RNA isolation, reverse transcription and polymerase chain
reaction procedures
Procedures were optimised for the amplification of specific Brucella genes from
both genomic DNA and cDNA templates.
Isolation of total RNA from Tri-reagentTM suspensions
RNA isolation from material suspended in Tri-reagenFM was performed
according to manufacturers instructions. The following modifications to these
standard procedures were applied. For material harvested from SDA plates it
was necessary to include an additional centrifugation step before the addition of
chloroform to the samples. Samples were centrifuged at 10,000 rcf for 5
minutes in order to sediment any agar harvested with the bacteria. The
supernatant, containing the released RNA in solution, was transferred to a clean
sterile tube for processing. The agar and bacterial debris in the pellet were
discarded. All other samples were processed as described in the manufacturers
guidelines.
Briefly, each Tri-Reagent sample was distributed into 1 ml aliquots in sterile
DNAse/Rnase free eppendorf tubes and 0.2 ml of chloroform (Molecular Biology
Grade Reagent) was added to each tube. These samples were vortexed briefly
and then incubated on ice for 5 minutes. Samples were centrifuged at 16,000
rcf (Heraeus Biofuge Fresco) at 4°C for 10 minutes, and the clear aqueous layer
carefully transferred to a new sterile tube. The pink solvent layer and opaque
interface were discarded. The RNA present in the aqueous phase was
precipitated by addition of 0.5 ml of isopropanol (Molecular Biology Grade
Reagent). Samples were briefly vortexed to ensure mixing, and incubated on
ice for 20 minutes before centrifuging (16,000 rcf, for 20 minutes at 4°C ,
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Hereaus Biofuge Fresco) to pellet the precipitated RNA. Precipitated RNA was
washed twice in 75% ethanol by centrifugation (10 minutes, 10,000 rcf, 4°C,
Hereaus Biofuge Fresco). The ethanol supernatant was carefully decanted and
the pellets air-dried for 20 minutes, before resuspension in 20 III of DEPC
treated water (Arnbiont"). Samples were 'cleaned up' using the Ambion™ DNA-
Free™ procedure to eliminate traces of genomic DNA.
Genomic DNA removal from total RNA samples
All samples were treated with the Ambion DNA-Free™ to remove traces of
genomic DNA. Ambion ™ DNA-Free™ procedures were conducted according to
the manufacturers instructions. Briefly, 5 III of DNAse1 was added to each 20 III
aliquot of RNA. Samples were incubated at 37°C in a water bath for 30 minutes.
10 III of DNAse removal agent was added to each tubes and mixed using a
Denley rotary cell mixer for 10 minutes. Samples were centrifuged (10,000 rcf,
4°C, for 1 minute, Hereaus Biofuge Fresco) to sediment the removal reagent.
Supernatant was transferred to a clean labelled sterile tube, and used
immediately in cDNA production or frozen at -80°C until use.
Reverse transcription of total RNA to generate cDNA
cDNA production was performed using the reagents supplied with the Ambion
Retroscript™ RT-PCR kit. For each RNA sample, Oligo dT primers or Random
decamers (Sourced from Ambion) were used to prime the reaction for reverse
transcription. Oligo dT priming was used in reactions with template RNA
obtained from Cos7 cells, whereas Random decamer priming was used for
reactions using Brucella RNA as template.
For Cos 7 RNA reverse transcription , 2 III of Oligo dT primer was added to 12
III of the RNA sample. The sample was then heated to 82°C for 3 minutes to
denature any secondary structures and open the RNA template for annealing of
the primer. Incubation at 82°C was carried out in a Progene thermal cycler
(Techne). The sample was immediately cooled to 4°C and remaining reagents
for RT-PCR added on ice. 4 III of 10 mM dNTP solution, 1 III of M-MLV -RT
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enzyme (or 5 IU), 1 III (or 5 IU) of Superasin™ RNAse inhibitor and 2 III of
reverse transcription buffer (Retroscript'") was added to each tube. The tubes
were heated to 42°C in the Techne™ Progene™ thermal cycler for 90 minutes,
and then heated to 80°C for 10 minutes to denature the enzymes and stop the
reaction, before cooling to 4°C. The cDNA was used immediately in specific
PCR reactions or stored at -80°C in 5 III aliquots until required.
Reverse transcription of Brucella total RNA was achieved using random
decamer priming. The procedure was essentially the same as that described for
Cos 7 RNA reverse transcription, except that only 5 III of RNA solution was
used as template in these reactions because quantities of this material were
more limited. RNA was prepared for reverse transcription as follows: 5 III of
RNA was added to a sterile PCR tube, 5 III of Nuclease-free water was added,
along with 2 III of random decamer™ primers. The sample was heated to 82°C
for 2 minutes in order to destroy RNA secondary structure and anneal the
random decamers™ to the RNA template. The rest of the procedure was
identical to that described above for the Cos 7 RNA samples.
Polymerase Chain Reaction
PCRs were developed to amplify the selected candidate antigen genes.
Reactions were devised to amplify the entire coding sequence of the selected
gene, and were optimised for amplification of either Brucella genomic DNA as
template for the generation of product for cloning, or for amplification of cDNA
template obtained from either Cos 7 RNA or Brucella RNA. Additional PCRs
were used in control reactions throughout these studies.
Primer design
PCR primers were designed to permit amplification of the entire ORF for each
selected candidate, and to introduce novel restriction cleavage sites to either
end of the product and a Kozac signal sequence (ribosomal binding site) to the
5' end of the product. Primer details are provided in the following table.
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Table 2.2: Primers used for the amplification of Brucella specific genes
IF-1*
Primer detailsTarget gene
omp25 Forward primer: AN4CTCGAGlCCGCCACCA TGCGCACTCTT AAGTCT
Reverse primer: ~CCGGATGCCTGAAATCCTT
acvB Forward primer: AAAAlGCTTG¢!GCCACCATGAAGAAAGAACGCGTA TTC
Reverse primer: ~CGCGCAGGGCGCGGCGGC
frpS Forward primer: AAJ¢TCGAGIGCCACCA TGAAGTTCACGAGAA TGCTG
Reverse primer: ~CAGAACTTGAAGGCCGTCTGGAAA
ia/S Forward primer: AN4GGATC¢lGCCACCA TGAAAAA TTATCGTG
Reverse primer: ~ ACTTGGTCAA TGCCTGAAT
ec Forward primer: ~TCGAG!GeCACCATGGCTAGCA TTCTTACAAACT
Reverse primer: ~CCGGTTTATTAGCCGCGGAACAG
omp25* Forward primer: TGCGCAACTCTTAAGTCTCTI
Reverse primer:TTAGAACTIGTAGCCGATGCC
Forward primer: ATGGCGAAAGAAGAAGTCCT
Reverse primer: ACTAGAACCTTGTCACCGGC (Eskra et al, 2001)
Restriction enzyme sites Iboxedl
Kozac sequence underlined * primers used only for RT-PCR investigations (not cloning)
Primers were synthesised by Sigma Genosys, or Oswellaboratories UK.
peR optimised for cloning
peR reactions were optimised for the amplification of each candidate product.
Reactions were set up using B. melitensis 16M genomic DNA as template, and
using the conditions specified for the IS711 Brucella specific peR (Bricker et aI,
1994). For each specific peR the conditions such as MgCI2 concentration,
Glycerol concentration, primer concentration, annealing temperature and
number of cycles per reaction were optimised from this starting point until a
clean product was obtained. Genomic DNA, obtained by phenol-chloroform
extraction procedure was kindly donated by the Brucella reference laboratory,
VLA Weybridge. The concentration of template DNA in each reaction was
adjusted to obtain optimal conditions. Concentration was estimated using
spectophotometric readings of absorbance at 260 nm. All PCR's were
conducted using a Progene thermal cycler (Techne). Optimised amplification
conditions for each gene are described in the following table.
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Table 2.3: Optimised peR conditions for cloning, using genomic DNA
from B. melitensis16M as template
Gene identity peR details
Total volume: 100 ~1.
omp25 Template: 20 ~I B. melitensis 16M genomic DNA @ 200 ~g/ml.
Reaction conditions: Perkin Elmer PCR system: X1 PCR Buffer 11,1.5mM
MgCI2, 1.0 mM dNTPs, 200 nM ea. Primer, 10% glycerol, 5U Taq
Cycling conditions:
• 1 [95°C X 5', 58°C X 2', 70°C X 3']
• 30 [95°C X 1', 58°C X 2', 70°C X 3']
• 1 [95°C X 1', 58°C X 2', 70°C X 12']
Product size: 750 bp
Total volume: 50 ~I
(rpS Template: 5 ~I B. melitensis 16M genomic DNA @ 200 ~g/ml
Reaction conditions: Perkin Elmer PCR system: X1 PCR Buffer 11,3.0mM
MgCI2, 2.5 mM dNTPs, 200 nM ea. Primer, 5U Taq
Cycling conditions:
• 1 [94°C X 5']
• 35 [95°C X 90", 56°C X 90", 72°C X 120"]
• 1 [72°C X 12']
Product size: 2008 bp
Total volume: 50 ~I
la/S Template: 5 ~I B. melitensis 16M genomic DNA @ 200 ~g/ml ,
Reaction conditions: Perkin Elmer PCR system: X1 PCR Buffer 11,10%
glycerol, 3,0 mM MgCI2, 2.5 mM dNTPs, 200 nM ea. Primer, 5U Taq
Cycling conditions:
• 1 [94°C X 5']
• 35 [95°C X 90", 56°C X 90", 72°C X 120"]
• 1 [72°C X 12']
Product size: 546 bp
Total volume: 50 ~I
acvSlvlrJ Template: 5 ~I B. melitensis 16M genomic DNA @ 200 ~g/ml
Reaction conditions: Perkin Elmer PCR system: X1 PCR Buffer 11,12%
Glycerol, 2.75 mM MgCI2,2.5 mM dNTPs, 200 nM ea. Primer, 5U Taq
Cycling conditions:
• 1 [94°C X 5']
• 35 [95°C X 90", 57°C X 90", 72°C X 120"]
• 1 [72°C X 12']
Product size: 1435 bp
Total volume: 50 ~I
file Template: 5 ~I B. melitensis 16M genomic DNA @ 200 ~g/ml
Reaction conditions: Perkin Elmer PCR system: X1 PCR Buffer 11,8%
Glycerol, 3.0 mM MgCI2, 2.5 mM dNTPs, 200 nM ea, Primer, 5U Taq
Cycling conditions:
• 1 [94°C X 5']
• 35 [95°C X 90", 56°e X 90", 72°e X 120"]
• 1 [72°C X 12']
Product size: 880 b
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peR optimised for use with eDNA templates
For peR from cDNA templates from both Brucella RNA and Cos 7 RNA, the
Accuprime ™ system was found to be more suitable than the reactions
described for cloning. Additional control reactions were also devised for use in
these studies. For each sample of cDNA assessed a control reaction using the
corresponding RNA sample as template was used. This reaction was included
in each assay to serve as a "no reverse transcription" control and verify the
absence of contaminant DNA from the sample.
For reactions utilising cDNA template generated from Brucella, a specific peR
for a constitutively expressed gene (IF-1) was used to determine the presence
of intact Brucella specific sequence in the template. This procedure was to act
as a simple control procedure to determine the quality of the RNA and cDNA
preparation. The IF-1 peR was based upon that developed by Eskra et ai,
(1997).
Amplification procedures for the candidate genes (and the IF-1 control) were
optimised using the Accuprime ™ system reagents. Accuprime reagents
provided a complete peR mastermix, to which the primers at an appropriate
concentration (0.2 nM), and the template cDNA samples were added. 2 -5 J..l1of
template cDNA was used in each reaction. Accurate quantitation of the amount
of cDNA in each template was not possible because of the small sample size,
but visualisation of a 1 J..l1aliquot of cDNA on agarose gel electrophoresis and
comparison of the intensity of ethidium bromide (EtBr) staining against a known
plasmid concentration indicated the concentration of each preparation to be
between 0.001 J..lg/J..l1and 0.01 J..lg/J..l1.
For each reaction 1 - 5 J..l1of template cDNA was used. Reactions were set up
in 50 J..l1total volumes, with 25 J..l1of the Accuprime I ™ reagent, 1 J..l1of each
primer at 0.2 nM concentration, and 19 - 22 J..l1of DEPe treated water. Each
reaction involved an initial denaturation and enzyme activation step at 94°e for
5 minutes, followed by 20 cycles of denaturation at 94°C for 30 seconds,
annealing at a specific temperature dependant upon the gene target for 30
seconds (specific annealing temperatures for these reactions are provided in
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table 2.4), and extension at 72°C for 30 seconds. A final prolonged extension
step for 5 minutes concluded the reaction.
Table 2.4: Annealing temperatures for specific Accuprime ™ peR
reactions
IF-1
Annealing TemperatureSpecific reaction
acvB
ialB
flie
frpB
omp25
59°C
56°C
58.5°C
58.5°C
56°C
58.5°C
Agarose gel electrophoresis
Visualisation of peR products, plasmids and RNA samples was performed by
agarose gel electrophoresis in the presence of ethidium bromide (EtBr).
Agarose gels were prepared as 0.8% - 1.2% agarose wlv in TAE (4.84 gIl Tris
base, 1.14 mill Glacial acetic acid, 20 mill 0.5M EDTA, pH 8.0) buffer. For
samples requiring isolation of the product from the gel, Low melting point (I.m.p)
agarose was used. For all other applications general-purpose laboratory grade
agarose was used. EtBr was added to the gels to give a final concentration of
0.05 J.1g/mljust prior to gel pouring. DNA samples were prepared in Sigma Blue-
Orange loading buffer, at a ratio of 5:1 (DNA sample: loading buffer), and
applied to gels. Samples were electrophoresed through the gels at 120 V until
the required resolution was obtained. The size of peR products (or other DNA
sample bands) was estimated through comparison with standardised molecular
ladders.
Gels were viewed under u.v light and images were captured using either a
Polaroid camera or directly via the Alpha-lmager™ Gel Documentation system.
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2.3: DNA cloning procedures
Extraction of peR products from agarose gels
Following successful amplification by peR, products were separated by
electrophoresis through 0.8 - 2% low melting point agarose gel. Products were
excised from the gel, and purified using the Qiagen Gel Extraction kit following
the manufacturers instructions. Briefly, the area of the gel containing the
required fragment was excised from the gel using sterile scalpel blades, and
solubilised using proprietary buffer and heating at 50°C for 10 minutes. 3 mM
Sodium acetate was added to the sample until the desired pH (approximation
based upon colour change) was achieved. Samples were added to Qiagen Gel
extraction columns and passed through the column matrix by centrifugation at
10,000 rcf for 1 minute (Hereaus Biofuge Pico). Fall through was discarded. The
process was repeated until all sample had been passed through the column.
The columns were washed twice with 750 ~I of prepared buffer PE, by
centrifugation. After the second wash, the columns were centrifuged again to
remove all residual buffer, and the columns were placed above clean sterile
collection tubes (Sterile, DNAse/Rnase free eppendorf tubes). 30 - 50 ~I of
Nuclease free™water (Ambion) was added directly to the membrane surface of
the column. The columns were incubated at RT for 5 minutes to allow the water
to penetrate the column matrix, and then centrifuged at 10,000 rcf for 1 minute
to elute the DNA from the column.
Purified product was visualised by agarose gel electrophoresis to confirm size
and purity, and quantified by spectrophotometry at 260 nm.
Estimation of DNA concentration by spectrophotometry
The concentration of plasmid genomic DNA samples was estimated through
measurement of the absorbance of a diluted preparation at 260 nm using a
spectrophotometer. DNA concentration was determined as 0.0 @ 260 nm X 50
X dilution factor.
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Ligation with plasm id vectors
Ligation of purified DNA product with appropriate vector was achieved using T4
ligase enzyme and optimised reaction buffers. DNA vaccine constructs were
generated through direct cloning of the PCR amplicon into selected TA cloning
vectors, capable of eukaryotic expression. Prokaryotic expression constructs
were produced by sub-cloning these gene specific inserts from the DNA
constructs into appropriately purified vectors. Ligation reactions were incubated
at 14°C for 16 to 18 hours, before transformation into the appropriate cell line
for plasmid propagation.
Transformation of DNA into E. coli host cells
• pCR3.1 based constructs
TOP10F' One Shot™ competent cells (Invitrogen) were transformed with the
pCR3.1™ based constructs. Transformations were conducted according to a
standard basic protocol. Briefly, an aliquot of competent cells was defrosted on
ice, 2 ~I of the relevant ligation mix, and 2 ~I of 2-mercaptoethanol was added
to each vial of cells and incubated on ice for 30 minutes. The mixture was then
heat shocked, by incubation in a water bath at 42°C for 45 seconds. After heat
shock SOC media was added and the vial was incubated with vigorous shaking
at 225 rpm at 3rC for 90 minutes. Finally, cells were plated onto selective
media (LB based agar supplemented with an appropriate selection antibiotic
(100 ~g/ml of ampicillin or, 50 ~g/ml of kanamycin. For each transformation the
cell mix was plated in one 50 ~I aliquot and one 150 ~I aliquot, and incubated at
37°C overnight to allow growth of the recombinant colonies.
• Prokaryotic expression plasmids
Prokaryotic expression constructs based on the pGEX or pRSET vectors were
transformed into TOP10 E. coli (For maintenance) or BL21 E. coli (For
expression) according to identical procedures to those described above.
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• pTargeT constructs
pTargeT based constructions were transformed into JM109 competent cells
using a slightly modified transformation procedure. For these constructs 5 ,.d of
ligation mix was used in transformation mixes, 2-ME was not added to the cells,
and 400 J.l1of SOC media was added to each reaction mix. Incubation of cells in
SOC media was performed at 37°C, with vigorous shaking at 225 rpm, for 120
minutes. Cells were plated onto appropriate selective media (100J.l11 plate), and
incubated at 37°C overnight to allow the growth of recombinant colonies.
Plasmid isolation using Qiagen™ Plasmid Prep kits
Qiagen plasmid prep methods utilise a range of proprietary buffers to lyse E.
coli host cells and release plasmid DNA into solution. The lysate from overnight
(O/N) E. coli cultures was applied to Qiagen columns containing a matrix that
binds plasmid DNA. Unwanted material was removed by washing with
proprietary buffers and plasmid DNA was eluted using the recommended
permitted volume of endotoxin free distilled water. To generate small volumes
and quantities of plasmid, Qiagen mini-prep t" (3-10ml cultures, yielding up to a
maximum of 20 J.lg of plasmid) or Midi-prep ™ columns (10-25 ml cultures
yielding up to a maximum of 250 J.lgof plasmid) were used. For larger volumes
Maxi-prep ™ (500 ml cultures, yielding up to 2.5 mg of plasmid) or Giga-Prep ™
(2.5 L of culture, yielding up to 10 mg of plasmid) columns were used. In all
cases buffers supplied with the Qiagen Endofree plasmid isolation kits were
used, and manufacturers instructions were followed. Plasmid was eluted into
endotoxin-free water.
Restriction endonuclease digestion
For analysis of recombinant plasmids, and generation of DNA fragments for
sub-cloning, restriction endonuclease cleavage was performed. For analytical
purposes assays were performed in 20 III volumes. For sub-cloning, where
purification of restricted product was required, 200 J.l1volumes were used. In all
cases restrictions were performed according to the enzyme manufacturers
guidelines. For 20 J.l1volume reactions 5 - 10 U of each enzyme was used in
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each reaction, together with the optimal buffer system (as per manufacturers
guidelines) and 5 Ilg of template plasmid. For larger volume digestions 40 - 100
U of each enzyme was used in each reaction. Restriction enzymes used include
BamH1, EcoR1, Hind111, Xho1, Xba1, Not1, and Sma1. All digestions required
incubation at 37°C in a water bath for 2 hours, denaturation of the enzyme by
heating to 80°C for 5 minutes. Fragments were analysed immediately by
agarose gel electrophoresis or used directly in sub-cloning procedures.
DNASequencing
Plasmid constructs selected based on their restriction profiles were sequenced
to confirm the sequence fidelity of the product insert. Briefly, 20 Ilg of plasmid
was sequenced by commercial sub-contracted service providers : Oswel
Sequencing laboratories (University of Southampton, Southampton, UK).
Sequencing of eukaryotic expression constructs was conducted starting from
the T7 primer site on the 5' strand, across the insert (each reaction provides
readable sequence for about 500 bp), and from the vector specific reverse
primer site on the 3' strand. Where necessary primer walking reactions were
employed to determine the sequence for the full length of the insert.
2.4: Determining expression of Brucella specific genes from
DNA vaccine constructs
Each DNA vaccine construction was assessed for the ability to express the
encoded Brucella gene. Since the DNA vaccine plasm ids can only express their
encoded products within eukaryotic cells, the plasmids were transfected into
Cos 7 cells for this analysis.
Transfection of Cos 7 cells
Transfections were performed using Lipofectamine-plus ™ reagent. The
transfection procedure was adapted from the manufacturers guidelines, for
73
optimal performance in a 12 well plate (cells grown on coverslips) format.
Briefly, endotoxin free plasmid DNA (purified by plasmid Giga--prep) was mixed
with the Lipofectamine ™ transfection agent in the presence of the Plus™
reagent. The mixture was incubated for 30 minutes at RT to allow formation of
DNAlLipofectamine complexes. Cell culture, in 12-well plates, at between 40 -
80% confluence was washed three times in serum and antibiotic free Modified
Eagles Media (MEM). After washing, each well was replenished with 0.4 ml of
serum and antibiotic free MEM to which 0.1 ml of the appropriate transfection
mixture or control solution was added. Plates were returned to the 37°C, 5%
C02 environment for 12 -18 hours, to promote uptake of the transfection
particles. After uptake (12-18 hours) media was supplemented with serum and
antibiotics, by the addition of 0.5 ml MEM, containing 20% Foetal Bovine Serum
and X2 Antibiotic Antimycotic solution (Stock solution: 10,000 U/ml Penicillin,
100 mg/ml Streptomycin, 25 mg/ml Amphotericin B). Cultures were then further
incubated at 37°C, 5% CO2 for between 24 to 72 hours depending upon the
assay to be performed.
Indirect immunofluoresence assay (lFA)
Detection of specific proteins produced from transfected cells was assessed by
indirect immunofluorescence assay. For the Omp25 DNA vaccines, the protein
was detected using specific monoclonal antibodies. Anti-Omp25 monoclonal
preparations were kindly donated by Prof Jean-Jacques Letesson, FUNDP,
Namur, Belgium. Specific antibodies were unavailable for the remainder of the
candidates, and therefore antiserum from B. melitensis infected ruminants (Anti-
Brucella) was used in this assessment.
At 72 hours post transfection cells were washed 3X with 0.1 M Phosphate
Buffered Saline (PBS), pH 7.6, prior to fixing for 30 seconds in ice cold (-20°C)
methanol. Cells were permeabilised by incubation in 0.01% Triton X-100 in 0.1
M PBS, pH 7.6, for 5 minutes at RT. Cells were then incubated with blocking
solution for 2 hours at RT. Blocking solution for the monoclonal antibody based
reactions consisted of 10% normal goat sera in 0.1 M PBS, pH 7.6. For the Anti-
Brucella sera reactions, blocking buffer comprised 10% normal rabbit sera in
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0.1 M PBS, pH 7.6. After blocking cells were rinsed briefly in PBS, and the
appropriate primary antibody solution (either AF59 (anti-Omp25 Mab) at 1: 500
diluted in 0.1 M PBS or anti-Brucella at 1: 200 in 0.1 M PBS} was added to the
cells and incubated for 1 hour at RT. Cells were washed 3 times by incubation
in 0.1 M PBS, pH 7.6 for 5 minutes each time, before application of an anti-
species Fluorecein Isothiocyanate (FITC) labelled secondary antibody. For
detection of the AF59 reaction Goat versus Anti-mouse Ig (whole molecule)
FITe conjugate (Sigma), at 1:500 dilution in 0.1 M PBS was used as the
detection antibody. For detection of the Anti-Brucella reaction Rabbit anti-Goat
Ig FITC conjugate (Sigma), at 1: 200 dilution in 0.1 M PBS was used.
Secondary antibody incubations were carried out at RT in the dark, for 1 hour.
Cells were washed, 3 times for 5 minutes as previously described, before
coverslips were removed from wells and mounted onto clean labelled glass
microscope slides (BOH), using the VectaShield mountant (VectaLabs,
California).
Fluorescence was observed with a Nikon Eclipse E400 Microscope, fitted with
u.v. light and filters for observance of FITC. Filters and conditions were adjusted
to minimise background for the untransfected and vector transfected samples
and maintained constant between each set of conditions.
2.5: The generation and preparation of DNA vaccines for in vivo
studies and the production Brucella specific protein antigens
Production and quality control of DNA vaccines for use in vivo
DNA vaccine preparations for assessment in vivo were prepared in-house or by
a commercial sub-contractor: PlasmidFactoryTM Inc. The method of production
used in each individual in vivo trial is indicated in each relevant chapter.
In-houseproduction of stocks of DNA vaccines
Large-scale in-house preparation of DNA vaccines was achieved using
Qiagen TM Giga-Prep and Mega-Prep Endo-Free ™ kits. These procedures are
described in section 2.3. Individual preparations of each vaccine were pooled as
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batches, to ensure uniformity of sample throughout each in vivo study. Each
batch was stored in appropriate volume aliquots at -20°C.
Commercial production of DNA vaccine stocks by PlasmidFactory
Twenty mg each of the plasm ids encoding omp25 (pCR3.1-omp25 and
pTargeT-omp25), p-ialB plasmids and pcDNA3.1 plasmids were prepared under
sub contract by Plasmid FactoryTM GmbH & Co. KG. (Bielefeld, Germany).
Plasmids were prepared to GMP standards, and were certified as greater than
99% closed circular supercoiled (CCC) formation, and virtually endotoxin free.
Plasmids were supplied at 1 mg/ml and 2 mg/ml concentrations in 0.1M PBS
and stored in appropriate volume aliquots (200 or 600 III per tube) at -80°C until
required.
Quality control of DNA vaccines
An aliquot of each batch of DNA vaccine was analysed by restriction
endonuclease cleavage, and sequencing as described in section 2.3, in order to
confirm identity prior to use in vivo. Additionally, the expression capability of the
encoded gene from each batch of DNA vaccine was confirmed by detection of
the presence of specific gene transcripts through RT -PCR performed on RNA
template isolated from speCifically transfected Cos 7 cells. This procedure was
performed as described in section 2.2.
The presence and quantity of endotoxin (E. coli LPS) was determined from
each batch of DNA using the Limulus Amoebacyte Lysate (LAL) test: E-
Toxate TM,and the pyrochrome test.
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Production of protein antigens
Production of specific protein antigens for the selected vaccine
candidates
Purification of recombinant Omp25-GST or Invasion protein 8 (laI8), for use in
ELISA and cell mediated immunology applications were outsourced to a
commercial protein production facility (Lionex GmBH, Braunschweig, Germany).
Crude specific recombinant protein Iysates for use in ELISA or western blotting
applications were produced in house and are illustrated in appendix 2.
B. melitensis 16M antigen
B. melitensis 16M antigen for use in immunology procedures was produced
from solid phase cultures grown on SDA as previously described. Cultures were
harvested after 4 days growth, and cells were washed twice by centrifugation
(4000 rcf, for 10 minutes at 4°C) and resuspended in a minimal volume of sterile
water. The preparation was rendered non-viable through heating to 80°C in a
water bath for 90 minutes. The sterility of the preparation was confirmed
through culture as described previously.
Brucellergene TM antigen
Brucellergene TM, a commercial preparation of cytosolic protein antigens from
the B. melitensis B115 strain, was used in these studies. The cytotoxic
preservative merthiolate was removed from Brucellergene ™ samples by
dialysis against 0.1 M PBS at 4°C overnight using 10 kDa cut off dialysis
cassettes (Pierce, UK). The content of Bruceliergene™ was checked by SDS-
PAGE before and after dialysis to confirm that protein components were not lost
during dialysis. Dialysis was able to abrogate the toxicity of Brucellergene ™
when applied to cultured mouse splenocytes. Dialysed Brucellergene ™ was
aliquoted and stored at -80°C until required.
Estimation of protein concentration
The concentration of total protein in each sample was estimated using the
Bicinchoninic Acid Micro and Standard Assay (BCA). The assays were
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performed according to manufacturers instructions, using a series of bovine
serum albumen (BSA) dilutions to generate a standard protein concentration
curve against which to compare test samples.
SOS-PAGE techniques
Protein electrophoresis was performed using Lamelli SOS-PAGE procedures,
with either the Bio-Rad Protean II mini-gel system with in-house produced
acrylamide gels, or the Pharmacia Multiphor Flat-bed electrophoresis system
using Excel-Gel™ pre-prepared commercially available gels.
SOS-PAGE mini-gels were set up using the Bio-Rad Protean II mini-gel
apparatus, with 1 mm gel spacers and 1 mm thick combs. Each gel was
prepared as a 12.5% bis-acrylamide, 1.5 M Tris-HCI (pH 8.0) separating gel and
5% bis-acrylamide, 0.5 M Tris-HCI (pH 6.0) stacking gel. Alternatively 12.5%
homogenous Excel-gels ™ (Amersham) were used.
For comparison and estimation of approximate molecular weight, See-Blue-2
protein molecular weight marker (Invitrogen) or Rainbow marker (Amersham)
was used. Between 5 and 10 J,llwas used in a single well.
Samples were prepared for electrophoresis by a 1:1 dilution of required
concentration sample in SOS-PAGE sample buffer, and heating to 80°C for 20
minutes. The total quantity of sample loaded into a single sample well on a gel
was between 1 J,lgand 20 J,lgdepending upon the application.
Electrophoresis using the Protean II system was conducted at 200 V (constant
voltage, variable current), for 25 - 45 minutes. The reaction was stopped at the
point when the dye front began to run off the end of the gel. Electrophoresis
using the Pharmacia Multiphor Flat-Bed system was performed at 600 V I 50
mA for approximately 80 minutes. The procedure was stopped as soon as the
dye-front reached the anodic buffer strip.
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Silver staining of Protean II and Multiphor II 50S-PAGE gels for
visualisation of protein.
Silver staining for detection of total protein within SDS-PAGE gels was
performed using the Amersham Pharmacia Biotech Protein Silver staining kit,
according to manufacturers recommendations. Briefly, gels were removed from
SDS-PAGE apparatus and in the case of the Multiphor Excel Gel system, rinsed
free of mineral oil in sterile distilled water. Gels were incubated in silver stain
fixative (40% methanol, 10% acetic acid solution) for a minimum of 1 hour at
room temperature (RT) with gentle agitation (rotary shaker at 30 rpm). Gels
were rinsed briefly, and then incubated in sensitiser solution for 30 minutes at
RT, shaking at 30 rpm. Sensitiser solution was decanted and gels were washed
3 X 10 minutes in sterile distilled water. Silver staining solution (10% silver
nitrate solution, 0.01% formaldehyde) was incubated with the gel for 25
minutes, 30 rpm, RT. Gels were rinsed first in sterile distilled water and then in
developer solution. The development of bands was observed and judged by
eye. When reaction was judged complete the gel was rinsed with sterile distilled
water before incubating in a stopper solution (5% EDTA) for 1 hour. Gel pictures
were recorded by scanning.
Coomassie Blue staining of Protean II and Multiphor II 50S-PAGE
gels for visualisation of proteins
Bio-Rad Simply Blue Safe Stain Coomassie stain was used to stain gels for the
visualisation of total protein load. Gels were rinsed in sterile water before
incubation in the stain at RT for 2 - 18 hours. The gel was then repeatedly
rinsed in sterile distilled water until the optimal staining effect was obtained. Gel
pictures were recorded through scanning.
Electrophoretic transfer of protein from Protean II SOS-PAGEgels to
nitrocellulose membrane
On completion of electrophoresis gels were placed immediately into a tray of X
1 CAPS (3-(cyclohexylamino)-1-propane sulphonic acid» solution (10 mM
CAPS, 10% methanol, pH 11.0) and incubated on a shaker platform for at least
15 minutes. CAPS pre-soaked blotting paper, cellulose sponges and 0.45 ~M
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Nitrocellulose membrane (Bio-Rad, UK), were assembled together with the gel
for electrophoretic transfer using the Mini Protean II blotting tank. Blotting
cassettes were submerged in X1 CAPS solution within the gel tanks. A sealed
ice block was added to the tank to assist with cooling during the reaction.
Current was applied at 200 mA (constant current, variable voltage) for 75
minutes.
Following transfer. membranes were removed from the apparatus and trimmed
to remove molecular weight markers. The main membrane was placed in
blocking buffer (4% dried skimmed milk powder (MarveI™). in TBS) for between
1 to 2 hours at RT. or overnight at 4°C, on a rocking platform. Following
blocking, membranes were either used immediately or washed 2 X for 5
minutes, with TBS-Tw wash buffer, and dried between clean blotting paper
before storing at -20°C until required.
2.6 Vaccination procedures
All in vivo investigations of vaccine immunogenicity and protective efficacy were
performed using a murine model.
Mice used in the study
Female BALB/c mice were sourced from Charles River, UK., and age six to
eight weeks old upon receipt at VLA. The mice were allowed time to acclimatise
prior to commencing the study. Mice were approximately eight to ten weeks old
at the time of the first procedure. Mice were housed within standard cages, in
groups of ten or less, and given standard unmedicated diet and water ad
libitum. Environmental enrichment was permitted.
Mice vaccinated or challenged with viable Brucella were housed in cages
maintained within flexible film isolators at containment level III.
Vaccinations
Mice were not anaesthetised for vaccination. B. melitensis Rev.1 vaccine was
delivered to mice as a single sub-cutaneous (sIc) inoculation of approximately 2
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X 105 CFU per mouse, into the scruff of the neck. B.melitensis 16M challenge
was delivered as a single intra-peritoneal (i/p) inoculation. Procedures were
performed within a class I microbiological safety cabinet. 27G X 1Y2fixed needle
tuberculin syringes were used to deliver the inoculation. A 100 ~I inoculation
volume was used.
For DNA vaccines, vector control, liposome-DNA, and PBS sham control,
inoculations were performed intramuscularly (ilm), into the hind quadriceps
muscles of the mice. For ilm delivery 27G X 1 % fixed needle tuberculin
syringes were sheathed with polyvinyl tubing (internal diameter 0.56 mm), to
control the depth of muscle penetration and ensure ilm delivery. At each
inoculation time mice received 50 ~I of inocula in each hind quadriceps muscle.
Liposome production and complexing with DNA
Liposomes were prepared and donated to this study by Dr J. Brewer
(Department of Immunology and Immunopathology, Western Infirmary,
Glasgow). Lipid vesicles were prepared from 1-monopalmitoyl glycerol,
cholesterol stearyl amine and cetyl trimethyl ammonium bromide (CTAB) in the
molar ratio 5:4:1:1, by the methods described previously (Brewer, 1998).
Plasmids were surface adsorbed to cationic lipid vesicles immediately prior to
administration. Briefly, 2 ml plasmid DNA at 1 mg/ml was added dropwise to an
equal volume of liposome preparation. Liposome: plasmid mixture was
incubated for 30 minutes at RT using a Denley Rotary Cell Mixer, and then
centrifuged at 2000 rcf (Hereaus Microfuge) to sediment the liposomes. 2 ml of
SN was removed. Remaining plasmid: Iiposome suspension was mixed gently
and used within 1 hour for the inoculation of mice. The 2 ml SN sample was
retrospectively assessed for the presence of residual DNA by
spectrophotometry and agarose gel electrophoresis.
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Immunological sampling
Serum was obtained from mice by venous puncture of the tail vein.
Mice were sacrificed by cervical dislocation, spleens excised aseptically.
Spleens were placed into sterile fluid: PBS, DMEM, or FF depending on the
intended use.
2.7 Immunoassay procedures
A number of immunoassays were developed for use in this study. Optimised
procedures are described in this chapter.
2.7.1: Serological assay procedures
ELiSAs were developed for measurement of vaccine induced antibody
responses from the test groups of BALB/c mice, and also from experimentally
infected sheep and goats.
Collection and processing of serum samples from mice
Blood samples were collected from individual vaccinated and infected mice at
various times for assessment of specific serological responses. Blood was
collected following venous puncture of the tail. Each sample was incubated at
RT for 2 - 4 hours and 4°C overnight, before centrifugation at 3000 rpm
(Hereaus Biofuge Fresco) for 30 minutes. The serum was transferred to a fresh
labelled eppendorf tube and incubated at 56°C for 30 minutes to inactivate
complement. The total volume of serum collected from an individual mouse at
any time during these studies ranged between 10 and 80 ~Iof serum. Samples
were stored frozen at -20°C until required.
10ul of serum from each individual mouse in a group were combined to provide
the pooled samples. Pooled samples were also stored at -20°C.
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B. melitensis 16M whole antigen ELISA for detection of Brucella
specific antibodies in mouse sera.
This ELISA was developed and optimised in-house (data not shown).
16M antigen was prepared as described in section 2.5, and coated to
Maxisorp 1M 96 well plates (Nunc). Antigen was diluted to 50 Ilg/ml in Carbonate
Coating Buffer (CCB): 0.034 mM Sodium hydrogen carbonate, 0.016 mM
sodium carbonate, pH 11.0, and applied to plates at 50 III per well. Plates were
incubated at 4°C overnight. Plates were washed twice with PBS-T wash buffer
and 200 III per well of blocking solution (4% skimmed milk powder (Marvel) in
PBS-EDTA buffer) was added to the plates, which were incubated at RT for ~ 2
hours. Test sera and the selected control samples were prepared for analysis
by dilution 1% marvel PBS-EDTA diluent buffer. Normal mouse sera (Sigma)
was used as a negative control in these ELiSAs. Positive control serum was
obtained from mice that had been infected with B. melitensis 16M in previous
research projects at VLA Weybridge. The serum was collected from 10 B.
melitensis 16M infected mice at day 84 post-infection and pooled for use as a
positive control.
After blocking, plates were washed once in PBS-T wash buffer and the test
serum dilutions and controls applied to the plate. Each individual dilution I
sample was plated into sufficient wells (50 III per well) to permit assay of
relevant isotype specific responses in duplicate. Plates were incubated at 37°C
for 90 ± 10 minutes. Plates were then washed five times with PBS-To Isotype
specific anti-mouse 19 enzyme conjugated reagents were used as detection
antibodies. Rat anti-mouse IgM (Il chain specific) peroxidase conjugated
antibody at 1 in 2000 in diluent buffer, Goat anti-mouse IgG1 peroxidase
conjugated antibody (STAR81P, Serotec) at 1 in 1000 in diluent buffer, and
Goat anti-mouse IgG2a peroxidase conjugated antibody (STAR82P, Serotec) at
1 in 1000 in diluent buffer were used. These antibody solutions were applied in
50 III per well volumes and incubated at 37°C for 1 hour. Plates were washed 5
times with PBS-T and blotted dry onto absorbent matting. TMB (3'3'5'5'
Tetramethylbenzidine) working solution was prepared from the stabilised
Substrate and Chromogen solutions (Vetoquinol) and added to the plates (100
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~I per well). Plates were incubated for 10 - 30 minutes in the dark for reaction
development. Reaction development was judged by eye, and when the IgG2a
positive control wells had achieved sufficient intensity of colour, the reaction
was stopped by the addition of 100 ~I per well of 0.1 M Citric acid solution.
Plates were read within 1 hour of reaction completion using a Titertek Multiscan
II to determine optical density at 450 nm.
OMP25-GST and GST ELISAs, for the detection of OMP25 specific
antibodies in mouse sera.
This procedure is essentially identical to that of the 16M antigen ELISA, except
for the initial antigen coating stages. In this ELISA recombinant fusion protein
Omp25-GST prepared from the pGEX-omp25 construct and purified under
contract by Lionex GmBH., was used as the antigen. Antigen was prepared in
Coating buffer to a concentration of 5 ~g/ml (or 0.5 ~g I well) and incubated at
4QC overnight for the initial coating step. The rest of the procedure was
performed identically to the 16M ELISA.
Recombinant lalB ELISA for the detection of lalB specific antibodies
in mouse sera.
This procedure is essentially identical to that of the 16M antigen ELISA, except
for the initial antigen coating stages. In this ELISA recombinant fusion protein
lalB prepared from the pGEX-laIB construct and purified under contract by
Lionex GmBH., was used as the antigen. Antigen was prepared in Coating
buffer to a concentration of 15 ~g/ml (or 1.5 ~glwell) and incubated at 4QC
overnight for the initial coating step. The rest of the procedure was performed
identically to the 16M ELISA.
SAT, iELISA and cELISA
Serodiagnostic assays routinely used in the Laboratory Testing Division (LTO),
and the brucellosis reference facility of VLA Weybridge, (serum agglutination
tests (SAT), indirect ELISA (iELlSA) and competition ELISA (cELlSA)) were
used in these studies. For use with sheep or goat samples these techniques
were performed by the staff of the Brucella reference laboratory at VLA
Weybridge according to UKAS accredited standard operating procedures.
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Brucella diagnostic serum agglutination tests (SAT), and competition ELISA
(cELlSA) were occasionally performed on pooled sera from groups of mice. In
these instances the serum was used at the maximum possible concentration
(Generally approximately 1 in 50). Again, standard referenced procedures were
followed.
Brucellergene TM ELISA for the detection of Brucella specific
antibodies in sheep or goat sera
An ELISA was developed in-house to assess the reactivity of serum samples
from Brucella infected sheep and goats against protein antigens of Brucella.
Brucellergene TM, which is free from the serodominant LPS of smooth Brucella
sp., was used in these studies was coated to Maxisorp plates at a concentration
of 45 ,....gI ml or 2.25 ,....gper well in CCB. Plates were incubated overnight at
4°C. The assay was essentially identical to that described for assessment of
mice samples with whole Brucella 16M antigens, except that test serum was
diluted 1 in 200 in diluent buffer for analysis, and identification of separate
isotype antibody responses was not performed. An Anti-sheep IgG Horse
Radish Peroxidase conjugate was used at a dilution of 1 in 4000 in diluent
buffer.
OMP25-GSTand GST ELISAs, for the detection of OMP25 specific
antibodies in sheep or goat sera.
ELISA plates were coated as described for the analysis of mice samples. The
assay was performed identically to that described for analysis of sheep and
goat samples in the Brucellergene TM antigen ELISA.
Invasion protein B specific ELISA for the detection of Invasion
protein B specific antibodies In sheep or goat sera.
ELISA plates were coated as described for the analysis of mice samples. The
assay was performed identically to that described for analysis of sheep and
goat samples in the Brucellergene TM antigen ELISA.
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Crude lysate ELiSAs to determine reactivity of sheep and goat
serum against recombinant Omp25, lalB, FrpB, AcvB and FIiC
antigens.
Purified recombinant preparations of the candidate vaccine proteins AcvB, FrpB
and FliC were unavailable for use in this study. Therefore, ELiSAs were
developed using crude lysate antigens from recombinant E. coli cultures
expressing these proteins.
Expression of the proteins was induced through optimised procedures (see
appendix 1) and confirmed through 50S-PAGE and where possible western
blotting against a sera reactive to the fusion moiety of the expressed protein.
Total protein concentration of Iysates was determined by BCA protein analysis
methods.
Crude lysate was coated to polysorp plates at 50 J,lgl ml overnight at 4°C, prior
to blocking. The blocking step utilised the standard blocking buffer (4% marvel
in PBS-EDT A) supplemented with rabbit anti-E. coli immunoglobulins
(DakoCytomation, Denmark). The anti-E. coli serum was diluted 1 in 4000 in
blocking buffer. The blocking stage was incubated at 25°C for 2 hours. Test
sera (from sheep and goats) was added to the plates diluted 1 in 200 in diluent
buffer and incubated for 1 hour at 37°C. Plates were washed six times with
washing buffer prior to the application of the anti-sheep IgG HRP conjugate.
The rest of the reaction was performed as described for the Brucellergene ™
ELISA.
2.7.2: Cell mediated immunology
In addition to the measurement of antibodies, the cell mediated immune
responses of vaccinated and infected BALB/c mice were also investigated. For
these assessments mouse splenocytes were isolated and fractionated.
Cytokine production in response to Brucella specific in-vitro stimulation was
measured using commercially available cytokine ELiSAs from Biosource and in
house optimised EllSPOT procedures.
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Spleen harvest and isolation of splenocytes for CMI investigations
Mice were sacrificed by cervical dislocation and spleens were aseptically
removed. Spleens were placed immediately in pre-warmed (3rC) oMEM
complete media (OMEM + Non essential amino acids, 1,000 U/ml penicillin, 100
Ilg/ml streptomycin, 25 Ilg/ml amphotericin B, and 10% foetal bovine serum), in
order to preserve viability. Spleens were diced using sterile surgical scissors
and macerated with the barrel of a 5 ml Syringe through a 80 11Mmesh cell
sieve to release splenocytes into the media. Splenocyte suspensions were
washed twice in FACSflow Sheath Fluid Buffer [FF] by centrifugation at 330 rcf
(Hereaus MegaFuge) for 15 minutes at 4°C, and resuspended in a minimal
volume (S 1ml) of FF buffer Viable cells were enumerated after suspension of
50 III of cell suspension in 450 III of white cell counting fluid (1% glacial acetic
acid in D-PBS, with a trace of Gentian violet dye), using the Neubauer
Haemocytometer. Cells were reconstituted to 5 X 106 I ml in oMEM complete
for stimulation for ELISA or ELISPOT reactions or used in T cell subset
depletion studies according to the protocol described below.
T cell sub-set depletion procedures
MidiMACSTM(Miltenyi Biotech) technology was used for the depletion of T cell
subsets from the whole splenocyte preparations. Anti-mouse CD4+ (L3T4)
magnetic beads were used to bind CD4+ expressing cells, and Anti-mouse
C08+ (Ly-2) magnetic beads were used to bind CD8+ expressing cells from the
total splenocyte population. Cell concentrations were adjusted to a total of 1 X
109 I ml by dilution in FF buffer and 100 III of bead suspension was added to
each 1 ml of cell suspension. Magnetic beads and cells were incubated on ice
for 30 minutes with occasional gentle mixing. MACS LS columns were
equilibrated with 3 ml of ice cold FF Buffer, and positioned within the
MidiMACSTMmagnets. Bead treated cell suspensions were applied to the LS
columns and the fall through fraction collected in a sterile Falcon Tube over ice.
Columns were washed through with 3 X 3 rnl of ice cold FF. Again the eluted
fraction was collected. Total eluate was diluted in ice cold FF and washed by
centrifugation (300 ref, 15 minutes, 4°C, (Hereaus MegaFuge», and
resuspended in a minimal volume of ice cold FF. Cells were enumerated and
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diluted to a final concentration of 5 x 106 I ml in DMEM Complete for use in
stimulation assays.
Stimulation of splenocytes with specific antigens
Antigens and control mitogen solutions were prepared to appropriate
concentrations in DMEM Complete media. The lectin Concanavalin A Type IV
purified (Con A) was used as the non-specific mitogen throughout the study;
Con A was prepared in DMEM complete to a concentration of 10 ~g/ml. Specific
antigens were prepared to the following concentrations, Brucellergene TM: 80
~g/ml, Recombinant OMP25-GST: 20 ~g/ml, Recombinant GST: 20 ~g/ml.
Recombinant Invasion protein B: 30 ~g/ml. Heat killed Brucella melitensis 16M
antigen: SO Ilg/ml. Antigen preparations were added to designated wells in
either 96 well pre-coated IFN-y ELiSPOT plates (100 III volumes per well), or
sterile 24 well tissue culture plates (SaO III volumes per well). An equivalent
volume of cells at a concentration S X 106 Iml were added directly to the
appropriate wells containing antigen. Thus, wells contained cells at a final
concentration of 2.5 X 106 Iml in either DMEM complete or a DMEM complete
solution of S Ilg/ml Con A, 40 Ilg/ml Brucellergene TM, 10 Ilg/ml OMP25-GST, 10
f.1g/mlGST or 15 Ilg/ml Invasion protein B. Stimulation cultures were incubated
at 37°C, S%C02 for either 24 (ELISPOT) or 48 (SN ELISA) hours.
IFN-y EllS POT
For ELiSPOT assays 96-well PVDF membrane filter plates were pre-coated
with 1.S J.lg/mlwell of anti-mouse IFN-y monoclonal (AN18) 18 to 24 hours prior
to harvest of splenocytes. On the day of splenocyte harvest plates were washed
2 X with PBS and blocked with 200 J.l1per well with DMEM Complete medium
for 2 - 4 hours at 37°C prior to addition of cells. Splenocytes were harvested
and stimulated as described above. The EllSPOT plates I stimulation cultures
were incubated for 24 ± 2 hours, loosely wrapped in aluminium foil, at 37°C in a
5% C02 atmosphere incubator. Following incubation cells were aspirated from
the filter plates using a multichannel pipette, and taking care not to damage the
membrane. Plates were washed 4 X with PBS-T wash buffer, and blotted dry
after the final wash. Anti-Mouse IFN-y biotinylated antibody was prepared to a
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concentration of 1 J.lg/ml in ELiSPOT diluent Buffer (1% BSA in PBS), and 100
J.l1per well was applied to the plates. Plates were incubated at 25°C for 1 hour
wrapped loosely in aluminium foil. Following incubation plates were washed 4 X
with PBS-T wash buffer, and blotted dry after the final wash. Streptavidin
Alkaline Phosphatase reagent was diluted 1: 1000 in ELiSPOT diluent buffer
and 100 J.l1per well added to the plates. This stage was incubated at 25°C,
plates wrapped loosely in foil, for 1 hour. After incubation plates were washed 4
X with PBS-T wash buffer and 2 X with distilled water, and blotted dry onto
absorbent towelling. BCIP-NBT fast tabs™ were used to prepare the substrate
solution. 1 tablet was dissolved in 10 ml of pre-warmed distilled water, and
filtered through a 0.2 J.lMsyringe filter prior to use. Substrate solution was
applied to wells at 100 J.l1per well, and plates were incubated in the dark at
25°C for between 10 to 30 minutes. Reactions were halted once the colour
development in the Con A stimulated sample wells was considered to be
complete. Rinsing the plates at least twice in distilled water stopped reactions.
The under drain section of the plate was then removed and the plates incubated
at 37°C overnight in order to dry the filters.
Since these assays involved splenocytes isolated from 16M or Rev.1 infected
mice, the splenocyte cultures were potentially infected with live Brucella spp.,
and procedures had to be conducted in a containment level III facility. Plates
were fumigated (using standard formaldehyde fumigation procedures validated
for use against Brucella spp.), before being removed from the facility for
reading. Plates were read using an AID ELiSPOT plate reader.
Measurement of SN cytokine concentration by ELISA
For ELISA work, stimulations were performed as described above using 1 ml
total volumes per reaction (500 III of antigen preparation and 500 III of cells) in
24-well plates. Plates were wrapped loosely in foil and incubated at 37°C, 5%
C02. After 72 hours incubation, the plates were centrifuged to sediment cells
and the SN dispensed in 200 J.l1aliquots into sterile 96 well plates. These
samples were treated with sodium azide (addition to SN to final concentration
1%) in order to kill Brucella and frozen at -SO°C until required for use in ELISA.
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Commercially available cytokine detection ELISA reagents were used to
measure the presence of the cytokines IL-4, TNF-a. IL-12 and IFN-y in the SNs
harvested from stimulated splenocytes. ELiSAs were conducted according to
manufacturers recommendations.
Samples were defrosted and applied to appropriate wells of the test plate.
Recombinant mouse cytokines supplied with the kits were prepared in diluent
buffer to generate a standard curve for quantitative analysis of the results. A
series of these 'standards' were included in each assay. Cytokine concentration
[pg/ml] in SNs was calculated through non-linear regression using GraphPad™
Prizm software, to generate a curve of the known concentrations [pg/ml] plotted
against the 0.0. values of the standards. The concentration of cytokine in each
unknown sample was interpolated from its 0.0. value. Where sample 0.0.5
were found to be out of range for the standard curve the sample was retested
following dilution in the appropriate standard diluent buffer.
For IFN-y and TNF-a analysis the SN from individual mouse splenocyte cultures
were analysed in ELISA. Each sample was tested in duplicate. For other
cytokines, SN was pooled for analysis, such that each sample consisted of the
combined SN of three mice from a single vaccine group stimulated with a single
antigen. Pooled samples were also tested in duplicate in the ELiSAs.
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Chapter 3: THE SELECTION OF CANDIDATE
GENES FOR VACCINE DEVELOPMENT
3.1: Summary
Five genes were identified from the B. melitensis 16M genome database as
potentially useful vaccine candidates. Selection was based primarily upon
assigned putative functions based on gene Similarity to related organisms. The
selected candidates were omp25 (BMEI 1249), ialB (BMEI 1584), frpB (BMEII
0105), flie (BMEII 0150) and acvS or virJ (SMEll 0681). With the exception of
omp25, these candidates had not previously been studied in Brucella spp.
Experiments were devised to demonstrate specific transcription of these target
antigens from in vitro cultured Brucella and Brucella isolated ex vivo from
infected BALBlc mice. Transcription from all targeted genes was determined in
material isolated from ex-vivo cultured Brucella, and transcription of omp25 and
ialB was verified in samples from in vitro cultured Brucella. These findings
provide evidence that these target genes are active during Brucella infection,
and thus imply that corresponding proteins may be generated under
physiologically relevant conditions. Such proteins are anticipated to be
accessible to the host immune response. The involvement of the proteins in the
generation of Brucella specific humoral immune responses was also
investigated. The presence of antibodies reactive to Brucella protein was
demonstrated using antisera from a panel of experimentally infected goats.
Together these data were used to demonstrate that each in silico selected
antigen is expressed during Brucella infection and to suggest their accessibility
to the host immune system, thus supporting their selection for investigation as
vaccine antigens.
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3.2: Introduction
Selection of candidate antigens
The development of defined non-living vaccines requires the identification of
protective antigens. The nature of protective immunity in brucellosis in natural
host species is poorly understood and consequently there has been little
definitive work to date on the identity of protective antigens. The recent
availability of the genome data for Brucella melitensis 16M (DelVecchio et ai,
2001), Brucella suis 1330 (Paulsen et ai, 2003), and Brucella abortus strains
(Sanchez et a', 2001., Hailing et ai, 2005), has dramatically improved the
process of antigen selection.
There are two important phases in the establishment of brucellosis that can be
targeted for vaccine development. Most obviously, intervention to prevent the
establishment of infection would prevent both disease in the individual exposed
animal and further transmission of the infectious agent. Vaccines promoting
immune responses against antigens of Brucella that are important in the initial
interaction have the potential to augment the destruction of Brucella, thereby
limiting the potential for development of disease. Generation of specific
antibodies to promote opsonic entry into macrophages, and to interfere with
initial host : Brucella interaction may reduce the ability of the Brucella to
establish infection. Furthermore, macrophage activation will increase bacterial
killing efficiency and the generation of antigen specific cytotoxic T cells will
promote clearance from infected cells. Direct experimental evidence for Brucella
specific invasion or adhesion-associated ligands is presently unavailable.
Although, this may be because these attributes have traditionally been difficult
to study.
The second important target for vaccination is the mechanism responsible for
Brucella survival and replication within the host cells. Targeting molecules
associated with the subversion of host phagosomes and establishment of the
intracellular replicative niche is anticipated to reduce the bacterial burden in the
host. Furthermore, promotion of cytotoxic immune responses against the
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antigens expressed at this stage of infection helps to eliminate established
infections.
Immune responses against antigens involved in both the initial host-Brucella
interaction and the maintenance of the intracellular infection are likely to be
required in an effective vaccine. In this study, the aim was to select some of the
proteins involved in these aspects of Brucella infection and target the immune
responses toward these effectors thereby hampering establishment of infection.
As a first step toward this aim five B. melitensis candidate antigens were
selected. Surface exposed antigens and putative secreted antigens were
sought as they were anticipated to have intimate contact with the host cells and
to be exposed to immune effectors.
Access to the B. melitensis 16M genome data enabled the candidate antigens
to be selected on the basis of predicted exposure of the protein to the host
immune system and the predicted involvement of the gene or protein product
with the establishment or maintenance of infection in the natural host. The
search facility of the WIT/ERGO genome database maintained at the University
of Scranton, Scranton, PA., USA, was used to identify candidates that had been
annotated to indicate relevant putative functions or qualities.
Information on the many candidates matching these criteria, and their nearest
homologues, was sought in the literature in order to provide supporting
evidence for their potential role as protective antigens. Candidates that had
been previously studied with relation to brucellosis immunity and vaccine
development were eliminated from the shortlist (with the exception of Omp25),
in order to give priority to novel antigens. Five candidates were chosen for
further study. These are summarised in table 3.1, and discussed in further detail
below.
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Table 3.1: A summary of the selected candidate antigens
Candidates implicated in the initial host-pathogen contact
omp25
SMEI1249
Predicted function: Invasion or adhesion associated
Predicted localisation: Secreted
Relevant homologues: Bartonella bacilliformis ialB, Rickettsia
prowesakii invB
ialS
SMEI1584
tlie
SMEll 0150
Predicted function: Invasion or adhesion associated
Predicted localisation: outer membrane
Relevant homologues: Mesorhizobium meliloti fliC,
Burkholderia cepacia FIiC.
Predicted function: Membrane structural protein. Highly
conserved in Brucella spp., Immunomodulatory properties
Observed location: outer membrane
Relevant homologues: Sinorhizibium meli/oti RopS, E. coli
OmpA
Candidates implicated in the maintenance and establishment of the
re licative niche
Predicted function: potential proteinaceous effector of the VirB
secretion system.
Predicted location: secreted
Relevant homologues: Agrobacterium tumefaciens acvB
virJ / aevS
BMEII 0681
trpS
BMEII 0105
Predicted function: involved in iron transport, acquisition,
metabolism
Predicted location: Outer membrane
Relevant homologues: Neisseria gonhorr9ae, Neisseria
meningitidis frpS
omp25
Of the five selected genes, only Brucella omp25 has been previously
investigated or characterised. The outer membrane proteins (amps) of Brucella
have been extensively studied (Cloeckaert, et a/1996, Bowden, et aI, 2000), to
elucidate their role in Brucella pathogenesis and protective immunity. The major
amps of Brucella were first identified in the SOS-I insoluble fraction of the cell
wall, and noted to have protective activity in the mouse model (Dubray and
Bezard 1992). The Group 2 amps (omp2a and omp2b) have received much
attention recently due to their relative genetic diversity which can be exploited
94
as typing tools or aids to strain identification (Cloeckaert et ai, 1995). In
contrast, the group 3 Omps consisting of the 25 kDa Omp (Omp25) and the 31
kOa Omp (Omp31), are relatively well conserved, sharing 34% sequence
identity to each other and 43% similarity to the Rop8 protein of Rhizobium
leguminosarum, another member of the a-2 proteobacteria (Cloeckaert, A., et
ai, 1999). However, the 31 kOa protein is underrepresented in B. abortus strains
due to a short deletion at the N terminus, which has bearing on the
development of conformational B cell epitopes, and may restrict it's value as a
potential vaccine candidate.
The 25 kOa Omp is the most conserved Omp across the known species of
Brucella, making it a good candidate as a vaccine for protection against
challenge with all currently recognised brucellae. A number of studies have
indicated Omp25 to have potential as a sub-unit vaccine, especially for
protection against challenge with rough strains of Brucella. Passive transfer
studies using monoclonal antibodies generated against hot saline extract
(containing LPS and Omps) of B. ovis, found the antibodies able to confer
protection against ram epididymitis caused by B. ovis infection (Bowden et ai,
1995). Identification of the Omps in the hot saline extract led to the cloning of
the omp25 gene and evaluation of an Omp25 expressing E. coli as a vaccine
candidate (Bowden et aI, 1998). As a vaccine, E. coli expressing Omp25, was
able to protect mice against challenge with rough strains of Brucella but gave
only limited protection against smooth strains. The variability of protection has
been attributed to the variation in accessibility of the Omps between the smooth
and rough strains: close association of Omp25 and LPS acts to stearically
hinder binding of anti-Omp25 antibodies on smooth Brucella. This implies a
limited range of protective activity for the Omp25 sub-unit vaccines, although
the generation of cell mediated immunity against Omp25 has yet to be studied
in detail and may not be as susceptible to stearic hindrance.
More recently, Omp25 has been implicated as an important virulence factor in
the pathogenesis of human brucellosis. B. suis Omp25 has been shown to
inhibit the production of TNF-a by stimulated human macrophages (Jubier-
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Maurin et aI, 2001), indicating a possible mechanism by which Brucella delays
or modulates the host inflammatory response thereby promoting the
establishment of infection. Blocking experiments using specific anti-Omp25 to
counteract the inhibition of TNF-(l indicate that the generation of appropriate
immune responses against Omp25 might be a valid component of a vaccine.
Investigation of B. melitensis omp25 deletion mutant, BM25, has indicated
reduced virulence in vitro (macrophage survival) and in vivo (decreased
persistence in the mouse model, and lack of abortogenicity in the goat)
compared to the wild type (Wf). When used as a vaccine BM25 was able to
generate protection equivalent to the recommended Rev1 vaccine, but with
advantages of reduced potential for causing abortion or shedding to the
environment (Edmonds, et a/2001, 2002a and b). Furthermore, mutant Brucella
defective in the BvrR/BvrS two component regulatory systems are reduced in
virulence and are known to be deficient in Omp25 expression (Guzman-Verri et
ai, 2001). Whilst BM25 and BvrR/BvrS studies do not support a role for Omp25
specific effectors in protective immunity, these studies indicate that Omp25 is
important in Brucella pathogenesis and is surface exposed. Other studies have
also shown that Omp25 is released from Brucella in blebs (Gamazo et ai,
1989), thus making it accessible for interaction with the immune system.
Together these data indicate that Omp25 is worth investigation as DNA vaccine
candidate.
lalS
The genome database was searched for proteins associated with 'adhesion' or
'invasion' and a number of potential ORFs were indicated which displayed
homology to functional proteins in related organisms. Among the ORFs in the
Brucella genome were genes designated 'Invasion proteins A and B'. These
genes share identity with genes in the pathogen Bartonella bacilliformis, the
causative agent of a haemolytic anaemia known as Oroya fever. These genes,
ialA and ialB, from Bartonella were shown to confer the invasive phenotype to a
non-invasive E. coli strain and increase the adhesion of the recombinant E. coli
to the host cells (Mitchell and Minnick 1995). The Bartonella baciJIiformis
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homologue of ialB has been shown to be essential for the invasion of host
erythrocytes. Isogenic deletion mutants (LliaiB) of B. bacilliformis are defective
in erythrocyte invasion. Similarity with ORFs located in the genome of Rickettsia
prowesakii (invA) (Andersson et aI, 1998) has also been indicated. These genes
remain unstudied in Brucella and their role in establishment of infection has yet
to be determined. Their inclusion in this project as potential vaccine candidates
may provide additional insight into their role in Brucella pathogenesis. If their
hypothesised role in invasion is correct, the generation of immune responses
capable of blocking the invasion protein may contribute the control of disease
through preventing establishment of infection. Therefore these genes are logical
choices for investigation as vaccine candidates.
fliC
Flagellae are well-known surface exposed antigens and virulence factors
involved in the initial host-pathogen interaction in other diseases. It was
recently demonstrated that the B. melitensis genome contains sequences
corresponding to flagella apparatus in other species. Since all known species of
Brucella are non-motile organisms, the inclusion in the genome of all the
elements required to produce functional flagella seems somewhat anomalous.
In other non-motile organisms similar flagellin homologues have been described
forming part of a type III secretion system (TISS). Indeed, TTS systems are
important in the pathogenicity of a number of bacteria including intracellular
pathogens such as Chlamydia spp., and the surface expressed or secreted
portions of these systems may serve as interesting vaccine candidates. The
flagella associated genes present in the Brucella genome, indicate three
flagellar loci, comprising 28 structural genes, but do not comprise a complete
TTSS (DelVecchio et aI, 2002, Letesson et aI, 2003). The gene and predicted
protein sequence similarities with related pathogens are greatest with the TTSS
of Rhizobium spp., which are implicated in the symbiotic interaction between the
bacteria and the host plant cells (Viprey et ai, 1998). Recent reports have also
indicated sequence similarities between the Brucella flagella and TTSS of
Burkholderia cepacia, which has been implicated in this organism's ability to
penetrate host epithelial barriers and thereby establish infection (Tomich et aI,
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2002). At the time of selection expression of flagellin associated genes in
Brucella had yet to be conclusively demonstrated, but their presence in the
genome was enigmatic and warranted further investigation. As explained
previously, it is possible that interference in the host pathogen interaction
through the generation of immune responses to inhibit or neutralise the
components involved in the interaction, would be a positive contribution to
vaccine development.
Thus, the candidates omp25, ialB and flie were selected for investigation based
on their anticipated surface location or secretion from the bacteria and their
hypothesised role in the initial host pathogen interaction. In particular targeting
putative ligands that participate in Brucella and host cell binding and possibly
influence the uptake or outcome of the phagocytic process.
As well as targeting host cell binding, factors involved with the modulation of the
host cell to create a bacteria favourable replicative niche were also pursued.
virJ
One of the mechanisms contributing to trafficking to the replicative niche is the
Type IV Secretion System (TFSS) of the Brucella virB operon (O'Caliaghan et
al,. 1999, Boschiroli et aI, 2002). The Brucella virB system is homologous to the
archetypal virB system of the plant pathogen Agrobacterium tumefaciens. In A.
tumefaciens the virB system is responsible for the transfer of T-DNA from
across the bacterial cell wall into the host cell. The T-DNA integrates into the
host chromosome and directs the production of phytohormones responsible for
plant cell proliferation, and the generation of opines which are essential
nutrients for the bacteria. Thus the virB system allows the bacteria to subvert
the host cells natural processes and create a niche acceptable for the growth of
the bacteria. In Brucella virB is believed to function in a similar manner, but
through the delivery of proteinaceous effector molecules rather than DNA, in
order to manipulate the environment of the host phagosome to create a suitable
niche for replication. These effector molecules have yet to be identified. VirB
mutants have been shown to be defective in their ability to survive within
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macrophage culture (Comerci et ai, 2001.), and exhibit much reduced virulence
(determined by persistence) in the mouse model (Hong et ai, 2000). VirB
appears to be activated by the stimulus encountered within the host
phagosomes, including vacuole acidification, but does not appear to be involved
in the initial interaction of host and bacteria and is therefore not involved in
invasion or adhesion (Boschiroli et ai, 2002).
The original B. melitensis 16M genome data revealed the presence of a virB-
associated gene with significant homology to the acvB gene of A. tumefaciens.
The gene was named acvB in the original WIT/ERGO database but is now
listed as virJ in the Entrez database (BMEII 0681). The acvB homologue in A.
tumefaciens has been identified as an exported protein effector molecule with
relevance to the tumorigenesis process (Kalogeraki and Winans 1995). The
presence or relevance of acvB as an effector molecule in Brucella infections
has yet to be determined. However, in the event that acvB is utilised for similar
purposes by Brucella it would seem logical that generation of immune
responses capable of blocking the action of acvB (virJ), would impair the ability
of Brucella to control it's environment and create a replicative niche. This
possibility indicates the acvB (virJ) gene to have potential as a vaccine
candidate.
frpS
Regulation of iron metabolism plays a major role in virulence in a number of
bacteria (Hantke 2001). The ability to acquire, store and effectively utilise iron in
the iron-limited conditions of the host environment contribute greatly to survival
of bacteria. Iron is essential for many biological processes, including electron
transport, enzyme function, and the deactivation of reactive oxygen species in
the form of peroxides. The concentration of available iron in mammalian tissues
is significantly below that required to support bacterial growth and therefore the
bacteria have developed a number of mechanisms by which to acquire iron
from host iron storage and transport molecules. A search of the genome data
for ORFs associated with iron acquisition or transport revealed a number of
proteins that had yet to be investigated in Brucella pathogenesis. Among these
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proteins was the Iron regulated outer membrane protein gene designated (rpB.
This ORF was identified through similarity to the frpB gene of Neisseria
gonorrhoeae. In both N. gonorrhoeae and N. meningitidis (rpB encode a 70 kOa
protein, which is both surface exposed and immunogenic (Beucher et aI, 1995).
The protein is reasonably well conserved amongst the Neisseria, and has been
shown to be susceptible to attack by bactericidal antibodies, making it an
appropriate choice for assessment as a vaccine candidate (Ala'Aldeen et aI"
1996). Its role in Brucella pathogenesis was undetermined, although in general
iron metabolism is known to be important in the development of infection (Roop
et aI, 2004).
In summary, five genes were selected from the B. melitensis 16M genome
database. These genes were omp25, ialB, (JiC, acvB (virJ) and frpB. Each of
these genes was ascribed a putative function related to Brucella intracellular
survival or access to the host cell. With the exception of omp25, direct evidence
for the function of these genes was not available. Therefore, the main aim of the
work described in this chapter was to provide experimental evidence for a role
for these candidates in Brucella pathogenesis, virulence and the development
of protective immunity. Thus providing data supporting the choices made in the
in-silico selection process.
3.3: Experimental procedures and aims
Part 1: Determining expression of candidate antigens from Brucella
melitensis 16M.
B. melitensis strain 16M was grown under various culture conditions and
assessed via candidate specific reverse transcriptase PCR (RT-PCR) for
evidence of specific gene expression. The aim of this work was to demonstrate
that it was possible for the selected genes to be expressed by the Brucella and
therefore possible that such expression would produce accessible protein
targets for attack by the acquired immune system of a vaccinated host. The
experimental processes are summarised in Figure 3.1.
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Chapter 3: Selection of candidate antigens
Figure 3.1: Experimental processes involved in determining transcription
of selected candidate genes from B. melitensis
1: Brucella meutensis 16M growth
a) SOA aulture
b) Albimi br th culture
c) In splenocytes withi infected mouse
2: Isolation of total NA from culture
3: Removal of contaminant DNA
4: Reverse transcrip ion of total RNA
using random de amer primers
5: Candida e sp-ecific PCR
(or constitutiv expression control
PCR) using eDNA template
To determine expression
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Part 2: Analysis of immunogenicity of candidate antigens
With the exception of Omp25, all antigens selected for investigation in this
project were not previously studied in relation to brucellosis pathogenicity,
virulence or immunogenicity. Consequently, there is limited knowledge
regarding the involvement of such antigens in the generation of immune
responses in either natural infection or vaccination. The generation of candidate
specific antibodies by a Brucella infected host would indicate an immunological
role for the candidate and thus strengthen the case for use of the candidate in a
vaccination scenario. Therefore assays were developed to measure the
presence of candidate specific reactive antibodies in sheep antisera.
A selection of 22 sheep antisera was obtained from the Brucella reference
laboratory at VLA Weybridge. These samples were sourced from a single study,
using B. melitensis experimentally infected sheep confirmed as infected by
culture. The animals were considered to be in the convalescent phase of
infection at the time when the blood sample was collected. That is blood was
sampled post-partum or post-abortion, and the Brucella load of the animal was
expected to be in decline. Samples had been stored lyophilised since initial
collection and assessment, and the reactivity of these sera in standard
brucellosis diagnostic iELlSA was known. The presence of specific antibodies
against the selected candidate vaccines was assessed for each of these sera
by immunoassay using either crude E. coli Iysates expressing the recombinant
Brucella proteins or purified samples of these recombinant proteins. Ideally
purified antigen preparations were preferred to the crude E. coli Iysates, as
these samples presented only the antigen of interest for reaction with the test
sera. However, with the exception of the recombinant Omp25-GST and
recombinant Invasion protein B antigens, purified samples of proteins were not
available for use in this study. Recombinant Omp25-GST and lalB expression
constructs were developed in-house but purified recombinant antigens were
produced under sub-contract by Lionex GmBH (Braunschweig, Germany) for
use in this study. The Anti-Brucella reactivity of samples was confirmed using
the Brucella indirect ELISA (iELlSA), and Brucellergene ™ ELlSAs.
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3.4: Results
Expression of selected genes by Brucella melitensis 16M
Candidate antigen gene transcription was determined by specific RT-PCR
following isolation of RNA from B. melitensis 16M cultured under different
conditions.
The specific RT-peR amplicons were resolved by agarose gel electrophoresis.
Table 3.1 summaries the results from this study and Figure 3.2 shows the
results from one of the replicate RT-peR assays of cDNA isolated from Brucella
infected splenocytes.
Table 3.1: A summary of the RT·PCR results demonstrating expression of
the selected genes under different culture conditions
Culture conditions IF·1
Pas
Specific PCR reaction
omp25 ialB fIIC scvB frpS
Pas Pas Neg (Pos) Pos
Pas Pas Neg Neg Neg
Pas Pas (Pas) (Pas) Pas
SDA plate culture
Albimi broth culture
Ex-vivo isolation from
macrophages
Pos
Pas
Pas Expression detected consistently in at least 3/3 assays
(Pas) Expression detected, but inconsistently. Expression
Neg detected in at least 1/3 assessments
Expression never detected (0/3)
The data were collated from three replicate studies of each condition. A single
representative example of the results from the infected splenocyte investigation
is provided in figure 3.2.
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Figure 3.2: Specific RT·PCR results obtained from B. melitensis 16M
infected splenocytes in this study
1 2 3 4 5 6 7 8 9 10 11 12 1314 15 16 1718 1920
- - .--=----- - _- 4I!II!lIJIII!II----'_ - - --- '-_- - =-'. - ..
21 23 25 27 29 31
22 24 26 28 30 32
peR amplicons from specific PCR reactions using B. melitensis 16M infected splenocyte total
RNA / cDNA template.
1: 1Kb ladder (Promega), 2 - 5: IF-1 reactions (164 bp product); 2: Negative control (water
template), 3: 16M genomic DNA template, 4: cDNA template from infected splenocytes, 5: RNA
template from infected splenocytes., 6: 1Kb ladder (Promega), 7- 10 omp25 reaction (642 bp
product); 7: negative control, 8: genomic DNA, 9: cDNA, 10: RNA, 11: 1 Kb ladder (Promega),
12-15 ialB reaction (512 bp product), 12: water, 13: genomic DNA, 14: cDNA, 15: RNA, 16-20
ffiC reaction(842 bp product), 16: water, 17: genomic DNA, 18: cDNA, 19: RNA, 20: 1 Kb ladder
(Promega)., 21: 1Kb ladder (Promega), 22 -25: AcvB reaction (1413 bp product); 22: Negative
control (water template), 23: 16M genomic DNA template, 24: cDNA template from infected
splenocytes, 25: RNA template from infected splenocytes., 26: 1 Kb ladder (Promega), 27- 30
frpB reaction(1985 bp product); 27: negative control, 28: genomic DNA, 29: cDNA, 30: RNA,
31: 1 Kb ladder (Promega), 32: ladder (Promega)
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Table 3.1 provides a summary of the expression data, determining consistent
expression of genes omp25 and ialB. Under all conditions investigated in this
study, specific transcripts for these genes were detected from random decamer
generated cDNA templates. Amplicons were not detected for equivalent
reactions utilising the corresponding RNA sample (no RT Control) as template,
indicating that the product was not generated through amplification of
contaminating genomic DNA. Expression of the other candidate genes was
determined on at least one occasion. The (rpB gene was expressed in solid
phase culture and from ex vivo macrophages, although expression was not
detected from Albimi broth cultures. Data from both the fliC and acvB gene
studies under all assessed conditions were inconsistent. AcvB expression was
detected in a single isolate of RNA / cDNA from SDA cultured B. melitensis
16M, and on two out of three occasions from samples recovered from ex-vivo
isolated splenocytes. FIiC specific amplification was detected from two out of
three samples recovered from splenocytes, but not from samples isolated under
other conditions.
Recognition of the chosen vaccine candidates by convalescent
sheep and goat sera in ELISA
ELlSAs were developed to determine the presence of antibodies reacting with
Brucella specific proteins. The reactivity of the sera samples in the
internationally recognised Brucella diagnostic iELISA was compared to that in
newly developed iELlSAs. For the iELlSA, data was interpreted through
comparison of test sample OD's to the OD of the international standard Positive
control sera. Samples with an OD > 10% of the positive control was considered
positive in this assay. For the recombinant antigen based ELiSAs a cut off (CO)
was assigned to each individual assay based upon the mean + two standard
deviations of the OD value of known negative serum in this assay.
Results from ELiSAs based upon crude E. coli Iysates or purified recombinant
proteins (lalB and Omp25-GST) are summarised in Table 3.2. The table
displays the ELISA result (positive or negative) for each of the known infected
serum samples in each of the ELiSAs. Crude lysate ELISA results are shown
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for the FrpB, AcvB and FliC reactions. Purified recombinant protein results are
given for the Omp25 and lalB reactions.
Table 3.2: Results from ELISAs to determine natural reactivity of Brucella
infected sheep to the selected candidate antigens
Purified recombinant Crude Iysates from Native antigens
anti ens recombinant E. coli -S-LPS +S-LPS
Sample ID Omp25 iaiB AcvB FrpB FliC Bru iELISA
3 + + + - - + +
4 + + - + + + +
5 + + + + + + +
6 + + + - - + +
7 + - + + + + +
10 + + - + - + +
12 + + - - - + +
14 + + - - + + +
16 + + - - + + +
18 + + + - - + +
24 + - - - + + +
25 + - + - + + +
26 + + - - - + +
27 + - - + - + +
29 + + + - + + +
30 + - - + + + +
33 + + + - + + +
34 - + - - + - +
35 + + + + + + +
36 + + - + - + +
38 - - - + - - +
39 + + + + + + +
91% 76% 45% 45% 59% 91% 100%
The table mdlcates the result determined from the each serum sample assayed at 11200dilution
in each ELISA test. The CO for defining positivity was determined from the mean OD value of
five known negative sera in each of the individual ELlSAs. Samples with a mean OD > CO are
indicated +, samples determined as negative (mean OD < CO) are indicated-.
CO values for each ELISA are Omp25 = 0.652, /a/B = 0.089, fliC = 0.340. acvB =0.51, frpB =
0.663.
These data indicate that 91% of the Brucella infected sheep produce antibodies
specific to proteins present in the Brucellergene ™ antigen or recombinant
Omp25-GST preparation. A smaller percentage of these animals produce
antibodies that react with the other recombinant antigens. These data indicate
that the selected antigens are recognised and targeted by the sheep humoral
immune system during a Brucella infection, although the results for AcvB, FrpB
and FIiC reactions require confirmation of specificity using purified recombinant
protein antigens.
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3.5: Discussion
The aim of the work described in this chapter was to select candidate antigens
for development into DNA vaccines, based upon their expression during
infection and their immunogenicity in the target species. Firstly, the transcription
of the candidate antigen genes in the Brucella organism was verified through
RT-PCR.
Detection of specific gene transcripts does not always equate to the generation
of full-length protein product. However, for the purposes of this investigation,
detection of specific transcripts in the RNA was considered evidence of the
initiation of the expression process. The detection of transcripts at least
indicates that the gene is active in Brucella. The data indicated that the Brucella
omp25, ialB and frpB genes are transcribed by the organism under standard
SDA culture conditions. Transcripts specific for acvB were detected
intermittently from RNA isolated from SOA cultured Brucella. Liquid broth
culture provided evidence of transcripts specific for the omp25, and ialB only.
Whereas, transcripts from all the selected genes were identified in the RNA
isolated from Brucella infected splenocytes on at least one occasion out of
three. Thus it appears that the omp25 and ialB genes were sufficiently important
to the Brucella growth that they were expressed under all the conditions
investigated. Contrastingly, the expression (or lack of expression) of frpB, acvB
and fliG altered with varying culture or environmental conditions.
Although direct evidence of the protein expression was not sought in this
investigation, direct evidence for expression of Omp25, FrpB and lalB have
since become available through other studies. The presence of Omp25 in
Brucella cell Iysates has been verified in numerous studies, and the protein is
known to be an important component of the outer membrane of the Brucella
spp. The protein is readily detected in killed preparations of cultured Brucella.
Data presented here indicate that Omp25 is expressed under all of the
conditions investigated. Furthermore, because of its surface location this protein
is immediately accessible to the host immune system upon infection.
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The ialB gene transcripts were detected under all conditions investigated. The
work of Wagner et aI, (2002) supports these findings, through demonstration of
the presence of the lalB protein in the proteome of SDA cultured B. melitensis
16M. The detection of transcription of ialB from ex vivo cultured splenocytes
indicates that the gene may be necessary for the survival of the Brucella within
the splenocyte, as well as its' hypothesised role in the initial host cell invasion.
Notably, ialB expression is not ubiquitous to all Brucella spp. Genomic
comparisons of the B. melitensis and B. suis ialB homologues indicates a frame
shift mutation in the B. suis 1330 ialB gene which is expected to result in a
truncated product (Paulsen et aI, 2003). In the context of vaccine candidate
selection, this suggests that a vaccine based upon the ialB gene may only be of
relevance to the B. melitensis infections and would not be applicable for use
against all species of Brucella.
Transcription of the frpB gene was detected in RNA isolated from SDA ex-vivo
splenocyte cultures (See Chapter 3 for details), and Wagner et aI, (2002) have
confirmed the presence of FrpB in the proteome of SDA cultured B. melitensis
16M. Furthermore, Eschenbrenner et aI, (2003), observed increased expression
of the FrpB protein in the B. melitensis vaccine strain Rev.1 in comparison to
the virulent type strain 16M. A role for the FrpB protein in the observed
attenuation of the B. melitensis vaccine strain Rev.1 was therefore suggested.
Eschenbrenner et aI, postulated that the over expression of this, and other
proteins, constituted energy inefficiency on the part of the Rev. 1 organism
which contributed to its reduced virulence in vitro and possibly in vivo. An
alternative hypothesis would be that over-expression of Frp8 leads to a greater
specific immune response, because of the increased availability of the antigen
to prime the reaction, and that specific anti-Frp8 responses actually contribute
directly to protection. For instance, binding of specific antibodies to Frp8 could
hamper the iron acquisition function of the protein and therefore restrict the
growth of the Rev.1 organism. In this study transcription of (rpS was detected
from SDA and ex-vivo splenocyte cultures but not from liquid broth. This implies
that Frp8 expression is not constitutive. Nevertheless the expression of the
FrpB protein from Brucella cultured on SDA, and isolated ex-vivo from
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splenocytes, suggests that this protein will be exposed to the host animal upon
infection and thus accessible to the immune response.
Expression or transcription of the mG and acvB (virJ) genes was not
consistently determined in these studies. AcvB (virJ) specific transcripts were
detected intermittently in the RNA isolated from both SDA and ex-vivo isolated
splenocytes. At the time of writing, evidence for the expression of Brucella AcvB
(VirJ) had not been reported. However, the Agrobacterium tumefaciens acvB
(virJ) homologues had been investigated and were proposed to function as an
effector or chaperone molecule transported through a VirB-like type IV
secretion system, although AcvB sec dependent secretion into the supernatant
(SN) of cultures was shown to occur independently of the VirB system (Chen et
aI, 2000). The VirB system of Brucella is essential for the establishment of the
intracellular replicative niche (O'Caliaghan et aI, 1999., Sieira et aI, 2000., Celli
et aI, 2003) but the effector molecules that are transported through this system
are currently unknown. The potential involvement of the acvB (virJ) gene
product in this process has been studied but remains undefined. Data
presented here indicate that the gene is transcribed by Brucella although not
constitutively. The conditions inducing transcription cannot be clearly defined
from this work. As the acvB I virJ gene product is a possible effector of a TFSS,
it's secretion from the Brucella into host cytosol or into the subverted
phagolysosomal vacuole is anticipated to make it accessible for antigen
presentation by infected cells and thus a target for the cell mediated immune
responses of the host. Secretion of the antigen from the host cell may also
make the protein available for antibody binding.
Expression of the flie gene was not detected consistently in this study. Ex vivo
splenocyte samples yielded the only evidence for expression of me in this
study, suggesting that expression of this gene is induced by or limited to an
intracellular location. Moreover, transcription from associated flagellar system
genes (flhB, fliP, fliR and fliF) was not detected in studies with SDA and Albimi
cultured Brucella (Abdullah et ai, 2003) supporting a lack of expression of this
gene under these culture conditions. More recently I intracellular flie gene
expression has been confirmed through reporter gene analysis (Fretin et ai,
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2005). In these studies expression of flie and other associated flagella systems
genes was detected transiently upon host cell invasion by the Brucella.
Moreover, this group were able to demonstrate significant attenuation of a
flagellar mutant B. melitensis strains, in both macrophage and BALB/c mouse
models of infection (Delrue et aI, 2005). These findings indicate a role for
flagellin in the pathogenesis of Brucella infection, although the exact function of
the flagellar system of Brucella, and indeed the particular role of the flagellin
(FliC) antigen, remains undetermined.
Thus, as with acvB, the expression of flagellin (FliC) antigen appears to be
restricted to certain conditions or induced by as yet undefined stimuli which
occur either through contact with host cells or occur intracellularly.
Nevertheless, evidence of transcription indicates that these proteins may playa
role in the establishment or maintenance of infection.
Overall, these data indicate that all selected candidate genes were transcribed
by B. melitensis 16M under certain conditions, thus supporting the notion that
the protein products of these genes may be presented as antigens to the
immune system of the host animal. Therefore, the results of this investigation
support the selection of the putative antigens as vaccine targets.
Although evidence of gene expression is a useful indicator of the potential
exposure of the protein to the immune system, exposure does not necessarily
result in protective or even appropriate immune responses. For this reason,
evidence of target antigen immunogenicity was sought through assessment of
the serological responses of a panel of twenty-two sheep serum samples from
experimental infection studies. For the Omp25-GST and lalB proteins, purified
preparations of these antigens were prepared for use in these investigations.
For the remaining antigens (FrpB, AcvB and FIiC), antigen preparations were
derived from recombinant E. coli cell Iysates expressing the recombinant
Brucella fusion proteins (FrpB-His, AcvB-GST, and FIiC-His). Overall, over 40%
of the sera from Brucella infected sheep were detected as positive in candidate
specific ELISA. Thus providing supporting evidence that the selected candidate
genes are not only transcribed, but also translated and recognised by the host
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immune system. However, more data from more stringent ELiSAs using highly
purified recombinant proteins would be required to confirm these results and to
determine whether these antigens have diagnostic potential.
In conclusion, antigens were selected from the B. melitensis 16M genome data
based upon amino acid similarity to virulence factors and immunologically
significant antigens in other important pathogens. The work described in this
chapter indicated that these genes (omp25, ialB, acvB, fliC, and frpB) are
transcribed by the Brucella organisms, and therefore the protein products of
these genes are potentially available to the immune system of the host and may
be useful targets for vaccination. Furthermore, the demonstration of a specific
antibody response from greater than 40% of Brucella infected sheep against
these proteins suggests that these proteins (Omp25, Invasion protein 8 (laI8),
Acv8, flagellin (FIiC) and Frp8) may have immunological significance in a
natural infection.
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Chapter 4: THE PRODUCTION AND IN VITRO
EVALUATION OF DNA VACCINES BASED UPON
THE BRUCELLA GENES omp25, ialB, frpB, acvB,
AND fliC
4.1: Summary
The candidate antigens selected from the B. melitensis 16M genome database,
and supported by the laboratory studies described in chapter 3, were produced
as DNA vaccines. Their production and characterisation is described in this
chapter. In total, six novel vaccines based upon the five selected antigens were
produced. The expression of the encoded Brucella gene from each construction
was confirmed by RT-PCR, providing indirect evidence that the vaccines were
expression competent. Furthermore, direct evidence of specific protein
production was obtained for pCR3.1-omp25 and pTargeT-omp25 vaccines from
monoclonal antibody based detection of the protein in transfected Cos 7 cells by
immunofluoresence assay. Similar studies, using anti-Brucella sera suggested
the presence of Brucella specific proteins from Cos 7 cells transfected with
pCR3.1-iaIB, pCR3.1-frpB and pCR3.1-acvB.
4.2: Introduction
Plasmid vectors suitable for use in DNA vaccination are commercially available.
In the most basic form each vector consists of a plasmid capable of replication
in E. coli K12 derived host strains (CoIEI origin of replication), a selectable
marker such as antibiotic resistance to facilitate selection of recombinants, and
the required elements to allow expression of the inserted coding sequence from
eukaryotic cells. A eukaryotic promoter (most commonly the Human
Cytomegalovirus Early Intermediate promoter (pCMV), or the promoter from
Simian Virus 40 (SV40)) drives the transcription of the inserted DNA sequence
within mammalian cells, and the polyadenylation signal (most commonly Bovine
Growth Hormone Polyadenylation signal (BGHPolyA)), which generates the
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poly A tail to the transcribed mRNA and thereby promotes stability of the
transcript. A number of modifications to this basic design can be made through
inclusion of additional sequences. The inclusion of a Kozac or eukaryotic
ribosome binding site signal (Kozac, 1988) has been shown to increase the
level of expression of the inserted sequence in vivo.
The use of DNA provides opportunities for manipulation and engineering of a
rationally defined vaccine. Techniques for manipulation of DNA are well
understood and make it possible to modify antigen genes and vectors for
different purposes. DNA vaccine plasmids can be engineered to direct and bias
immune responses to the encoded antigen by, for example, modifying antigen
expression and enforcing certain routes of antigen presentation. The backbone
of the plasmids may be engineered to contain immunostimulatory or adjuvant
DNA sequences such as CpG motifs and expression enhancing sequences
such as intron elements, in order to augment the immune response to the
encoded antigen (Kreig, 2000., Klinman, 2000., Heeg and Zimmermann, 2000).
Specific immunological molecules such as cytokines can be incorporated into
DNA vaccine constructs either with the antigens of interest or into a separate
plasmid. Administering both the cytokine and specific antigen constructs serves
to modify and direct immune responses (Pan et ai, 1999).
A defined DNA vaccine is also readily identifiable, enabling vaccinates to be
easily differentiated from naturally infected hosts, due to the inclusion or
exclusion of specific diagnostic or marker antigens. In addition to the
practicalities of construction and purification of the vaccine, data have indicated
DNA vaccination to induce Th 1 biased immune responses. This bias is related
to the non-specific stimulus effect of the CpG motifs in the plasmid DNA, and
the endogenous production and presentation of the encoded antigen. Th 1
based immune responses are essential for the clearance of intracellular
pathogens and the generation of inappropriate immune responses (non - Th 1)
is one contributing factor to the previous lack of success with sub-unit or dead
whole bacterial vaccines. In addition, the immune stimulus from conventional
sub-unit antigens is short lived and booster immunisations are required in order
to assure the development of the necessary memory response. In contrast,
113
;·1
antigen presentation from DNA vaccines can be prolonged, with the plasmids
within host cells capable of producing the antigens over a significant period.
Additionally, DNA vaccination induces specific responses that are not directed
against the plasmid vector itself, therefore making repeat administration of the
same vector possible. Other advantages include the reported application of
DNA vaccines in neonatal animals (Bot and Bona, 2002) and the ease with
which vaccine constructs can be co-delivered or formulated to produce multi-
partite vaccines. A number of review articles are available discussing the
relative merits of DNA vaccination (Gurunathan et aI, 2000., Ulmer, 1996.,
Davis and Whalen, 1995)
Ultimately the vaccine vector needs to be simple, well characterised and safe to
use in clinical applications. A number of commercially available plasmid vectors
have already been used as the basis of DNA vaccines undergoing clinical trials.
Among the most widely cited commercially available DNA vaccine vectors are
the pCMV based vaccines, including pcDNA3.1™ and it's derivatives produced
by Invitrogen. pCR3.1™ (Invitrogen) is a TA cloning vector based upon the
pcDNA3.1™ vector. pTargeT™ is a TA cloning vector similar in construction to
pcDNA3.1™ but with the inclusion of an intron element immediately upstream to
the insertion site. These TA cloning vectors were chosen for use in this study,
as they permit rapid direct cloning of PCR products, are competent for
mammalian expression, and are among the simplest of the eukaryotic
expression vectors.
4.3: Experimental procedures and aims
The experimental procedures for design and construction of the DNA vaccines,
and evaluation of expression are summarised in figure 4.a. Details of the
materials and methods used for these experiments are described in chapter 2.
The eukaryotic expression vectors pTargeT™ (Promega) and pCR3.1
(Invitrogen) were used to generate DNA vaccines. Basic plasmid maps and
sequence details are provided in appendix 1.
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Figure 4.1: A summary of the experimental procedures used to create and
evaluate DNA vaccines.
1: PCR amplifGat~ n of target gene
Primer design, PCR op imisati n, amplification for cloning
"Ligation of amplicon a d euk ryotic expression vector,
transformation of Ecoli host
of
3: Confirmatlon of vaccine production
Plasmid production, restriction mapping, sequencing
. ~. ~~fific~ti R at. ene exp ession f Q
.tr.ansfected ammalian cells
tal, A isolationfrom
Co cells at 24 hours
post-transfection, Oligo-
dT primed reverse
transcription, Specific
PCR
munofluroresence assay of Cos 7
cells at 72 hours post-transfection
U ing anti-Brucella sera or specific
monoclonal antibodies
Expression capable constructs
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4.4: Results
Amplification of Brucella specific genes
Figure 4.2., shows the results of the optimised PCR reactions resulting in
amplicons of the calculated sizes. These amplicons were purified and used to
clone into the DNA vaccine vectors pTargeT or pCR3.1.
Figure 4.2: Amplicons obtained from optimised peR procedures
flie frpB ialB
546 bp product.
omp25
750 bp
product.
acvB
Cloning of Brucella specific candidates
Purified amplicons were cloned into the TA cloning vector pCR3.1™
(Invitrogen). The omp25 amplicon was also cloned into the vector pTargeT™
(Promega). Cloning was performed according to standard protocols. Analysis of
potential recombinant E. coli was carried out by isolation of plasmids from single
colonies and restriction cleavage of these plasmids to demonstrate the
presence and orientation of the cloned insert. These restrictions are detailed in
table 4.1 and results shown in Figure 4.3. Recombinants showing the correct
size and orientation insert were retained for further analysis and the identity of
the insert was confirmed through sequencing.
1453 bp 880 bp product. 2008 bp product.
product +
smaller 580 bp
roduct
peR amplicons for the selected candidate genes.
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Table 4.1: Expected restrictions of the DNA vaccine plasmids
Restriction
Vaccine Plasmid enzymes Expected restriction fragments
construct size introduced to IBoxed IBrucella specific insertsequence
ends
Hind III I
Hindlll only: 53 + 6441 bp
pCR3.1-acvB 6494 bp BamH1only:1459 + 5034 bpBamH1
HindllllBamH1: 114421+ 35 + 18 + 4999 bp
Xho1 only: 915 + 5024 bp
pCR3.1-fIiC 5939 bp Xho11 Xba1 Xba1 only: 12 + 5927 bp
Xho1/Xba1: ~ 46 + 6 + 5018 bp
Xho1 only: 2043 5033 bp
pCR3.1-frpB 7076 bp Xho11 EcoR1 Xba 1 only: 7076 bp
Xho1/Xba1: ~ + 6 + 5027 bp
BamH1 only: 36 + 5569 bp
pCR3.1-iaiB 5605 bp BamH11 EcoR1 only: 547 + 14 + 5044 bpEcoR1 BamH1/EcoR1: 15341+ 13 + 23 + 14 + 5021
bp
pCR3.1-
Xho1 only: 784 + 5025
5809 bp Xho11 Xba1 Xba1 only: 53 + 5756 bpomp25
Xho1/Xba1: rn+ 53 + 5019 bp
pTargeT-
Xho1 only: 18 + 6402 bp
6420 bp Xho11 Xba1 Xba1 only: 6420 bpomp25
Xho1/Xba1: 173~+ 12 + 5653bp
Full plasmid maps and sequences are provided in appendix 1.
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Figure 4.3: Restriction enzyme cleavage results for each DNA vaccine
construct, to illustrate the presence and size of the inserted DNA
pCR3.1-omp25 and pTargeT-omp25 pCR3.1-frpB
1: 1kB marker (Life technologies), 3: unrestricted pCR3.1- 1: 1 kB ladder (Promega), 3:
omp25, 4: Xho1 restricted pCR3.1-omp25, 5: Xba1+ Xho1 Unrestricted pCR3.1-frpB, 4: Xho
restricted pCR3.1-omp25., 6: Unrestricted pTargeT-omp25., 1 restricted pCR3.1-frpB, 5: Xho1
7: Xho1IXba1 restricted pTargeT-omp25, 8: Xba1 + Xho1 I + Xba1 restricted pCR3.1-frpB
restricted pTargeT-omp25. (2043 bp insert)
(737 bp insert)
1·=====:"'::::::::':·· ..··- ..--------·-,- ..···..-..··..--·--·-- ..·- ..·..··..·--·--·-····-··..·--··-·..··..·..·-·-·..·..········--....l·--·-·--'-''''-''''-''''-'-''''-''''-''''-'''''-'_'-'-'-'-'-''-'.''-"".-"""-"..",.,..,-.-,..-.,,,-...,
pCR3.1-acvB
1: 1kB marker (Life
technologies), 3:
unrestricted pCR3. 1-acvB,
4: Hind111 + BamH1
restricted pCR3.1-acvB, 5:
Hindlll restricted pCR3.1-
acvB. 6: BamH1
restrictedpCR3.1-acvB
(1442 bp insert)
pCR3.1- ialB
1: 1kB marker (Life
technologies), 3: EcoR1
restricted pCR3.1- ialB, 4:
EcoR1 and BamH1 restricted
pCR3.1- ialB, 5: BamH1
restricted pCR3.1- ialB, 6:
unrestricted pCR3.1- ialB.
(534 bp insert)
pCR3.1-fIiC
1: 1 kB ladder (Promega), 3:
Unrestricted pCR3.1-fliC, 4: Xba1
restricted pCR3.1-fliC, 6:
Unrestricted pCR3.1-fliC, 7: Xho1
+ Xba1 restricted pCR3.1-frp8
(869 bp insert)
Each construction contains an appropriately sized and orientated insert
Expression of inserted sequences from DNA vaccine constructs
Candidate gene expression from the DNA vaccine plasm ids was assessed
following transfection of Cos 7 cell cultures with the plasmid. Expression was
determined through RT-PCR following isolation of total RNA from the
transfected cell cultures. The successful isolation of RNA was confirmed
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through standard agarose electrophoresis to show the presence of the major
18S and 23S ribosomal RNA subunits in the preparation. RNA samples are
shown in figure 4.4.
Figure 4.4: RNA isolated from Cos 7 cel/s, at 48 hours post-transfection.
1: 1kb marker (Promega), 3: Untransfected Cos7 RNA, 4: pCR3.1-omp25 transfected Cos 7
RNA, 5: pTargeT-omp25 Cos? transfected RNA, 6: pCR3.1- ialB transfected Cos? RNA, r.
pCR3.1-acvB transfected Cos? RNA, 8: pCR3.1-fliC transfected Cos? RNA, 9: pCR3.1-frpB
transfected Cos7 RNA, 10: pcDNA3.1 transfected Cos7 RNA.
The picture shows the initial total RNA isolation samples from the Cos 7 cells.
23S and 18S ribosomal RNA bands are clearly visible at approximately (1.8 and
1.2 Kbp) respectively. The faint band visible at 300 bp is the 5S ribosomal RNA.
The smearing visible in each lane could be due to either the presence of
multiple mRNAs of different size or to contaminating fragments of genomic
DNA. The genomic DNA removal step (DNAFree™ protocol) was used on this
preparation to remove genomic DNA contamination. Samples of cleaned RNA
were used immediately to generate cDNA, and the cDNA used as template in
the Brucella specific RT-PCR. The results of the candidate specific peR are
shown in figure 4.5.
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Figure 4.5: Candidate specific RT-PCR reactions for the transfected and
control Cos 7 cells
omp25 PCR reactions
1: 1 Kb ladder (Promega), 2: 100 bp ladder (Promega), 3 - 12: omp25 PCR results
3: Untransfeeted Cos7 eDNA temp/ate, 4: pCR3.1-omp25 transfeeted Cos7 RNA temp/ate (No
RT control), 5: pCR3.1-omp25 transfected cell cDNA temp/ate, 6: B. melitensis 16M genomic
DNA temp/ate (100 pg / rxn), 7: pCDNA3.1 transfected Cos7 cDNA temp/ate, 8: pTargeT-
omp25 transfected Cos7 RNA temp/ate (No RT control), 9: pTargeT-omp25 transfected cell
cDNA temp/ate, 10: B. melitensis 16M genomic DNA temp/ate (50 pg I rxn), 11 & 12: Sterile
water temp/ate (Negative control)
ia/B, frpB, flie and acvB PCR reactions
1: 1 Kb ladder (Promega), 2: 100 bp ladder (Promega), 3-6: ia/S reactions, 7-10: frpB reactions,
11-14: fliC reactions. 15-18: acvB reactions
3: B. melitensis 16M genomic DNA template (100 pg / rxn), 4: pCR3.1- ialB transfected Cos7
cDNA template 5: pCR3.1- ialB transfected Cos7 RNA template (No RT control), 6: Sterile water
template (Negative control), 7: B. melitensis 16M genomic DNA template (100 pg / rxn), 8:
pCR3.1-frp8 transfected Cos7 cDNA template 9: pCR3.1-frpB transfected Cos7 RNA template
(No RT control), 10: Sterile water template (Negative control), 11: B. melitensis 16M genomic
DNA template (100 pg / rxn), 12: pCR3.1-fliC transfected Cos7 cDNA template 13: pCR3.1-fliC
transfected Cos7 RNA template (No RT control), 14: Sterile water template (Negative control),
15: B. melitensis 16M genomic DNA template (100 pg / rxn), 16: pCR3.1-acvB transfeeted Cos7
cDNA template 17: pCR3.1-acvB transfected Cos7 RNA template (No RT control), 18: Sterile
water tem late Ne ative control
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Figure 4.5, shows the summarised results from the Cos 7 expression data
analyses. For each cell sample transfected with a particular vaccine construct
the data shows positive PCR from the control samples using B. melitensis 16M
genomic DNA as template, and cDNA isolated from the appropriate transfected
cells demonstrating the presence of the specific DNA vaccine encoded
transcript (mRNA). Reactions using appropriate RNA (the 'No RT' control) from
each transfection isolation showed negative (no band) results, indicating the
absence of the plasmid DNA from the RNA isolations. This is important as any
contamination of the RNA sample by the plasmid DNA could be carried over
into the cDNA sample to provide an alternative source of template for the peR,
and therefore generate a false positive result. Control reactions using
untransfected or pcDNA3.1 transfected Cos 7 RNA and cDNA samples as
templates were also negative, as were specific PCRs of heterologous
transfected cells (For example: PCR for omp25 conducted on cDNA samples
derived from pCR3.1-fliC transfected Cos 7 cells) (data not shown). This
confirms the specificity of the peR for the plasmid encoded Brucella
sequences.
Detection of Brucella specific proteins by Immunofluorescence
assay
Immunofluorescence assay was used to determine the production of the
Brucella specific protein from the transfected Cos 7 cells. For the omp25
transfected cells a monoclonal antibody specific for the Omp25 protein was
used in these assays. The monoclonal antibodies AF59 (Anti-Omp25) and A43
(anti-P39) were kindly donated by Prof Jean-Jacques Letesson (Namur,
Belgium). For other candidates specific sera was unavailable and therefore anti-
Brucella polyclonal sera was used.
The findings of these studies are summarised in figures 4.6.1 to 4.6.6.
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Figure 4.6.1: IFA results for pTarget-omp25 and pCR3.1-omp25
transfected cells and controls, using monoc/onal antibody (AF59) to
detect Omp25.
(a) p- Targe T-omp25 transfected cells,
detected using AF59 antibody and
Anti-mouse Ig FITC labelled detection
(c) pcDNA3.1 transfected cells,
detected using AF59 antibody and
Anti-mouse Ig FITC labelled detection
antibody
(b) pCR3.1-omp25 transfected cells
detected using AF59 antibody and
Anti-mouse IgFITC labelled detection
antibody
(d) pCDNA3.1 transfected Cos7 cells
strained with A43 antibody and Anti-
mouse Ig F ITC labelled detection
antibody
Figure 4.6.1(a - d) shows FITC labelled Omp25 in the cells of the pCR3.1-omp25 and pTargeT-
omp25 transfected cells (Images (a) and (b», and the absence of any labelling in pcDNA3.1
transfected cells using equivalent antibody reactions (c). Picture (d) indicates the lack of
reaction seen when non-specific monoc/onal antibodies are used as the detection reagent.
Together these data indicate the presence of the Omp25 protein in the transfected Cos7 cells
and therefore demonstrate that expression of the Brucella specifiC protein from the DNA vaccine
can occur within eukaryotic cells in vitro. Approximately 2 to 3 positive (labelled) cells were
detected in each field of view for cells transfected with either construct, suggesting equivalent
levels of expression of the antigen from both pCR3.1 and pTargeT vectors.
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Figure 4.6.2: IFA results for pTarget-omp25 and pCR3.1-omp25
transfected cells and controls, using B. melitensis infected goat sera to
detect OMP25.
(e) pTargeT-omp25 transfected cells,
detected using Brucella melitensis
infected Goat sera
(g) pTargeT-omp25 transfected cells,
detected . uninfected Goat sera
(f) pCR3. 1-omp25 transfected cells,
detected using Brucella melitensis
infected Goat sera
(h) pCR3.1-omp25 transfected cells,
detected un-infected Goat sera
Figure 4.6.2 (e - h) demonstrated that expression of Omp25 could be detected from the cells
that were transfected with the omp25 based constructs, using the monoclonal anti-Omp25
reagent. Figure 4.6.2 (e - h) illustrates that detection is also possible using the serum of an
infected goat (anti-Brucella sera) as the detection antibody, although the sensitivity of this
particular detection system is less than when using the specific monoclonal reagent. In
transfected cell samples at 48 hours post transfection between 1and 2 clearly labelled cells
were detected in an average field of view (at X 400 magnification), corroborating the data from
the monoe/onal antibody investigations, but strong background reactions were observed
reducing the sensitivity of the reaction in comparison to that of the monoclonal study.
Nevertheless in optimised assays protein was not detected in the untransfected or control cells
indicating that the detected protein was a specific product of the transfected plasmids. The
optimised anti-Brucella sera assay was then used to assess the cells transfected with the other
DNA vaccines.
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Figure 4.6.3: IFA results for pCR3.1- ialB transfected cells and controls.
using B. melitensis infected goat sera to detect the presence of Brucella
specific protein (Invasion protein B)
(a) peR3.1-/aIB transfected cel/s,
detected using Brucel/a melitensis
infected goat sera and anti-sheep/goat
Fire label/ed detection antibody
(b) peR3.1-/aIB transfected cel/s
detected using un-infected goat sera
and anti-sheep/goat FITe label/ed
detection antibody
Figure 4.6.3 demonstrates clear staining of transfected cells, achieved through binding of the
Brucella specific antisera and lalB protein expressed by the pCR3.1- ialB transfected cells. The
background staining in this reaction is particularly high, and a clear cellular location of the
proteins cannot be determined. The stain seems localised to the periphery of the cells or within
cellular vesicles. Staining of this nature was restricted to cells transfected with the pCR3.1-laIB
plasmid, and was not witnessed for identically processed untransfected cells or cells transfected
with other expression capable plasmids (data not shown). Furthermore staining of this kind was
not seen for the transfected cells with the negative control sera (Image (b». This effect can
therefore be attributed to the presence of the pCR3. 1- ialB plasmid, and expression of the
encoded protein product.
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Figure 4.6.4: IFA results for pCR3.1-acvB transfected cells and controls,
using B. melitensis infected goat sera to detect the presence of Brucella
specific protein (AcvB)
(a) pCR3.1-acvb transfected cells,
detected using Brucella melitensis
infected goat sera and anti-sheep/goat
FITC label/ed detection antibody
(b) pCR3.1-acvb transfected cel/s
detected using un-infected goat sera
and anti-sheep/goat FITC label/ed
detection antibody
Results for the transfection and IFA of the pCR3.1-acvB construct (Figure 4.6.4) show a single
brightly label/ed cel/ within a field of view containing a number of diffusely stained cells. Staining
distinct from the background was scarce but appeared specific to the pCR3. 1-acvB transfected
cell preparations. Brightly labelled cells were detected at a rate of one in every 5-6 viewing
fields (i.e.: 0.2 per field of view). This result reflects either a low transfection efficiency for this
particular plasmid, a reduced level of expression compared to the other pCR3. 1based
vaccines, or a low level of antibodies specific to the AcvB protein present in the B. melitensis
detection sera leading to a low sensitivity assay.
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Figure 4.6.5: IFA results for pCR3.1-frpB transfected cells and controls,
using B. melitensis infected goat sera to detect the presence of Brucella
specific protein (FrpB)
(a) peR3.1-frpB transfected cells,
detected using Brucella melitensis
infected goat sera and anti-sheep/goat
FITe labelled detection antibody
(b) peR3. 1-frpB transfected cells
detected using un-infected goat sera
and anti-sheep/goat FITe labelled
detection antibody
For the pCR3. 1-frpB transfected cells specific staining was detected, indicating the presence of
a Brucella sera reactive protein, thought to be the FrpB protein, in the cell preparation (image
(a». Strong staining was evident in the pCR3.1-frpB transfected cell cultures but absent from
the untransfected cells stained with the same antibody (data not shown), or transfected cells
stained with a non-Brucella reactive sheep sera (image (b».
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Figure 4.6.6: IFA results for pCR3.1-fliC transfected cells and controls,
using B. melitensis infected goat sera to detect the presence of Brucella
specific protein (Flagellin)
(a) pCR3.1-fliC transfected cells,
detected using Brucella melitensis
infected goat sera and anti-sheep/goat
FITC labelled detection antibody
(b) pCR3.1-fliC transfected cells
detected using un-infected goat sera
and anti-sheep/goat FITC labelled
detection antibody
For the fliG transfected cells, specific staining was not detected using the anti-Brucella sera
(Image (a)). This suggests that either the cell preparation does not contain Brucella specific
proteins, or that proteins are present but specific anti-f1agellin reactive antibodies are absent
from the Anti-Brucella sera. Therefore these data do not preclude the possibility of f/agellin
production from the transfected cells, but merely indicate that the Anti-Brucella IFA is unsuitable
for use with this particular construct.
Overall, IFA data demonstrates Brucella specific protein production from each
of the candidate vaccines (with the exception of FliC production from pCR3.1-
fliC) following transfection of Cos7 monolayers with the plasmid constructs.
4.5: Discussion
The data discussed in this chapter describes the development of the vaccine
constructs. Six DNA vaccines were constructed based upon five selected
candidate antigens. Expression was assessed for each of these candidates by
specific RT-PCR and IFA. These studies were necessary to confirm that the
eukaryotic expression plasmids were functional prior to use in in vivo studies.
RT-PCR was used to demonstrate the presence of candidate specific mRNA
transcripts from Cos 7 cells at 24 - 48 hours post transfection. Detection of
specific mRNA transcripts indicated that the expression process had been
initiated, and that the plasmid constructions were functional in this cell culture
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setting. Although this result does not confirm expression of the actual encoded
protein, it does indicate that all of the constructs are able to generate relatively
stable specific mRNA signals within a eukaryotic cell host. Translation of the
mRNA species into protein is then under control of the host cell protein
synthesis apparatus.
Detection of the actual protein was considerably more difficult to achieve as
specific immunological reagents for the detection of the novel candidates were
unavailable with the exception of Omp25. For Omp25, a monoclonal antibody
(AF59) was donated by Prof. J.J.Letesson (FUNDP, Namur, Belgium),
facilitating accurate detection of the protein from transfected Cos 7 cells. Using
this specific reagent it was possible to confirm expression from pCR3.1-omp25
transfected cells. These omp25 transfected cells were then used to optimise an
assay in which sera from Brucella infected goats (anti-Brucella sera) was used
to detect protein expression in IFA. The B. melitensis infected goat sera, which
is currently standardised for use as the positive control reagent for the
diagnostic Brucella iELlSA, was shown to contain antibodies that react with a
protein of 22- 26 kDa molecular weight in native B. melitensis 16M antigen
preparation in western blot, and also with the recombinant Omp25-GST protein
(data not shown), thereby indicating the suitability of this serum for detection of
the Omp25 protein in transfected cells. An IFA was then optimised that was
able to confirm the production of a Brucella specific protein by the pCR3.1-
omp25 and pTargeT-omp25 transfected Cos 7 cells, although the reaction was
not as distinct as that seen with the monoclonal antibody reagents. Heavy non-
specific background staining of cells was encountered when using sheep and
goat sera (both Brucella infected and the uninfected control) at high
concentrations in the assay resulting in poor sensitivity. Consequently, the final
sensitivity of the Anti-Brucella sera IFA for the detection of Omp25 was reduced
in comparison to the monoclonal antibody reaction. However, with both assays
the presence of the FITC labelled protein within transfected Cos 7 cells was
clearly visible, supporting the data from the RT-PCR study by confirming
production of the protein from the DNA vaccines.
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The conditions optimised for assessment of Omp25 expression using Anti-
Brucella sera were used to assess expression from the other candidate
antigens by IFA. The suitability of the sera for detection of the putative invasion
protein (laIB) was demonstrated using this sera in immunoblotting (data not
shown). The presence of Brucella specific proteins was demonstrated in Cos7
cells transfected with pCR3.1-laIB following reaction with Brucella infected goat
antisera. Staining of the transfected Cos 7 cells showed brightly labelled
vesicles within cells against a diffusely stained background. Repeated analysis
indicated that this effect was specific and reproducible for this construct. One
possible explanation for this effect is that the expressed protein is packaged
within vesicles for export or secretion from the cells. The strongest staining can
be seen within the vesicles and the associated with cell membranes, where
concentrated protein is suspected to be present. The diffuse staining
surrounding the cells is attributed to the release of soluble protein from the cells,
which remains associated with the membrane surfaces. Support for the
possibility of protein secretion was obtained during the development of
purification techniques for the recombinant laIB-GST and lalB-His fusion
proteins. It was determined that the protein was exported from the E. coli host
cell, and that the removal of the fusion tag and secretion of the lalB protein was
mediated through the ;alB gene (see appendix 1 for details). From this data it
appears that this secretion mechanism is also active within the eukaryotic host
cells. Further studies that were not considered within the scope of this thesis
would be necessary to confirm this hypothesis. For the purposes of this
investigation, the demonstration of the specific RT-PCR result from this pCR3.1-
ialB construct, and the demonstration of a specific but non-quantifiable protein
staining effect in IFA was considered sufficient to verify the expression
capabilities of the vaccine.
Transcription of acvB in pCR3.1-acvB transfected cells was conclusively
demonstrated by RT-PCR studies. However, the lack of specific anti-AcvB
reagents made the detection of the protein difficult. The anti-Brucella IFA
showed weak specific staining of a relatively low number of cells per slide. The
limited number of specifically stained cells may be attributed to a poor
transfection or expression capacity for this construct, or also influenced by the
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limited sensitivity of the IFA. Anti-Brucella sera was found to react poorly with
recombinant AcvB protein in crude E. coli Iysates (data not shown), and thus a
low concentration of AcvB specific immunoglobulins was expected to be present
in the sera resulting in a low sensitivity IFA.
For the pCR3.1-frpB construct, RT-PCR results indicated specific transcription
of the Brucella frpB sequence. IFA data supported the conclusion that the FrpB
protein was expressed from the DNA vaccine by showing specific staining of
transfected cells. Under the conditions used in this assay expression was
detected readily and reproducibly.
Evidence of expression from the pCR3.1-fliC constructs was only demonstrable
through RT-PCR. IFA was attempted on cells transfected with this construct but
failed to detect any proteins reacting with the Brucella specific serum, indicating
either the absence of the protein in the Cos7 cell samples, or the absence of
Flagellin reactive antibodies in the Brucella specific antisera. The lack of anti-
flagellin antibodies in Brucella antisera was corroborated by studies with
recombinant FliC protein, whereby a convincing reaction was not detected when
the anti-Brucella sera was tested for reactivity against recombinant Flagellin-His
protein by western blotting (data not shown). These data suggest that the
detection of the flagellin protein from the Cos7 cells using Anti-Brucella sera is
unlikely if not impossible. Thus, the RT-PCR data indicate functional
transcription of the fliG gene from transfected mammalian cells, but the
presence of the corresponding protein could not be confirmed using the
reagents available for IFA.
In summary, these data indicated that each DNA vaccine construct was capable
to generating Brucella gene specific transcripts from appropriately transfected
mammalian cells. IFA was able to provide direct evidence of Brucella specific
protein production from five of the six DNA vaccine plasmids.
Production of the Brucella specific protein by vaccine transfected cells is an
essential first step in the DNA vaccination process. A number of authors have
endorsed the use of plasm ids that promote high levels of antigen expression in
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order to generate greater magnitude responses (for review see Garmory et aI,
2003). The efficiency and quantity of protein production will undoubtedly
influence the development of the specific immune response, and thus high-level
expression in vitro may be indicative of a good vaccine candidate. However,
since the specificity and sensitivity of the anti-Brucella sera IFA was optimised
with respect to one antigen (Omp25), in this investigation, it is not possible to
accurately compare the efficiency of protein expression between constructs
using the techniques described herein. Hence, it is difficult to determine if any of
the constructs are superior or inferior in the expression of protein. This work
demonstrates only that candidate antigen expression is possible, and thus
indicates that vaccines are able to produce the Brucella proteins thereby
exposing them for interaction with the host.
It should be noted that a number of further factors beyond the scope of this
investigation have been shown as important for the efficient generation of
proteins from DNA vaccine constructs. These include a requirement for codon
optimisation and the influence of varying post-translational modifications
between the eukaryotic host cells and the original bacterial systems. During the
construct design, the Brucella gene sequences were assessed to confirm the
absence of eukaryotic termination signals in the gene sequence, but codon
optimisation and identification and elimination of potential glycosylation motifs
was not undertaken. This does not appear to have prohibited transcription in
this setting, although it is possible that due to sub-optimal gene sequences, the
production of the protein is affected during the mRNA processing, or translation,
and truncated or exotic forms of the protein may be produced. Furthermore, the
folding of the encoded polypeptide sequence into the quaternary structure of the
mature protein may have been aberrant, or post-translational modifications that
do not normally take place in Brucella may have occurred, rendering the protein
conformationally dissimilar to the native Brucella proteins. Such sub-optimal
processing could result in the generation of proteins or protein fragments that
cannot be detected by antibodies raised against conformational epitopes of
native Brucella proteins. With this in mind it should be noted that the absence of
staining (e.g.: from flie transfected celis), or comparatively weak staining (e.g.:
from acvB transfected cells) with anti-Brucella sera, might not necessarily
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indicate poorer levels of protein expression. On the other hand, generation of
proteins, which are structurally distinct from native proteins, may limit the
potential of the vaccine to evoke immune responses against potentially
important conformational epitopes. The possible generation of antigenically
restricted responses and the effect that such restriction may have on the
development of protective immunity cannot be judged from these in vitro
investigations, but may become important in subsequent in vivo investigations.
In summary six novel DNA vaccines, comprising five candidate antigens were
produced. Each construct was checked to determine the identity of the Brucella
gene through sequencing across the plasmid insertion site. The ability to
express the encoded Brucella protein was verified through specific RT-PCR for
all vaccines, and supported by IFA studies for five out of six of the vaccines.
These studies provided essential evidence to show that the vaccine plasmids
were appropriate for further study.
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Chapter 5: ASSESSMENT OF THE PROTECTIVE
ACTIVITY OF THE NOVEL DNA VACCINES IN THE
MURINE BRUCELLOSIS INFECTION MODEL
5.1: Summary
Following construction of six novel DNA vaccines, analysis of their protective
efficacy was performed. A laboratory animal model of protection was selected
and refined to permit an initial assessment of protective efficacy. A BALBlc
mouse model, involving challenge with approximately 1x 104 CFU B. melitensis
strain 16M with assessment of Brucella numbers in the spleen at day 15 ± 1
post-challenge was determined to be optimal.
Immunogenicity of the vaccines was determined through an ELISA based upon
B. melitensis 16M antigen. Specific antibodies were detected following p-omp25
[1], p-omp25 [2] p-iaIB, or p-acvB DNA vaccination. Protective efficacy was
determined by comparison of the recovery of viable Brucella from the spleens of
the vaccinated and control groups. Data indicated that the vaccines based upon
the putative invasion protein B (IalB) antigen and the 25 kDa outer membrane
protein (Omp25) were able to impart significant protective activity. Other
candidates were not significantly protective.
5.2: Introduction
The protective effect of a Brucella vaccine can defined in terms of either the
relative number of vaccinated animals protected from developing disease, or
the ability of those animals to control the bacterial replication and persistence in
vivo, following challenge. The method of choice will depend upon the pathogen,
presentation of clinical disease symptoms, and the host system under
investigation.
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Brucellosis in livestock is a disease associated with abortion. The Brucella
organisms colonise the reproductive tract of the infected animal and the
associated lymphoid tissues. Clinical indications of infection in non-pregnant
animals are not detectable. Thus determining vaccine potency and efficacy in
the ruminant host ultimately requires the use of an abortive challenge model, in
which pregnant vaccinates are challenged with virulent Brucella and the
protection is correlated with the effects on normal full-term delivery and survival
of the foetuses. Since all significant Brucella spp., are ACDP category III
pathogens, and work in the UK is also restricted by DEFRA SAPO (1998)
regulations, such studies require containment level III laboratories and suitable
large animal accommodation facilities. As such these are difficult and expensive
to perform and there are ethical considerations regarding the use of pregnant
animals and late term foetuses in experimental settings. In addition, the
gestation period for a sheep is 147 days and the abortive nature of brucellosis is
not seen until the final trimester of the pregnancy, making any study a
protracted one. Therefore, for both practical and ethical reasons small animal
models have been developed that allow faster evaluation of vaccine candidates.
Development of animal models that accurately reflect any disease in a separate
and dissimilar host is a difficult task. With brucellosis the broad host specificity
(with restricted preferences), generalised non-specific symptomology and lack
of overt clinical symptoms further complicate the issue. A number of laboratory
animal models of brucellosis have been described in the literature: different
models are useful for different purposes.
The rabbit, rat, hamster and gerbil are widely used laboratory animal species,
but their use in brucellosis research has been limited. Rats (Rattus spp.) are
considered relatively resistant to Brucella infection, Golden or Syrian Hamsters
(Mesocricetus auratus) are susceptible and although they have been used in
the past they are not recommended as models because of a high degree of
variation in individual animal susceptibility. The rabbit (Oryctolagus cuniculus) is
only partially susceptible to Brucella infection, and variation between individuals
is significant. Pregnant rabbits, rabbits in a state of pseudopregnancy or
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progesterone treated rabbits show an increased susceptibility to Brucella
infection. but no evidence of uterine infection. Only very limited data is available
on the use of gerbils (Meriones unguiculatus) in brucellosis research. (Garcia-
Carillo, 1990).
Guinea pigs (Cavia porcel/us) were widely used in early brucellosis work. and
are considered to be among the most susceptible of the laboratory animals to
Brucella infection. They are readily infected by all common routes of inoculation
with low infectious doses of all the Brucella species except B. neotomae and the
severity of the disease is correlated with an obvious retardation in body weight
gain. Macroscopic and microscopic lesions are detected in the spleens of
infected animals. and a splenic weight index (weight of spleen I body weight of
animal) is considered a useful correlate for pathology. Brucella can be found in
the semen of experimentally infected guinea pigs and experimental infection of
pregnant females results in congenital transmission and abortion. Neonatal
transmission of the infection has also been reported in this species. The
Brucella colonisation of the reproductive system and abortive pathology
observed in guinea pigs makes this a particularly suitable laboratory animal for
the study of pathogenesis. However. a relative paucity of immunological
reagents specific for the guinea pig means that any assessment of cell
mediated protective immunity in this model is restricted to aspects such as
lymphocyte proliferation and delayed type hypersensitivity reactions. The most
frequent use of the guinea pig in brucellosis research has been in the
standardisation or potency testing of the DTH antigen, Brucellin
(Brucellergene TU, Synbiotics Corps, France). Data regarding the specifics of the
cell-mediated response in guinea pigs to Brucella antigens, infection, or
vaccination are limited.
The mouse (Mus musculus) is the most widely used of all laboratory animals
and is the small animal model of choice for present day brucellosis research.
The availability of specific immunological reagents for mouse work and the
accumulated wealth of knowledge regarding mouse immunology and genetics
afford considerable practical advantages over other model hosts. In the mouse,
infection with Brucella causes a transient bacteraemia. Upon initial infection
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most of the bacteria are destroyed via innate immune mechanisms. Those that
survive invade and subvert the host phagocytes, and are trafficked to the
draining lymph nodes and the spleen of the infected animals. There are reports
of Brucella spp., colonising the reproductive organs of the mouse, although the
presence of the organism does not cause either abortion or foetal distress
(Bosseray, 1980). Since mice do not suffer abortive disease, murine brucellosis
is characterised by a systemic infection without overt clinical signs.
Splenomegaly is often the only clinical indication of infection. The lack of
abortive pathology in mice means that the number of organisms in the spleen at
intervals post-infection is more readily used as a read-out of pathology and
immunity. Enumeration of Brucella retrieved from the spleens of mice following
infection indicates there is a brief lag phase in growth after inoculation followed
by a period of multiplication during the first two weeks. The bacterial numbers
are maximal after 10 - 15 days, and then decline in a manner corresponding to
the chronic or latent phase of infection in other hosts. The time to clearance
varies depending upon the virulence and dose of the infecting Brucella
organisms and the immune status of the host animal. Infected mice are
resistant to reinfection when challenged. Although the infection may be chronic
or protracted, it is not lethal and the mouse eventually clears the infection.
Plommet and Bosseray conducted many studies with the mouse model relating
to vaccine development and assessment. In 1984 they proposed a standard
method for the titration of novel vaccines against a reference vaccine using the
mouse model. Over the years, modifications have been made to the procedures
and standardisation between laboratories is rudimentary, but use of the mouse
model for the assessment and comparison of vaccine potency is well
documented. The procedures are described in the DIE manual of vaccines and
standards (DIE, 2000). Assessment of the vaccine strains B. melitensis Rev. 1
and B. abortus S19, are described. In both cases vaccine strains are
administered as a sub-cutaneous (sic) inoculation of approximately 2 x 105CFU
per mouse at 30 - 45 days prior to challenge with a virulent strain. The
challenge dose, a virulent B. abortus strain such as 2308 or 544, is given
intraperitoneally as a dose of - 1 X 106CFU and protective efficacy is estimated
through enumeration of the viable challenge strain Brucella in the spleens of the
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mice. In the case of the Rev.1 vaccination, heterologous strain challenge is
considered acceptable for the quality assurance of the vaccine in the animal
model, although it should be noted that optimal protection against heterologous
strain challenge does not occur in the natural host (Schurig et ai, 2002).
Overall, the mouse is a useful infection model because it allows the virulence of
the live vaccine strains to be estimated and permits assessment of the impact of
immunity on the progress of the disease. There is a correlation between the
persistence of a Brucella strain in the mouse and it's virulence in the natural
host: attenuated strains are eliminated more rapidly in either host. Protective
immunity is most clearly demonstrated as a reduction in the number of viable
Brucella retrieved from the spleens of immune mice compared to non-immune
mice at 15 days post-challenge. The ability of vaccines to promote clearance of
Brucella in a murine model corresponds well to its protective efficacy in target
species.
Numerous laboratory strains of mouse exist, each with particular assets for use
in vaccine research. Importantly, there is variation in susceptibility between
different laboratory strains of mice. The C57/Bl-6 mouse is considered
relatively resistant to brucellosis in comparison to the BAlB/c mouse. (Baldwin
and Parent 2002). In the investigations described in this thesis, the BAlB/c
mouse was selected as the animal model of choice. Previous investigations
using this mouse model at VLA Weybridge (N.Commander, unpublished
observations) had suggested that protection mediated by DNA vaccination
studies were not reproducibly efficacious against heterologous strain challenge,
and therefore a B. melitensis 16M challenge was considered most appropriate
for the assessment of vaccines based upon putative antigens in the B.
melitensis 16M genome. Rev.1 vaccination was selected as a positive control
for effective immunity as this is the currently recommended gold standard
vaccine for protection of small ruminants against B. melitensis.
The aim of these investigations was to refine and standardise the BAlB/c
mouse model for analysis of anti-Brucella DNA vaccines and to utilise the model
to identify the most promising DNA vaccine candidates for further analysis.
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5.3: Experimental procedures and aims
The DNA vaccines developed in Chapter 4 were assessed for protective
efficacy in a BALB/c mouse model of brucellosis.
Two separate studies were conducted to estimate the protective efficacy of the
six novel DNA vaccines against challenge with virulent Brucella melitensis, in
the BALB/c mouse model. The first study involved the challenge of vaccinated
mice with a relatively high dose (-1 X 106CFU per mouse) of B. melitensis 16M,
and the second study involved challenge with a lower dose of this strain (-1 X
104 CFU per mouse). The high dose challenge value was selected based upon
the experimental regime used in previous B. melitensis and B. suis challenge
studies in our laboratory (Mansour, E.A., 2003). The low dose challenge dose
was selected based upon recommendations for the determination of residual
virulence and immunogenicity of the Rev.1 control vaccine cited in the O.I.E.
manual of laboratory standards and diagnostics (O.I.E., 2004). The general
vaccination, challenge and sampling schedule for both studies is provided in
figure 5.a. A summary of the vaccines and controls used in these studies is
provided in Table 5.1.
The schedule of four 100 III intramuscular (ilm) DNA vaccinations given at three
week intervals was adapted from that described by Chambers et a', 2000. A
non-vaccinated group of mice (PBS inoculated) was used as a non-protected
control. Two groups of mice were inoculated with the B. melitensis Rev.1
vaccine strain: Group Rev.1 (V1) received inoculation with 2 X 105 CFU viable
Rev.1 coincident to the time of the first DNA vaccination. The purpose of this
group was to permit monitoring of the development of the Brucella specific
immune response in comparison to that observed from DNA vaccinated mice.
Group Rev.1 (V4) was inoculated at the time of the fourth DNA vaccination in
accordance with the recommended protocols for measuring vaccine efficacy
(O.I.E., 2004). All groups of mice were challenged at 30 days post-vaccination.
Protective efficacy was measured in terms of the number of Brucella per spleen
harvested from mice at 15 ± 1 days post-challenge.
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To assess the immunogenicity of the vaccines serum was collected from all
mice at three week intervals. 16M antigen ELISA was used to determine
Brucella specific antibody in the sera of the mice. Specific IgM, IgG1, and IgG2a
isotype responses were assessed at week two, five, eight and eleven of the
trials.
The general outline for the experimental schedule is provided in figure 5.1.
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Figure 5.1: General outline of the experimental schedule for the vaccine
efficacy trials
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Table 5.1: Vaccines and controls used in this study
Group identity:
Inoculated with ... Details
Rev.1 @V1 B. melitensis Rev.1 live vaccine strain. Given at a dose of - 2 X 105
CFU per mouse (sic) at time V1 (week 0).
Primarily to be used for immunogenicity analysis.
Rev.1 @ V4 B. melitensis Rev.1live vaccine strain. Given at a dose of - 2 X 105
CFU per mouse (sic) at time V4 (week 9): 30 days before challenge.
Positive control group I Known efficacious vaccination.
PBS Sterile D-PBS: DNA vaccine diluent.
100 III @ V1, V2, V3, V4.
Sham vaccination. Negative I unprotected control.
pcDNA3.1 pcDNA3.1 plasmid without inserted gene. Used as vector control.
50 Ilg per quadriceps (1 mg/ml) @ V1, V2, V3, and V4.
p-omp25 [1] omp25 gene from B. melitensis 16M, inserted into the pCR3.1 TM
vector from Invitrogen. Developed for this project.
50 Ilg per quadriceps (1 mg/ml) @ V1, V2, V3, and V4.
p-omp25 [2] omp25 gene from B. melitensis 16M, inserted into the pTargePM
vector from Promega. Developed for this project.
50 Ilg per quadriceps (1 mg/ml) @ V1, V2, V3, and V4.
p-acvB acvB gene from B. melitensis 16M inserted into the pCR3.1 TM vector.
Developed for this project.
50 Ilg per quadriceps (1 mg/ml) @ V1, V2, V3, and V4.
p-fliG The gene encoding the putative 28.5kDa Flagellin (FIiG) from B.
melitensis 16M inserted into the pCR3.1 ™ vector. Developed for this
project.
50 Ilg per quadriceps (1 mg/ml) @ V1, V2, V3, and V4.
p-frpB frpS gene from S. melitensis 16M inserted into the pCR3.1 ™ vector.
Developed for this project.
50 Ilg per quadriceps (1 mg/ml) @ V1, V2, V3, and V4.
p- ialB The gene encoding the putative invasion protein B from B. melitensis
16M inserted into the pCR3.1 TM vector. Developed for this project.
50 I-1gper quadriceps (1 mg/ml) @ V1, V2, V3, and V4.
pCI-P39 A vaccine encoding the immunogenic P39 protein of B. abortus.
Previously shown to have protective activity against B. abortus
challenge (AI-Mariri et aI, 2002). Donated to this project by Prof. J-J
Letesson (FUNDP, Namur, Belgium)
50 Ilg per quadriceps (1 mg/ml) @ V1, V2, V3, and V4.
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5.4: Results
Protective activity of vaccines
The protective activity of the vaccines was measured through the enumeration
and comparison of viable Brucella recovered from the spleens of challenged
mice at 15 days post-challenge. Two studies were performed using identical
vaccines and control strains, but two different challenge doses: The data from
the 1 X 106 and 1 X 104 challenge dose studies are summarised in figures 5.2
and 5.3.
Figure 5.2: Scatter plot showing the number of viable B. melitensis strain
16Mrecovered from mice at 15± 1days post-challenge, in the high dose
challenge study.
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Figure 5.2., shows the number of viable B. melitensis 16M recovered from
vaccinated mice following challenge with approximately 106 CFU B. melitensis
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Scatter plot indicating the quantity of Brucella in the spleens of mice at 15 days post-challenge.
Data points for individual Brucella load per mouse with a line to depict the median value. Actual
vaccination doses: Rev.1 (V1) - 1.48 X1cf CFU /mouse, Rev.1 (V4) - 1.14 X 105 CFUI mouse.
Challenge dose for all mice - 3.25 X 1cf CFU B. melitensis 16M /mouse. Zone 2: Brucella load <
challenge inocula, indicating some control of bacterial replication. Zone 3: Greater Brucella load
than the challenge inocula indicating active replication of the Brucella in the mouse (Not
protected). Five mice per group were used in the study.
Mann-Whitney U Test was used to compare the CFU /mouse recovered from PBS (non
immune) mice and vaccinated mice. * indicates a statistically significant reduction in Brucella
splenic load.
The detection limit of the culture technique is 10 CFU per spleen.
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16M. Statistical interpretation of results using the Mann-Whitney U test to
compare each vaccine group against the PBS (unprotected) inoculated controls,
indicated that only one of the vaccines p-ialB, was able to contribute a
statistically significant reduction in the Brucella load of challenged mice (p =
0.0159). The mean (± standard deviation) log Brucella CFU per spleen in these
mice was 4.66 ± 0.49. Direct comparison of this value with the unprotected PBS
controls indicates a protective effect of 0.93 protection units (Protection units =
Mean Log CFU per spleen of PBS mice - Mean Log CFU of vaccinated mice).
Although some mice in other groups had Brucella counts lower than the
challenge dose, these were not statistically significant reductions compared to
the PBS group (p = 0.2857 [Rev.1 (V4)], p = 0.1905 [Rev.1 (V1)], p = 0.1111
[pcDNA3.1], p = 0.1905 [p-omp25 [1]], P = 0.8875 [p-acvB]). Statistical
comparisons were not possible from the p-omp25 [2] group because there were
not enough data points from this group as only two mice survived to this point in
the investigation. Importantly, significant protection is not evident in either of the
Rev.1 vaccinated groups in this study. Furthermore, statistical significance is
not achieved when ANOVA with Dunnetts post-test (comparing each group
against PBS) is applied to the study.
It is important to note that during the course of this investigation (prior to
challenge) a substantial number of mice were euthanised due to ill health.
During this time, thorough investigations were conducted and evidence of
extraneous infectious agents was not obtained in the affected mice.
Furthermore, mice appeared to be in good health at the time of sacrifice and
examination at necropsy did not reveal any macroscopic lesions in the mouse
organs. A similar problem in the second experiment led to the conclusion that
the cause of the morbidity was related to a mechanical injury inflicted by faulty
apparatus used during the blood sampling procedure. Practices were
immediately modified following this finding and no such problems have since
been encountered.
The second investigation also used BALB/c mice and an identical vaccination
and challenge schedule. However, for this study the challenge dose was
reduced to approximately 1X 104 CFU.
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Figure 5.3: Scatter plot showing the number of viable B. melitensis strain
16Mrecovered from mice at 15± 1days post-challenge. Low dose
challenge study.
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Scatter plot indicating the quantity of Brucella in the spleens of mice at 15 days post-challenge.
Data shown as individual CFU per mouse with a line to depict the median value per group.
Actual vaccination doses: Rev.1 (V1) - 0.B2 X105 CFU /mouse, Rev.1 (V4) - 0.97 X 1(t CFUI
mouse. Challenge dose for all mice - 0.B7 X 105 CFU B. melitensis16M Imouse. Zone 2:
Brucella load < challenge inocula, indicating some control of bacterial replication. Zone 3:
Greater Brucella load than the challenge inocula indicating active replication of the Brucella in
the mouse (Not protected). Five mice per group were examined.
Mann-Whitney U test was used to compare the Brucella CFUI mouse from the PBS (not
protected) mice against the Brucella CFU Imouse of the vaccinated mice. * indicates statistical
Significance (p < 0.05). Notably p < 0.01 for p-iaIB, p-omp25 [1J and [2J, and Rev.1 [V1J and [V4J
only.
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Figure 5.3 shows the number of viable B. melitensis 16M recovered from
vaccinated mice challenged with approximately 104CFU B. melitensis 16M.
1000-
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Mann-Whitney U Test to compare the CFU Imouse recovered from PBS (non-
immune) mice and vaccinated mice, indicated a statistically significant reduction
in Brucella load in Rev.1 (V1) and (V4) vaccinated mice (p = 0.0079) and in
mice receiving vaccination with p-omp25 [1], p-omp25 [2] and p- ialS (p=
0.0079). The data clearly illustrates that the Rev.1 vaccinated mice are
controlling the Brucella infection, as there is clear significant reduction in the
bacterial load compared to the non-immune groups (PBS and pcDNA3.1
inoculated groups). Rev.1 (V1) and Rev.1 (V4) vaccinated mice control B.
100-
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melitensis 16M replication such that this organism is not present in large
numbers in the spleens of challenged mice. Rev.1 (V1) group mice consistently
yield Brucella loads of around 10 CFU per spleen (Mean Log (± standard
deviation) CFU per spleen: 1.10 ± 0.19), which forms the lower detection limit of
this assay. Viable Brucellae were not recovered from Rev.1 (V4) vaccinated
mice suggesting a reduction of Brucella load to below detectable levels. This
protective effect can be expressed as 3.63 protection units, and> 3.7 protection
units for Rev.1 (V1) and Rev.1 (V4) respectively. For the non-immune groups
(pcDNA3.1 and PBS inoculated) the number of Brucella isolated from the
spleen on Day 15 ± 1 post-challenge appears in excess of the actual challenge
dose. These data points therefore fall within Zone 3 of the graph, representing
uncontrolled Brucella replication in the natve host.
p-omp25 [1], p-omp25 [2] and p-ialB vaccines compare favourably with the
Rev.1 control vaccines in terms of protective efficacy. p-omp25 [1] vaccinated
mice contained a mean (± standard deviation) Log Brucella CFU per spleen of
2.14 ± 1.3, which was equivalent to 2.58 protection units in this experiment. p-
omp25 [2] vaccinated mice contained 2.10 ± 0.97 Brucella CFU per spleen,
equivalent to 2.63 protection units, and p- ialB vaccination resulted in 2.02 ±
0.54 mean (± standard deviation) Log CFU per spleen or 2.7 protection units.
It is logical to assume that data points showing Brucella counts within zone 3
(above the level of the Brucella challenge dose) reflect that fact that mice have
been unable to adequately control the replication of the challenge dose.
However, a statistically significant difference (reduction in bacterial load) was
determined comparing the Brucella load of the pCI-P39 and p-frpB groups to
the PBS controls (p = 0.0159 and p = 0.0317 respectively), despite the fact that
these data points are within Zone 3.
The B. abortus specific pCI-P39 vaccine was donated to this study. This
vaccine had been previously investigated for protective efficacy against B.
abortus challenge. In this study the vaccine was unable to adequately restrict
growth of the B. melitensis 16M challenge dose (All data points in Zone 3), but
was found to result in a significantly lower (p = 0.0159) Brucella load than the
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non-immune (PBS inoculated) mice in this study. Thus indicating a possible
weak protective effect from the vaccine toward control of B. melitensis 16M.
Analysis of the p-fliC group was not performed in this study, as the mice were
euthanised prior to challenge. This was because a mouse in this group
developed an illness similar to that witnessed in the high dose challenge study,
and therefore to reduce the risk of transmission of any infectious agents all mice
in the group were destroyed. Pathological analysis indicated no obvious cause
of illness.
Serological analysis of mouse response to vaccination.
The serological response of the mice to vaccination was determined from
samples collected in the low dose challenge study using the 16M antigen
ELISA. Samples were considered positive when the recorded OD was greater
than the mean + 2 X standard deviations of the negative control serum.
Although serum was tested at dilutions of 1 / 100, 1/ 500 and 1/ 1000 (antisera 1
diluent), positive reactions were only detected from the 1/ 100 dilutions, and
therefore only data obtained with this dilution are presented herein.
Brucella specific antibodies were detected from mice that were vaccinated with
the DNA constructs p-acvB, p-ialB, p-omp25 [1] and p-omp25 [2]. The response
of most DNA vaccinated mice was undetectable until the eleventh week of the
study, corresponding to two weeks after the final vaccination. The kinetics of the
Brucella specific antibody response are summarised in figure 5.4., which
illustrates the mean IgM, IgG1, and IgG2a Brucella specific ELISA responses
(OD).
146
Figure 5.4: The anti-Brucella response induced by vaccination against
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Substantial and specific IgM responses were only detected from the Rev.1 (V1)
group. As expected these responses were maximal at week two and declined
with time. Substantial specific IgM responses were not determined from the
other groups until week eleven and then these were of lower magnitude than
the corresponding Rev.1 response.
The greatest magnitude and earliest detectable IgG1 Brucella specific response
was also detected in the Rev.1 (V1) group: specific IgG1 was evident at week
five of the study, and continued to increase through to the final sampling time.
At the end of the investigation, corresponding to week eleven of the study or
two weeks after the fourth DNA inoculation, IgG1 antibodies were also detected
from the mice inoculated with p-acvB or p- ialB.
IgG2a Brucella specific antibodies were detected in the sera of Rev.1 (V1)
inoculated mice from week eight of the study. Detectable levels of specific'
IgG2a antibody were found in three of the DNA vaccinated groups of mice
investigated in this study at week eleven of the study (after the fourth
inoculation with DNA). The strongest mean responses were seen from the p-
acvB vaccinated group, where all mice were determined to be seropositive at
week eleven. The second highest mean OD readings were obtained from the p-
ia/B vaccinated mice. Again all animals were determined to be seropositive at
week eleven of the study, although the magnitude of response was variable
between individuals. The strongest reaction in this group achieved an OD value
of 3.22, and the weakest 0.122. Three out of five of the p-omp25 [1], and four
out of five p-omp25 [2] vaccinated mice were determined to be IgG2a
seropositive when measured at week eleven. Notably, the difference between
the p-omp25 [1] and p-omp25 [2] group responses was not considered
statistically significant (p >0.05) (Mann-Whitney U test, comparing mean OD
from 1/100 serum dilution assay).
The proportion of seropositive mice per group at week eleven of the study is
summarised in table 5.2.
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Table 5.2: The percentage of mice in each group determined to be
seropositive at two-weeks post vaccination (week 11).
Vaccine group IgM IgG1 IgG2a
Rev.1 (V1) 100 100 100
Rev.1 (V4) 100 0 0
PBS 0 20 0
pcDNA3.1 1 0 20
pCI-P39 80 0 20
p-omp25 [1] 20 20 60
p-omp25 [2] 20 0 80
p- ialB 80 80 100
p-acvB 20 40 100
p-frpB 40 0 0
p-fliC 20 0 20
ASSAY C/O 0.250 0.151 0.089
..
Cut-off (C/O) OD determmed as mean + 2X standard deviations NegatIVe control serum
Neither SAT nor cELlSA methods showed any of the DNA vaccinated animals
to be positive. Weak positive cELlSA responses were detected from the Rev.1
vaccinated mice, but not from any other samples.
The relationship between antibody production and protective
efficacy
There was no overall correlation between the magnitude of serological
responses in ELISA (measured as OD from sera diluted 1:100) and the Brucella
load recovered from the spleens of these mice. These data are summarised in
figure 5.5.
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ChaRter 5: Assessment of Qfotective activity
Figure 5.5: Anti-Brucella serological responses at 2 weeks prior to
challenge compared with Brucella splenic load post-challenge.
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Right X axis: Brucella load (per group) in the spleen at 15 ± 1 days post challenge. Brucella load
is displayed as mean of the group with error bars depicting standard error of the mean. Left X
axis: OD in ELISA. IgM, IgG1 and IgG2a mean OD per group is indicated on the chart.
The graph indicates that there is not a direct relationship between the
generation of anti-Brucella immunoglobulins and the protective effect of
vaccination. Relatively strong IgG2a responses are demonstrable in the sera of
p- ialB, p-acvB and p-omp25 [1] vaccinated mice, as well as Rev.1 (V1) mice.
However, whilst a protective effect is observed from p-omp25, p-ialB and Rev.1
vaccination, the p-acvB vaccinated mice do not appear to be protected despite
the presence of antibody. Conversely, strong protection is evident in mice
vaccinated with Rev.1 at time V4, although Brucella specific IgG1 and IgG2a
are not evident at this time.
5.5: Discussion
In this investigation, a mouse model of brucellosis was used to determine
whether any of the novel vaccines were able to protect mice against virulent B.
melitensis 16M challenge. One of the principal aims of the experiment was to
optimise the BALB/c mouse model to show the best distinction between
protected and unprotected mice. Previous work in this laboratory had produced
inconsistent results with a standard challenge of approximately 1 X 106 CFU per
mouse, B. melitensis 16M used to measure the efficacy of Rev.1 or DNA
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(pcDNA-62) vaccination (Commander and Spencer, unpublished observations).
Assessment of two different challenge doses was undertaken in an attempt to
reconcile the previous results and conflicting information reported in the
literature. Although this was a major aim of the study the main outcome was
anticipated to be not only the selection of an appropriate challenge dose but
also identification of the most protective of the six novel DNA vaccine
candidates, which would then be investigated in greater detail. The
immunogenicity of the vaccines measured in terms of their ability to promote
production of Brucella specific antibodies was also assessed.
The results of these investigations showed that the B. melitensis 16M 104 CFU
per mouse challenge dose was the most robust method for evaluating
protective efficacy, and that vaccines encoding the Brucella genes ialB and
omp25 were the most capable of promoting protection. The aim of this study
was therefore fulfilled in clarifying the challenge model and allowing selection of
two protective antigens for further study. In addition, the assessment of the
specific humoral response indicated that the p-iaIB, p-acvB, p-omp25 [1] and p-
omp25 [2] vaccines were able to promote IgG2a dominated Brucella specific
antibody in over 60% of vaccinated mice in each group after four inoculations,
proving that in vitro expression of the encoded antigen had occurred, and that
the antigen was presented appropriately for the generation of Th 1 type immune
responses.
High challenge dose (3.25 X 105 CFU per mouse) was not found to be suitably
robust for use in small-scale efficacy trials. The difference between control
protected mice, i.e.: those that have been vaccinated with Rev.1 and the
unprotected mice is unclear. Furthermore, statistical analysis (Bartlett's test for
equal variance) reveals considerable variation (p < 0.001) between groups
making data interpretation on this small number of samples difficult. This finding
differs from other protection models using Rev.1 or S19 as control vaccines
where alternative virulent challenge strains of Brucella, such as B. abortus
2308, 544 or B. suis 1330 at doses of approximately 1 X 106 CFU per mouse
are frequently used without problem (OI.E, 2000, Bosseray and Plommet 1984),
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and previous investigations in this laboratory that indicated that Rev.1 could
protect against this challenge dose of B. suis 1330 or B. melitensis 16M
(Mansour, 2003). In contrast, Bosseray and Plommet (1982) have previously
noted a relative increase in virulence for a B. melitensis strain (H38) which was
manifest as an increased initial growth rate of the bacteria following infection
and a longer persistence of the strain in the model host than is observed for
other Brucella strains. Although 16M (not H38) was used in the current study, a
relative increase in the initial replication of B. melitensis strains compared to B.
abortus or B. suis strains in the mouse model may explain the failure to observe
the expected protective effect at 15 days post-challenge in this study.
An alternative hypothesis to explain the failure of the Rev.1 vaccine to protect
these mice against this challenge is the possibility of sub-optimal vaccine
preparation. The live Rev.1 vaccine is notorious for instability, with phase
dissociation being a common source of increased attenuation leading to vaccine
failure (Grillo et aI, 2000., Bosseray, 1991). In this study Rev.1 cultures were
examined carefully to ensure a preparation of entirely smooth phase colonies
was used to produce the inocula and it is therefore unlikely that a shift to rough
phase phenotype contributed to any vaccine failings. The Rev.1 organism was
not recovered from the mice during the post-challenge bacterial enumeration
studies, and whilst this suggests a rapid clearance of the vaccine from the host,
it is not considered sufficiently rapid to be indicative of a hyper-attenuated state.
Moreover, the detection of antibodies in the Brucella diagnostic cELISA (data
not shown) indicated that the Rev.1 (V1) vaccinates were exposed to the
Brucella smooth OPS and the vaccine was sufficiently immunogenic and
persistent within the mouse to promote a detectable and suitably avid IgG
response. Despite the failure of the Rev.1 vaccine to provide protection in the
high dose challenge study, and the significant variation between groups, results
from this trial indicated a statistically Significant reduction in Brucella load of the
p- ialB mice compared to the PBS inoculated mice (Mann-Whitney test, p =
0.0159). This is a promising result indicating a potent protective effect (0.93
protection units) from the p- ialB vaccine.
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The data generated in the low dose (104 CFU per mouse) challenge study was
more informative. Importantly this combination vaccine and challenge doses
was suitable for the measurement of difference in splenic Brucella load between
mice that had received the positive control vaccination Rev.1, and mice that had
been sham immunised with PBS. Rev.1 vaccination resulted in demonstrable
reduction of Brucella load in the spleens of mice at 15 days post challenge.
Moreover, in this particular study Rev.1 vaccination given at either V1 or V4 was
able to protect mice against virulent challenge. Neither the vaccine strain nor B.
melitensis 16M challenge strain were recovered from the spleens of the Rev.1
(V4) mice at 15 ± 1 days post-challenge. This implies that Rev. 1 organisms
were processed and eliminated relatively rapidly following vaccination and that
the subsequent viable Brucella challenge was rapidly dealt with through
induction of adaptive immune responses.
The persistence of a live vaccine strain such as Rev.1 is often correlated with its
potential for generating appropriate immune responses. From many replicated
analyses of Rev.1 infection kinetics in CO-1 mice, Bosseray (1995) surmised
that the average time for clearance (RT50) of a protective dose of Rev.1 (-2 X
105 CFU per mouse) from infected mice was approximately 7.6 ± 1.3 weeks
(Between 45 and 60 days). Rev.1 batches with shorter RT50 times were often
sub-optimal in terms of protection against virulent challenge in the model and in
the target species. Thus the absence of Rev.1 recovery from the spleens of
Rev.1 (V4) group challenged mice at 45 days post-vaccination in this
experiment represents a relatively rapid clearance of the vaccine strain, but is
just within the expected and acceptable time frame for an effective batch of
vaccine.
Since the detection limits of the bacterial culture technique are restricted to 10
CFU per spleen, this absence of Brucella recovery does not necessarily indicate
sterile immunity but does provide a quantifiable measure of the protective effect
of a licensed vaccine (Rev.1), that can be directly compared with the novel
candidate vaccines. Moreover, protective immunity was clearly demonstrated in
terms of a reduction in the number of viable Brucella recovered from Rev.1
vaccinates in comparison to the PBS inoculated controls. Thus, confirming in
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this particular experiment the vaccine and challenge inocula had performed as
expected and the protocol was proven an effective method suitable for the
evaluation of novel candidates. Furthermore, the measurable success of Rev.1
against the 104 challenge dose compared to failure against the -105 challenge
dose indicated that the lower dose challenge model should be adopted in the
subsequent studies.
Both groups of Rev.1 vaccinated mice (Rev.1 (V1) and Rev.1 (V4» were
considered protected following challenge with 104 B. melitensis 16M (3.62 and ;::
3.72 protection units respectively) , although using splenic load as a quantitative
correlate of protection indicated that the protective effect of the V4 vaccination
was greater than that of the V1 vaccination. This suggests that the protective
effect of Rev.1 vaccination in the BALB/c mouse reduces slightly over time.
Evidence of a decline in protective efficacy of Rev.1 was not recorded in the
studies of Bosseray and Plommet (1990) when using similar methods with CO-1
mice and a B. melitensis strain H38-S challenge administered at either 45 or
150 days post-vaccination. However, for assessment of immunogenicity of
vaccine seed-lot strains an interval of between 30 and 45 days between
vaccination and challenge of mice is recommended in order to standardise the
model (O.I.E, 2004), and many years of experience of the model in this
laboratory have shown that the results from challenge studies conducted at
greater than 40 days post-vaccination are subject to greater variability
(Commander and Spencer, unpublished observations). Interestingly, a
reduction of protective effect over time has also been observed in target
species. Sheep were shown to have a protection rate of approximately 80%
when Rev.1 vaccinates were challenged during the third trimester of their first
pregnancy post-vaccination, but only 62% if vaccinates were not challenged
until a comparable gestation period of their second pregnancy (Verger et aI,
1995). This observation suggests that the declining protective efficacy is a real
effect but that this is difficult to measure or standardise in the mouse model.
Consequently, for the purposes of these investigations where the Rev.1
vaccination is included as a positive or protected control, the data obtained from
the Rev.1 (V4) group, but not necessarily the Rev.1 (V1) group, should be
considered the protected control.
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Statistical analyses (Mann-Whitney U test) were used to evaluate the Brucella
load in the spleens of vaccinated mice in comparison to those of the PBS sham
vaccinated mice. Overall, the DNA vaccines p-omp25 [1]. p-omp25 [2], p-frpB,
pCI-P39 and p-ialB showed a significant reduction in bacterial load compared to
that of the PBS inoculated controls. The protective effect of these vaccines (p-
omp25 [1], p-omp25 [2], p-frpB, pCI-P39 and p-iaIB) was 2.57,2.63 1.01, 1.13
and 2.70 protection units respectively. This data confirms the observations
regarding a possible protective effect from p-ialB that were made in the high
dose challenge study, and furthermore indicates that some of the other
plasmids are also promising DNA vaccine candidates. Control of the splenic
Brucella infection was most consistently observed for mice in groups vaccinated
with p-ialB or p-omp25 vaccines. There was not a sizeable reduction of Brucella
load observed for the p-frpB and pCI-P39 vaccinated mice, although the effect
was considered statistically significant. Vaccination with p-acvB did not result
any measurable protective effect, and although p-f1iC protective efficacy was not
measured in this particular investigation, a repeat investigation at this challenge
dose (with only p-f1iC, PBS and Rev.1 study groups) failed to indicate protective
activity from this candidate (data not shown).
In support of the protection data, antibody responses against B. melitensis 16M
antigen were measured from Rev.1 vaccinated mice and from DNA vaccinated
mice. Brucella specific antibodies were measured at the final time point from
100% of the mice receiving vaccination with Rev.1 (V1) and p- ialB and p-acvB,
clearly demonstrating that these vaccines were consistently able to evoke
Brucella specific adaptive immune responses. On average 70% of mice
vaccinated with either of the p-omp25 based constructs were IgG2a
seropositive ELISA at this time, indicating only a slightly less robust
immunogenicity compared to the p-acvB and p-ialB vaccines. However, only
two mice vaccinated with p-frpB produced measurable levels of IgM specific
antibody, and IgG1 and IgG2a were not detected from these mice suggesting
that this vaccine was a weak immunogen. Only one p-fliC vaccinated mouse
was shown to produce 16M reactive IgG2a antibodies at week 11 of the study.
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The kinetics of the serological response to Rev.1 vaccination followed the
expected course. IgM was generated first and IgG1 and IgG2a became evident
at week five of the study. As the response developed the IgG2a isotype of
antibody became dominant. The magnitude of antibody response measured in
ELISA from the Rev.1 mice was significantly greater than that for the DNA
vaccines, and although this may reflect improved immunogenicity on the part of
the live vaccine it is also attributable to the measurement of a more
comprehensive polyclonal antibody response against the multi-component 16M
antigen ELISA than would be expected from the monospecifically responsive
DNA vaccinated mice. In the case of the DNA vaccines, a specific response can
only be directed and measured against the encoded protein. Interestingly, the
data shows that whilst IgG1 and IgG2a antibodies are not apparent at week five
and maximal at week 11, protective efficacy is greater following challenge at
week four-five (30 days) post-vaccination. Thus supporting the claim that
antibodies are less significant than other aspects of the immune response for
protection against brucellosis.
Although the ELISA data are of limited value in comparing the immune
response of the various groups of DNA vaccinated mice, the data provides
important supplementary evidence that can be used to justify or eliminate
candidate vaccines for further study. For instance, a lack of demonstrable
antibody from p-frpB vaccinated mice consolidates the decision to eliminate this
weakly protective candidate from further investigations. The p-frpB vaccine
provided a slight but statistically significant reduction of bacterial load. However,
the effect appeared to be largely the result of a single mouse in the group with a
very low Brucella load and was therefore considered more likely to have been
caused through an error in the challenge inoculation procedures than vaccine
mediated protection. Moreover, the ELISA results indicate that a detectable
specific immune response is not elicited, suggesting that either the vaccine is a
weak immunogen, or the assay is unsuitable for the detection of FrpB specific
responses. Investigations described in chapter 3 showed that approximately
45% of Brucella infected sheep contain antibodies that react with the crude
lysate of BL21 E. coli expressing the Brucella FrpB protein suggesting that the
native FrpB protein is immunogenic. Furthermore, Brucella FrpB was known to
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be present in 16M antigen preparations (Wagner et aI, 2002 and chapter 3)
indicating that the 16M based ELISA was theoretically suitable for the
measurement of anti-FrpB responses. The possibility of p-(rpB being a non-
functional or non-expressing construct was considered unlikely since the
structure and sequence were confirmed as appropriate for expression, and
transcription from Cos7 cells was demonstrated in vitro. However, these results
reflect in vitro conditions and do not confirm effective transfection, transcription
and translation in vivo. It is possible that either in vivo transfection efficiencies or
protein expression levels from the construct were too low to generate adequate
immune stimulation. Alternatively, protein production from the in vivo
transfected mouse cell could have produced a protein that was structurally
dissimilar to native FrpB and therefore presented inappropriate epitopes to the
immune system. The exact reasons for the relative lack of response remain
undefined. However, overall these antibody and protection data suggest that p-
(rpB is not useful for further investigation as a Brucella vaccine. In contrast, the
homologous FrpB proteins of Neisseria spp. have been shown to be
immunogenic and contribute to vaccine efficacy (Beucher et aI, 1995).
Moreover, Roop et aI, are currently investigating the virulence of B. abortus
2308 mutant strains in which the BMEII 0105 gene ((rpB, or alternatively named
bhuA) has been deleted. These mutants are reported to have a reduced ability
to utilise heme as an iron source. Experiments to confirm the role of the bhuA in
iron transport are reported to be underway (Roop et aI, 2004). It is possible that
whilst the (rpB DNA vaccine does not appear to be protective in these studies,
(rpB or bhuA mutants may prove useful as attenuated live strains.
The protective efficacy of p-fliC vaccination was not completed in the low dose
study because of ill health in the mice of this group. Humoral immune
responses were measured from these animals throughout the experiment up
until the time of euthanasia, but conclusive evidence of Brucella specific
antibodies was not detected. It must be noted however that the RT-PCR
expression discussed in chapter 3 suggested that the Brucella fJagellin (FIiC)
protein was not expressed during SDA based culture, and consequently the
absence of this specific protein from the 16M ELISA antigen would make the
detection of a FliC specific response impossible in this assay. Due to the
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problems associated with this assay, a separate protection experiment was set
up at a later time to assess the p-fliC vaccine, but a protective effect was not
observed in this study (data not shown). For this separate study specific
antibody responses were evaluated by ELISA using FliC-His BL21 E. coli cell
lysate as antigen: FliC specific responses were observed from p-fliC vaccinated
mice but there was no evidence of FliC reactive antibodies in control Rev.1
vaccinated samples (data not shown). Thus, immunogenicity and protective
efficacy data from repeated p-fliC vaccine analysis suggested that this was not
a suitable candidate for further study. As suggested for the frpB candidate,
recent evidence suggests that flagellar based mutants may be useful as
attenuated live strain vaccines (Fretin et ai, 2005, Delrue et ai, 2005).
The p-acvB vaccine produced some interesting results. Whilst the ELISA results
indicate that AcvB is strongly immunogenic with 100% of the vaccinated mice
producing measurable Brucella specific IgG1 and IgG2a following the full
course of vaccinations, the protection study shows that this response does not
contribute to a control of infection. A role for AcvB in Brucella infection has yet
to be defined. The AcvB (VirJ) proteins of A. tumefaciens are located in the
periplasm and believed to function as chaperones binding the T-DNA during
transport through the TFSS. Moreover, D.acvB(virJ) mutants are attenuated in
A. tumefaciens (Wirawan et ai, 2003). A similar role for Brucella AcvB (VirJ)
protein as an effector of the VirB system cannot be ruled out, although Tn5 and
STM screens have not indicated this gene to be essential in Brucella invasion or
intracellular replication (Foulongne et al., 2000, Min et ai, 2000., Lestrate et aI,
2003). Similarly, this failure of AcvB specific immunoglobulin to promote a
measurable reduction in splenic Brucella load suggests that this protein is either
inaccessible to the immune system or not an essential facet of Brucella
virulence. In conclusion, AcvB is not a protective antigen, and therefore is not
worthy of further investigation as a component of a sub-unit vaccine.
For the p-omp25 vaccines Brucella specific IgG2a antibodies and protection
were evident. This is in keeping with the results of other studies regarding the
antigenicity of the Brucella Omp25 protein, but represents the first report of
Omp25 specific immune effectors generating protection against smooth strain
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B. melitensis 16M challenge. In passive transfer studies Cloeckaert et a/ (1991)
assessed the potential of Omp25 specific monoclonal antibodies to protect mice
against smooth and rough strain Brucella challenge. The antibodies were able
to provide limited protection against challenge with rough strain Brucella
species, such as B. ovis, but were inefficacious against challenge with smooth
strains such as B. melitensis or B. abortus. Similarly, analyses of the Omp25
protein have indicated that this may be a useful protective antigen against rough
strain Brucella challenge, but have been unable to demonstrate equivalent
protective activity against the more virulent smooth strains. Bowden et a/ (1998)
assessed the immunogenicity and protective efficacy of a strain of E. coli
engineered to produce the B. melitensis Omp25 on its surface. This approach
was able to generate anti-Omp25 antibodies principally of the IgG2a isotype,
and demonstrable protection of BALB/c mice against challenge with rough B.
melitensis strains B115, Smooth-rough B. melitensis EP, and notably the
smooth B. melitensis strain H38 (H38-S). However, protection against challenge
with smooth strain B. melitensis strain 16M was not achieved. Notably, the
protective effect reported in the Bowden studies was small with less than a one
log difference in the splenic load of protected and unprotected mice. In the
investigation described here, p-omp25 [1] and p-omp25 [2] vaccination caused
a mean 2 log and 1.5 log reduction of splenic load respectively (2.57 and 2.63
protection units), indicating that DNA based delivery of the Omp25 antigen is
potentially a superior strategy.
Interestingly, protective efficacy and immunogenicity measured for p-omp25 [1]
and p-omp25 [2] was not significantly different (Mann Whitney U test: p > 0.05).
Thus suggesting that the presence of the intron element, considered to promote
greater in vivo antigen expression, does not affect the success of the
vaccination procedure. Further study of omp25 based DNA vaccines are
required to confirm their protective potential and elucidate the cell-mediated
immune responses evoked by vaccination.
The p-ialB vaccine showed the most consistent protective activity against B.
melitensis 16M challenge in both the high and low dose challenge studies, and
specific antibodies of the IgG2a isotype were detected in the sera of all p-ialB
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vaccinated mice suggesting the antigen is a good immunogen. Furthermore,
results described in chapter 3 suggest that this antigen is expressed by Brucella
under all conditions investigated and elicits production of specific antibody
during natural infection. Together these data suggest that lalB may be an
important protective antigen. As a previously unstudied antigen with
demonstrable immunogenicity and protective efficacy against high and low dose
challenge (0.93 and 2.70 protection units respectively) the lalB protein and p-
ia/B vaccine warrants further investigation.
Finally, it is widely accepted that protective immunity in brucellosis relies upon
the generation of Th 1 immunity. Results generated so far have confirmed the
antibody production from protected DNA vaccinated mice (p-ia/B and p-omp25
groups) was biased toward generation of IgG2a, thereby implying the
involvement of the crucial Th 1 effector IFN-y in promoting the antibody class
switch. Since IFN-y is known to be essential for the clearance of Brucella spp.,
the generation of IgG2a antibodies is an indicator that the vaccines are evoking
appropriate Th 1 biased specific immune responses necessary for protection.
However, unfortunately, an overall direct correlation between the production of
Brucella reactive IgG2a and protective efficacy could not be demonstrated in
this experiment. In particular, the lack of protective efficacy in the face of
detectable anti-Brucella responses from p-acvB vaccinates indicates that
production of this particular IgG2a does not result in protection. Conversely, the
kinetics of the antibody response evoked by vaccination with Rev.1 indicate that
detectable IgG2a is not present in the Rev.1 (V4) mice at the time of challenge,
and therefore cannot be considered essential for the protective effect observed
in these mice. Together these findings indicate that whilst Th 1 biased immune
responses are undoubtedly important in protection against brucellosis, the
measurement of IgG2a production by simple anti-Brucella ELISA is not
sufficient to fully illustrate the complex relationship between immune effectors
and a reduction in bacterial load in this model. It is therefore concluded that a
more direct assessment of the cell mediated immune effectors would be
required in order to characterise protective immune responses elicited by the p-
ia/B and p-omp25 vaccines.
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In conclusion, these investigations to assess the immunogenicity and protective
efficacy of the six novel DNA vaccines (five candidate antigens) indicated that
the p-ialB and the two omp25 based plasmids were the most promising vaccine
candidates. These candidate vaccines provided demonstrable protective
efficacy and convincing evidence of induction of Brucella specific immune
responses. Another aim of this work was to determine the optimal challenge
dose to be used in the BALB/c model for determining protective efficacy. A
challenge dose of approximately 1 X 104 CFU per mouse given 30 days post
vaccination, and assessment of bacterial load at day 15 ± 1 post-challenge
generated the most reliable data. This low dose challenge model and vaccines
p-omp25 [1] and [2], and p-ialB were thereby selected for use in all subsequent
studies.
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Chapter 6: FURTHER STUDIES ON THE
IMMUNOGENICITY AND PROTECTIVE EFFICACY
OF DNA VACCINES ENCODING B. MELITENSIS
omp25 AND ialB
6.1: Summary
DNA vaccines based upon the B. melitensis genes omp25 or ia/S were studied
to confirm the protective effects observed in previous investigations and to
determine the immunological effectors elicited by vaccination. The data
obtained substantiated the previous finding that four inoculations of either
omp25 or ialB based DNA vaccines were immunogenic and able to provide
significant protection against virulent challenge.
Antigen specific induction of the essential cytokine IFN-y was recorded from
Rev.1, p-omp25 and p-ialB vaccinated mice. The anti-Brucella response in
Rev.1 group mice was Th 1 dominated with production of IFN-y mainly
contributed by CD4+ effector cells. The antigen specific response in p-ialB
vaccinated mice was characterised by CD4+ dominated IFN-y production and
high balanced IgG1: IgG2a titres, whereas the specific response observed from
p-omp25 vaccinated mice was characterised by relatively lower antibody titres
and CD8+ dominated IFN-y production. Each vaccine provided equivalent
protective activity in the murine infection model.
6.2: Introduction
In previous investigations, the p-omp25 [1], p-omp25 [2], and p-ialB plasmids
were shown to be both protective and immunogenic, and therefore selected for
further investigation. The first aim of the experiments discussed in this chapter
was to measure and compare the principal immune effectors of the DNA
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vaccines and the gold standard live vaccine Rev.1, in order to expand
understanding of the immunological correlates of protection in murine
brucellosis, and advance the knowledge regarding the role of Omp25 and lalB
as protective antigens.
The earlier studies had established the presence of antibodies recognising B.
melitensis 16M antigens in the serum of p-omp25 or p-ialB vaccinated mice.
Although high titre specific antibody responses are usually associated with
smooth strain Brucella infection, specific antibody alone is insufficient to protect
animals against infection. Moreover, cell mediated immunity is known to be
essential in the control of intracellular infections such as Brucella (Mackaness,
1971, Cheers 1984). Although the full range of cellular immune effectors
required for protection are not yet understood, it is widely accepted that
activation of a Th 1 type response is essential for clearance of a Brucella
infection. In particular the ability of a vaccine to evoke production of antigen
specific IFN-y is critically important: IFN-y is essential for the clearance of
Brucella (Murphy et aI, 1996). Other Th 1 cytokines support and bolster the
action of IFN-y (Baldwin and Parent, 2002), and both CD4+ and CD8+ cells
contribute to Brucella control (Oliveira and Splitter, 1995).
B. melitensis omp25 based DNA vaccines were selected for study. The
immunogenicity of outer membrane proteins has been investigated for a wide
variety of pathogens. Notable examples include the use of Omp preparations as
vaccine components for protection against human infection with Neisseria
meningitidis (Rosenstein et aI, 2001., Urwin et aI, 2004). The protective effect of
Neisseria Omps appears to be largely antibody dependant. More significantly
Omp induced Th 1 immune responses have been shown to confer protection
against Chlamydia trachomatis (Eko et aI, 2004), indicating that cell mediated
responses against Omps can be effective in the control of intracellular
pathogens. The conserved Omp25 antigen of Brucella spp. is known to be
immunogenic and has already been investigated for protective efficacy in a
number of studies. Significantly, passive transfer studies using Brucella Omp
specific antibodies, and attempts to use recombinant Omp25 as a subunit
vaccine have not been entirely successful (Bowden et ai, 1998). In contrast, the
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omp25 based DNA vaccines created in this study show significant efficacy
against B. melitensis 16M challenge, suggesting that the DNA vaccine
approach is particularly beneficial for this antigen. One of the principal
objectives of the studies described in this chapter is to elucidate and compare
important effectors of protective immunity induced by the successful DNA
vaccine and the live vaccine Rev.1.
The p-ialB was also selected for further study. A role for lalB in Brucella
virulence has yet to be determined. However, it has been recently documented
that the B.suis ialB gene contains a frame shift mutation, which abrogates
expression of this protein in the wild type B. suis (Paulsen et aI, 2002). Thus,
expression of the ialB may be restricted to B. melitensis infections and as such
this antigen may be a useful species-specific marker, or a determining factor for
the observed host preference of this species. However, in the context of
vaccination the absence of this antigen from B. suis means that a p- ialB
vaccine would not be useful for prophylaxis against this particular challenge.
A homologue of Brucella ialB exists in Bartonella spp., where it is believed to
play an important role for in establishing infection. The iaiA and ialB genes of
Bartonella were shown to confer an invasive phenotype onto E. coli strains
DH5a.and HB101, and postulated to playa role in the invasion of erythrocytes
(Mitchell and Minnick, 1995). Whether or not this important virulence factor is a
protective antigen for the Bartonella pathogens was not assessed in these
investigations. Brucella lalB protein shares between 30 - 35% amino acid
identity with Bartonella spp. homologues, but whether ialB plays a significant
role in Brucella virulence remains to be determined. Current studies have
demonstrated a significant protective effect from the p-ialB DNA vaccine, and
thus determination of the immune effectors triggered by this vaccine is an
important step towards understanding lalB as a protective antigen.
A protective brucellosis vaccine is expected to prime Th 1 cellular immune
responses, resulting in production of IFN-y, TNF-a., IL-12 and IgG2a isotype
specific antibodies. Conversely, Th 2 cellular responses represented by IL-4
and IL-5 production are not effective at combating Brucella infection. Successful
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Brucella vaccines are associated with a strongly Th 1 biased immunity.
Moreover, virulent or attenuated Brucella strain infections or exposure to killed
Brucella organisms triggers Th 1 cytokine production (Zaitseva et aI, 1995). This
property of Brucella has been exploited in an adjuvant capacity for promoting Th
1 biased responses to unrelated pathogens (Scott et aI, 1998). The capacity of
whole Brucella based vaccines to stimulate Th 1 responses is crucial to their
success, and conversely the absence of strong Th 1 priming from traditional
sub-unit vaccines limits their effectiveness. Notably, DNA vaccines are
recognised to promote strong Th 1 responses. Thus, the aim of the work
described in this chapter is to characterise the immune response induced by
both the control vaccine Rev.1 and the novel DNA vaccines, with particular
emphasis on the ability of each to promote production of the crucial cytokines
IFN-y, IL-12 and TNF-a., or counteractive Th 2 and Tregtype immune responses
(IL-4 and IL-10 respectively). Comparing the Rev.1 and DNA primed antigen
specific immune responses is necessary to reveal any qualitative or quantitative
distinctions in antigen specific response brought about by the different modes of
delivery: live versus DNA vaccine. Furthermore, measurement of the immune
response is critical to understanding the action of the vaccines and to enable
extrapolation of results and hypotheses from the BALB/c mouse infection model
to the intended targets of vaccination: small ruminants or humans.
6.3: Experimental procedures and aims
Two separate investigations assessing the omp25 and ialS based vaccines
were carried out. Each study compared the efficacy and immunogenicity of the
selected DNA vaccine against that provided by the gold standard live vaccine
Rev.1. In the first investigation, a DNA vaccine preparation based upon omp25
was assessed. The p-omp25 [1] and p-omp25 [2] DNA vaccines (omp25 cloned
into the pCR3.1 (Invitrogen) and pTargeT (Promega) vectors, respectively) were
previously shown to have equivalent protective activity, indicating that the
different vector formulations offered no practical advantages in terms of vaccine
efficacy in this model. Furthermore, significant quantitative and qualitative
differences were not observed in either antigen production from plasmid
transfected Cos 7 cells, or in the induction of basic anti-Brucella antibody
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responses. Therefore, as it was not possible to identify one vaccine as being
superior to the other, a mixture of both plasmids (referred to as p-omp25) was
prepared for use in all subsequent studies. In the second study, the ialB DNA
vaccine was assessed.
For these investigations each of the DNA vaccines: pCR3.1-omp25 (p-omp25
[1]), pTargeT-omp25 (p-omp25 [2]), p- ialB, and the pcDNA3.1 vector control
were produced by Plasmid Factory GmbH & Co. KG. (Bielefeld, Germany) to
GMP standards. Plasmids were suspended in sterile Dulbecco's Phosphate
Buffered Saline (D-PBS) to a final concentration of 1 mg/ml. Preparations were
certified as > 98% closed circular supercoiled (CCC) structure and determined
to have an endotoxin content of less than or equal to 0.1 E.U. (endotoxin units)
per ~g of DNA. p-omp25 [1] and p-omp25 [2] were combined in equal ratios to
produce the vaccine formulation p-omp25. Sufficient p-omp25 was prepared as
a single batch for use throughout this vaccine trial. All plasmid stocks were
maintained at -80DC in 600 ~I aliquots until required for use.
The BALB/c murine brucellosis model was used. Protective efficacy was
assessed through challenge with 1 X 104 CFU per mouse as previously
described. Antigen specific immune responses against killed B. melitensis 16M,
recombinant lalB or recombinant Omp25-GST were measured in terms of
antibody or specific cytokine production from in vitro restimulated splenocytes
by ELISA and ELiSPOT. Killed B. melitensis antigen preparations were
prepared in-house. Recombinant E. coli were created in-house but recombinant
protein purification was subcontracted to Lionex GmbH (Germany).
A flow chart summarising the investigations described in this chapter is provided
in Figure 6.1.
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Figure 6.1: Experimental outline for the evaluation of p-omp25 or p-ialB
protective efficacy and immunogenicity in the BALBlc mice
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Three mice per group were used in each CMI experiment. No less than four mice per group
were used for protection assay. Five mice per group were used in EL/SPOT assay. Procedures
and methods are described in chapter 2.
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6.4: Results
6.4.1: Protective efficacy results
The effects of p-omp25 or p-ialB vaccination on the control of B. melitensis 16M
are illustrated in figures 6.2 and 6.3 respectively.
Figure 6.2: p-omp25 vaccine assessment: The recovery of Brucella
melitensis 16M from the spleens of vaccinated and challenged mice.
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Mann-Whitney U Test to compare the CFU Imouse recovered from PBS (non-
immune) mice and vaccinated mice confirms a statistically significant reduction
in Brucella load in p-omp25 (p = 0.0286) and Rev.1 (V4) (p = 0.0286)
vaccinated mice. Although a slight reduction is also evident in Rev.1 (V1) this is
not quite significant in this assay (p = 0.0571). There is no evidence of a
protective effect in pcDNA3.1 inoculated mice (p = 1.0).
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Scatter plot indicating the quantity of Brucella in the spleens of four mice per group at 15 days
post-challenge. Individual data points are plotted with a line to depict the median value per
group. Actual bacterial inocula: Rev.1 (V1) - 1.55 X105 CFU /mouse, Rev.1 (V4) - 2.66 X 105
CFUI mouse. B. melitensis 16M challenge: 2.66 X 1(t CFU per mouse. Zone 1: a Brucella
reduction is observed of protection equivalent to the Rev.1 (V4) gold standard B. melitensis
vaccine. Zone 2: delimits Brucella loads lower than the given challenge inocula, and thus
reflects control of Brucella replication. Zone 3: Brucella loads greater than the given inocula,
representing active replication of the organism in the host. Mann-Whitney U tests were
performed to compare the bacterial load of each group against the PBS group. Statistically
significant reductions (p< 0.05) are indicated with *. The detection limit of the culture technique
is 10 CFU per spleen.
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A comparison of the Brucella CFU per mouse recovered from each of the
groups clearly shows a reduction in bacterial load for the p-omp25 and Rev.1
(V4) vaccinated mice: In terms of protection units (Mean Log CFU per spleen of
PBS group - Mean Log CFU per spleen vaccinated group) the Rev.1 (V4) and
p-omp25 vaccines provide 3.45 and 3.42 protection units respectively. In each
of these groups Brucella were not cultured from three out of the four mice,
suggesting less than ten Brucella per spleen. The fourth mouse had significantly
fewer Brucella CFU in its spleen than the non-immune (PBS) control mice. The
bacterial load measured from the p-omp25 vaccinated mice was not found to be
significantly different to that of the Rev.1 (V4) mice (p = 0.8857), suggesting an
equivalent reduction of bacterial load in these two vaccine groups. Mice
vaccinated with Rev.1 at V1 (90 days prior to challenge) also demonstrated a
slightly lower number of Brucella recovered from spleens compared to PBS
mice, although this reduction was not found to be statistically significant. The
mean Brucella per spleen in this group was approximately 2.17 X 104 CFU,
indicating a 0.08 log reduction from the given challenge inocula, and a 0.54
protection units compared to the Brucella load of the non-immune mice.
169
Figure 6.3 : p-ialB vaccine assessment: The recovery of Brucella
melitensis 16M from the spleens of vaccinated and challenged mice.
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Scatter plot indicating the quantity of Brucella in the spleens of mice at 15 days post-challenge.
Individual data point« are plotted with a line to depict the median value per group. Actual
bacterial inocula: Rev.1 (V1): 0.95 X 105 CFU per mouse, Rev.1 (V4): 1.95 X 105 CFU per
mouse, B. melitensis 16M challenge: 2.26 X 10" CFU per mouse. Zone 1: a Brucella reduction
is observed of protection equivalent to the Rev.1 (V4) gold standard B. melitensis vaccine. Zone
2: delimits Brucella loads lower than the given challenge inocula, and thus reflects control of
Brucella replication. Zone 3: Brucella loads greater than the given inocula, representing active
replication of the organism in the host. Mann-Whitney U tests were performed to compare the
bacterial load of each group against the PBS group. Statistically significant reductions (p< 0.05)
are indicated with *. The detection limit of the culture technique is 10 CFU per spleen.
In the investigation represented in Figure 6.3, Mann-Whitney U Test comparing
the CFU I mouse recovered from PBS (non-immune) mice and vaccinated mice,
confirmed a statistically significant reduction in Brucella load in p-ialB and Rev.1
(V4) (p = 0.0079) vaccinated mice. A significant effect was also evident in Rev.1
(V1) vaccinated mice (p = 0.0317). Rev.1 vaccination is protective when given
at time V1 or V4 in this study. All mice in these group had Brucella loads lower
than the inocula dose: the mean reduction was around 1.5 logs. In the Rev.1
(V1) group Brucella were recovered from all mice, albeit in very low numbers. In
the Rev.1 (V4) group viable Brucella was not recovered from two of the mice,
indicating a bacterial load of less than ten CFU per spleen from these mice. The
protective effect recorded for the p-ialB vaccination was similar to that
demonstrated in the Rev.1 (V4) group, whereby two of the mice in each group
did not harbour detectable levels of Brucella (S 10 CFU per spleen) post-
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challenge. A statistically significant difference was not indicated between the
Rev.1 (V4) and p-iaIB, or Rev.1 (V1) and p-ialB bacterial loads (p = 0.8413 and
0.6905 respectively). In terms of protection units, p-ialB ~ Rev.1 (v4) > Rev.1
(V1) (2.15, 2.12, and 1.83 respectively).
It should be noted that these data show a number of PBS and pcDNA3.1 group
mice with Brucella levels falling within the range defined as the control zone
(zone 2), where fewer Brucella than the challenge dose were recovered from
the spleen. For example, mice in the pcDNA3.1 group have Brucella splenic
loads within the Control Zone (Zone 2). However, comparison against the PBS
(unvaccinated control) mice indicates that this apparent reduction is not
statistically significant (p = 0.8413).
The results of the two studies, summarised in figures 6.2 and 6.3 confirmed that
p-omp25 and p-ialB are protective against B. melitensis 16M challenge in the
mouse, and indicate that the protective effect is not significantly different to that
achieved by Rev.1 vaccination.
6.4.2: The specific immune response to vaccination
The ability of each of the vaccines to induce specific antibodies and cell
mediated immune responses was measured.
Humoral immune responses
For p-omp25 vaccine assessments, p-omp25 , pcDNA3.1, PBS and Rev.1
group antisera (pooled by group) were assayed by simple indirect ELISA
against B. melitensis 16M antigen, recombinant Omp25-GST and GST
antigens. Each group sample was assayed in serial dilution from 1/40 (antiseral
diluent) through to 1/5120. Figure 6.4 shows the antibody responses, in terms of
specific IgG1 and IgG2a titres, as measured in the Omp25-GST and 16M
ELiSAs during the experiment.
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Figure 6.4: Specific antibody production in response to vaccination
observed in the p-omp25 investigations
300012000 [a) l le
Figure 6.4 illustrates that anti-Brucella and anti-Omp25 antibodies were
confirmed from both Rev.1 vaccinated and p-omp25 vaccinated mice. Specific
antibody was demonstrable from the vaccinated mice from week two of the
study. Individual serum samples were also assayed at a dilution of 1/100 at
week eleven of the study: none of the samples were positive in the GST ELISA,
but all mice in the Rev.1 and p-omp25 groups were detected as positive in the
Omp25-GST and 16M ELlSAs (data not shown). Specific responses were not
detected from either PBS or pcDNA3.1 inoculated mice at any time during this
study.
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In the p-ialB investigations, serological responses were measured in ELISA
against 16M or recombinant lalB antigen. The data is summarised in figure 6.5.
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Each graph indicates the endpoint titres of pooled serum samples measured by ELISA at
intervals post-vaccination. [a]lgG1 antibody detected by 16M ELISA, [b] IgG2a detected by 16M
ELISA, [cl IgG1 detected by recombinant Omp25-GST ELISA and [d] IgG2a detected by
recombinant Omp25-GST ELISA. The times at which p-omp25, PBS or pcDNA3.1 inoculations
were given are indicated as V1, V2, V3 and V4. Rev.1 inoculation was given at V1 only.
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Figure 6.5: Specific antibody production in response to vaccination
observed in the p-ialB investigation
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IgG1 detected by recombinant lalB ELISA and [d] IgG2a detected by recombinant lalB ELISA.
The times at which p-ialB PBS or pcDNA3. 1 inoculations were given are indicated as V1, V2,
V3 and V4. Rev.1 inoculation was given at V1 only.
Figure 6.5 indicates the development of anti-lalB and Anti-Brucella antibodies
following vaccination. Brucella specific IgG1 and IgG2a antibodies are detected
from both Rev.1 and p-ialB vaccinated mice. Individual antisera were also
assayed at week eleven of this study: all five mice in the p-ialB vaccine group
were positive in both the 16M and lalB ELISA (data not shown). lalB specific
antibodies were not observed in either the Rev.1, PBS or pcDNA3.1 control
mice at any sampling time.
The development of antibodies in Rev.1 vaccinated mice
In the studies summarised in Figure 6.4 and 6.5, Rev. 1 vaccination resulted in
high titre IgG1 and IgG2a isotype antibodies detected in the 16M ELISA. 16M
specific antibodies were first detectable at week five during the p-omp25
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investigation (Figure 6.4 [a] and [b]) and week eight during the p-ialB
investigation (Figure 6.5 [a] and [b]). In both studies, high titres of both IgG1 and
IgG2a were recorded at the final sampling time (eleven weeks post-
vaccination).
A Rev.1 response to Omp25 antigen was detectable early post-vaccination: low
titre specific IgG1 was detected in the sera of the Rev.1 vaccinated mice at two
weeks post-vaccination. By five weeks post-vaccination relatively high titre
Omp25 specific antibodies were evident in these mice, suggesting that the
Omp25 antigen is immunologically significant in Rev.1 vaccination. In contrast,
a significant reaction specific to the lalB antigen was not detected from the
Rev.1 group mice at any stage during the p-ialB investigations, suggesting that
Rev.1 vaccination does result in immunological recognition of this particular
antigen.
The development of antibodies in p-omp25 vaccinated mice
The maximal antibody titres detected from the p-omp25 vaccinated mice in the
16M antigen ELISA are 1/520 for IgG2a and 1/360 for IgG1. When using the
recombinant Omp25-GST assay the titre of IgG1 specific antibody is
approximately 1/420, which is comparable to that achieved in the 16M ELISA.
However, the IgG2a titre measured by this assay is significantly greater than
that measured by 16M ELISA (1/1280). Furthermore, IgG2a responses were
detectable in the Omp25-GST assay at week two of the investigation after a
single immunisation with p-omp25, and were maximal by week five, following a
single booster immunisation. IgG1 responses were first detected at week five,
and reached their maximum by week eight, following a third DNA inoculation.
The development of antibodies in p·;aIB vaccinated mice
High titre (~ 1/5120) IgG1 and IgG2a isotype antibodies were detected in
antisera from mice receiving p-ialB inoculations (Figure 6.5). Antibodies were
detected by both the 16M and the recombinant lalB ELISA. These responses
became detectable at week eight for the lalB ELISA and week eleven for the
16M ELISA. Responses were maximal at week eleven of the study.
174
Cell mediated immune responses
Splenocytes were harvested from three individual mice per group and cultured
in the presence of Brucella specific antigens: 16M antigen, Brucellergene™,
recombinant lalB or recombinant Omp2S-GST (depending upon the particular
investigation), mitogen control (Concanavalin A) or in media (OMEM alone).
Splenocytes were harvested and assayed at three week intervals throughout
the study period. After 48 hours, SN was removed from these cultures and
tested for the presence of cytokines. The concentration of IL-10, IL-4, IFN-y , IL-
12: p70 and p40 and TNF-a in SNs was determined using Biosource Quantikine
ELiSAs.
IFN-y production measured in splenocyte supernatants
IFN-r production in response to mitogen stimulation
Concanavalin A stimulation of mouse splenocytes resulted in the generous
production of IFN-y (~SOO pg/ml) from all groups of mice except for those in
the Rev.1 group during the p-omp25 investigation at week 11 of the study. Thus
indicating that except for these samples all cells were viable and capable of
proliferation and cytokine production. Negligible IFN-y (or indeed any cytokine)
was detected from Rev.1 immunised mice at week 11 of the p-omp25
investigation, in response to any of the stimulating antigens. The time delay
incurred through processing the splenocytes at containment level III most
probably contributed to a decline in viability of this particular set of splenocyte
cultures: consequently these data were not representative of the IFN-y
production from Rev.1 vaccinated mice at this time. Concurrent samples from
the PBS, pcDNA3.1 and p-omp25 groups in this investigation were not
adversely affected: the expected response to mitogen stimulus was recorded in
these samples. An appropriate mitogen response was observed at week eleven
of the p-ialB investigation from the Rev.1 vaccinated mice, confirming the ability
of mice to produce IFN-y at this stage post-vaccination.
Significant differences in ConA induction of IFN-y between mice that were
inoculated with p-omp25, p-ialB, pcDNA3.1 or PBS were not noted. The mean
concentration of IFN-y in all of these samples was between 350 and 850 pg/ml,
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indicating that the ability to respond to mitogen stimulus was not influenced by
the different vaccine inoculations. However, mice vaccinated with Rev.1 showed
overall lower IFN-y concentrations (in response to GonA stimulation) at both five
and eight weeks post-vaccination in both investigations (mean IFN-y
concentrations between 50 and 450 pg/ml) suggesting a reduced capacity to
produce IFN-y following Rev.1 vaccination. However, this effect was not found
to be statistically significant (Mann-Whitney U test, p ~ 0.05).
IFN-r production in response to Brucella specific antigen stimulation
Brucella specific antigen stimulation resulted in different IFN-y responses from
each group of mice depending upon vaccine and time of sampling. These
results are summarised in table 6.1.
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Table 6.1: IFN-y production in response to specific antigen stimulation
Time and [# DNA inoculations)
Week 5 (2) Week 8 (3)Week 2 (1) Week 11 (4)
Brucellergene TM stimulation
Rev.1
p-omp25
p- ialB
86.7 ± 92.9 315.8 ± 156.6 * 323.6 ±177.23 * 390.3 ± 239.3 *
NO 18.6 ± 2.3 * 1.66 ± 0.99 92.9 ± 130.3
s 1.0 2.9 ± 2.8 2.2 ± 1.9 s 1.0
Omp25-GST stimulation
Rev.1 NO
NO
5.9 ± 6.9
15.1 ± 9.1 *
11.2 ± 6.9 *
136.5 ± 164.47
F
97.1 ± 127.5p-omp25
lalB stimulation
Rev.1 s 1.0 s 1.0 s 1.0 s 1.0
p-ialB S1.0 S1.0 2.9±2.8 11.0±13.5
Table showing mean ± standard deviation IFN-yconcentration (pg/ml) in the SN of stimulated
splenocyte cultures after 43 ± 6 hours.
All DNA vaccine related data derived from assay of three mice per group at each sampling time.
Rev.1/Brucel/ergene stimulation data derived from six mice group (except for week 11 data,
which used only three mice per group).
NO: Not determined.
F: failed assay.
* indicates samples with IFN-yconcentrations significantly different to those measured in the
corresponding antigen netve (PBS or pcDNA3.1 vaccinated) samples (Mann Whitney U test).
Detection limits the assay = 1.0 pg/ml.
Brucella specific IFN-y production in Rev.1 vaccinated mice
Brucellergene™ stimulation resulted in consistently high mean quantities of
IFN-y production (between 80 - 1000 pg/ml) from Rev.1 vaccinated mice at
weeks five, eight and eleven of the experiments. Omp25-GST stimulation was
able to promote limited IFN-y production from the Rev.1 vaccinated mice. In
contrast, lalB stimulation of Rev.1 mice did not result in detectable production of
IFN-y. A summary of IFN-y responses to antigen stimulation is given in table
6.1, and Omp25-GST specific IFN-y responses are summarised in figure 6.6
Brucella specific IFN-y production in DNA vaccInated mice
Brucellergene TM stimulation did not reveal consistent or statistically significant
IFN-y production from p-ialB or p-omp25 vaccinated mice. Furthermore,
significant IFN-y was not observed from lalB stimulated p-ialB group mice.
Limited IFN-y production was recorded from p-ialB inoculated mice in response
177
Chapter 6: Further assessment of p-omp25 and p-18/B
to lal8 stimulation at week eight and week eleven of the study (summarised in
Table 6.1), but these responses were not determined to be statistically
significant. It is possible that the quantity of antigen specific IFN-y observed (S
30 pg/ml) is of biological significance and contributes to the protective response,
but a larger sample size or more sensitive method for IFN-y detection would be
required to validate these observations. These data suggest that despite the
detection of high titres of IgG2a antibody, significant IFN-y production is not
evoked by the p-ialB vaccinations. These results are summarised in Table 6.1.
In contrast, Omp25 specific induction of IFN-y was observed in p-omp25 group
mice (data summarised in Figure 6.6).
Figure 6.6: Net IFN-r production in response to Omp25-GST stimulation
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,
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time of sampling (weeks)
Mann-Whitney U Test of each data set presented figure 6 f was carried out to
determine if the IFN-y concentration of a sample from vaccinated mice was
significantly different to that from PBS vaccinated mice. Production of IFN-y in
_ Rev. 1 C::J PBS EJ p-omp25 c=J pcDNA3.1
Bars represent the mean NET IFN-yconcentration {pg/ml], and error bars the standard
deviation. • indicates samples for which the concentration of IFN-y is significantly greater than in
the corresponding PBS samples. NO: not determined. F: failed assay.
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response to Omp25-GST antigen stimulation is clearly evident in both p-omp25
and Rev.1 vaccinated mice. However, because of high non specific responses
these responses were not always considered statistically significant in
comparison to the responses of antigen narve mice (PBS or pcDNA3.1 groups).
At week 5, significant IFN-y production was detected in the p-omp25 inoculated
mice (p= 0.0022) samples that had been stimulated with Omp25-GST. At week
eight only Rev.1 samples showed any statistically significant IFN-y production (p
= 0.0022), and at week 11 none of the responses were determined to be
statistically significant (Note that the Rev.1 assay failed). Note that although
responses are observed at both week eight and week eleven from the p-omp25
inoculated mice they are not determined to be significant in the Mann-Whitney
U analysis because of variability in the response between individuals in the
group.
In summary, analysis of IFN-y concentrations in the SNs of stimulated
splenocyte cultures revealed Omp25 specific IFN-y production by Rev.1 and p-
omp25 vaccinated mice. lalB specific IFN-y was not confirmed for either Rev.1
or p-ialB vaccinated mice.
Further analysis of the IFN-yresponse through ELlSPOT and T cell subset
depletions following completion of the full course of vaccinations
ELiSPOT and T cell subset depletion procedures were used in detailed analysis
of the IFN-y production from splenocytes of vaccinated mice. Pooled splenocyte
samples of five mice per group, harvested at week twelve of the investigations,
were used in these assays. This corresponded to a time of three weeks after
the final DNA (or PBS control) inoculation, and three weeks post-vaccination for
the Rev.1 (V4) group. This time was selected to reflect the available effectors
present after the full course of vaccinations and shortly before challenge in
these investigations. The summarised results of these studies are shown in
tables 6.2 and 6.3.
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Table 6.2: A comparison of the frequency and phenotype of IFN-r
secreting cells from mice receiving p-omp25 or control vaccine Rev.1. L1
IFN-r secreting cells per million in response to stimulation with specific
antigens
Vaccine Net responsive cells
Total cell
population
CD4+ depleted
cell population
CD8+ depleted
cell population
Stimulation with recombinant Omp25-GST [10 flgl ml]
Rev1 @ 3weeks 15.5 ± 1.44 4.0 ± 1 18.5 ± 2.5
pcDNA3.1 [X4] 0 0 0
10.8 ± 3.5p-omp25 [X4] 73.3 ± 20.3 41.0 ± 5.2
Stimulation with Brucellergene ™ [40 )..lgIml]
Rev.1 @ 3 weeks
pcDNA3.1 [X4]
p-omp25 [X4]
41.36 ± 13.66 10.0 ± 15.04
o
o
o
o
28.0 ± 10.76
o
o
The number of IFN-y secreting antigen specific cells detected in splenocyte preparations from
vaccinated mice. Data is displayed as L1SFC/ million, where L1 SFC is derived by subtraction of
the background response of corresponding unstimulated cells. Data is displayed as mean L1
SFC Imillion ± Standard deviation. Two way ANOVA analysis confirms statistically significant
differences between the vaccine groups and the T cell subset responses (p < 0.0001)
SFC: Spot Forming Cells.
Results presented in Table 6.2 illustrate that Brucellergene ™ stimulation
resulted in the greatest frequency of antigen specific IFN-y secreting cells from
Rev.1 vaccinated mice. T cell subset depletion indicated that the CD4+ cell
subset was largely responsible for the production of IFN-y in response to this
antigen, since depletion of CD4+ cells from the reaction resulted in a 76%
reduction in the number of Brucellergene ™ specific IFN-y secreting cells
detected. In contrast depletion of CD8+ cells resulted in 33% reduction in the
number of Brucellergene ™ reactive cells detected. A response was also
detected in Rev.1 group splenocytes following stimulation with the recombinant
Omp25-GST antigen. Within this Omp25 specific population depletion of the
CD4+ subset contributed the greatest reduction in IFN-y secreting cells,
resulting in a 74% decrease in the mean number of responsive cells. CD8+
depletion of splenocytes from these mice did not result in detectable reduction
in the number of Omp25 responsive cells.
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The ELiSPOT data reveals that p-omp25 vaccination produced greater total
numbers of IFN-y secreting cells in response to stimulation with Omp25-GST
than Rev.1 vaccinated mice (73.3 Spot Forming Cells (SFC) versus 15.5 SFC,
respectively). Measurement of depleted cell populations in the p-omp25
samples indicated a significant decrease (-85%) in the number of responsive
cells in the CD8+ depleted population. CD4+ subset depletion from this
splenocyte population resulted in a 44% decrease in the number of responsive
cells. This data suggested that that both CD4+ and CD8+ antigen specific IFN-y
secreting cells were induced by inoculation of p-omp25 but there was a bias
toward the CD8+ population. This result was in direct contrast to that observed
for Rev.1 vaccinated mouse samples stimulated with the Omp25 antigen where
CD4+ cells appeared to be the main population of responder cells.
Brucellergene™ or Omp25-GST specific IFN-y producing T cells were not
detected from vector or PBS control groups (data not shown).
In a second study (data presented in table 6.3) the CD4+ dominated response
to Bruceliergene™ antigen was confirmed in the Rev.1 vaccinated mice, with
CD4+ depletion causing an 81% reduction in detectable responder cells, and
CD8+ depletion resulting in a less pronounced effect (58% reduction).
Interestingly, IFN-y secreting cells were not detected following recombinant lalB
stimulation of splenocytes harvested from Rev.1 vaccinated mice at this time.
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Table 6.3: A comparison of the frequency and phenotype of IFN-r
secreting cells from mice receiving p-ialB or control vaccine Rev.1. LiIFN-
r secreting cells per million in response to stimulation with specific
antigens
Vaccine Net responsive cells
Total cell
population
CD4+ depleted
cell population
CD8+ depleted
cell population
Stimulation with recombinant lalB [20 I=lg/ml]
75.02 ± 18.37 11.0 ± 4.85
o
o
36.25 ± 2.92
Rev.1 @ 2 weeks
pcDNA3.1 [X4]
p-ialB [X4]
o 0
o 0
Stimulation with Brucellergene ™ [40 I=lg1mI]
Rev.1 @ 2 weeks
pcDNA3.1 [X4]
p-ialB [X4]
42.50± 20.06 8.1 ± 4.03
o 0
o 0
18.0 ± 6.02
o
o
The number of IFN-y secreting antigen specific cells detected in splenocyte preparations from
vaccinated mice. Data is displayed as L1SFC/ million, where L1SFC is derived by subtraction of
the background response of corresponding unstimulated cells. Data is displayed as mean L1SFC
/million ± Standard deviation. Two way ANOVA revealed a statistically significant difference
between the SFC detected in different vaccine groups and for different subsets (p < 0.05).
From the p-ialB vaccinated samples a high number of lalB specific cells were
detected. T cell depletion studies revealed that elimination of the CD4+ subset
resulted in the most noticeable reduction in IFN-y secreting cells. CD4+
depletion effected an 85% reduction in the number of responsive cells whereas
CD8+ depletion only achieved a 51% reduction, suggesting that p-ialB
vaccination results in priming of both CD4+ and CD8+ antigen specific cells, but
CD4+ cells are the dominant phenotype.
In summary the ELISPOT results presented in Tables 6.2 and 6.3, indicate a
CD4+ dominated IFN-y response from Rev.1 and p-ialB vaccinated mice, and a
CD8+ dominated response from p-omp25 .
IL-4, IL-12, IL-10 and TNF-a production
In addition to IFN-y, the antigen specific generation of two other key Th.1
cytokines (IL-12 and TNF-a.) was determined from the SN samples of each
group at each sampling time. Th 2 cytokine production (IL-4) and
182
11 '
immunoregulatory cytokine production (IL-10) was also assessed. All cytokines
were measured using Biosource Quantikine ELlSAs to assess the concentration
of cytokine in 48 hour splenocyte cultures. These data are summarised in table
6.4.
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Table 6.4: TNF-a, IL-12p 40 and p70, IL-4 and IL-10 production in response
to Brucella specific antigen stimulation
Time
Week2 Week 5 Week 8 Week 11
Net TNF-a production (Mean ± standard deviation) pg/ml
Brucellergene™ stimulation
Rev.1 22.7 ± 27.7 48.8 ± 69.4 104.2 ± 95.5 195.9 ± 12.9*
p-omp25 1.6±1.0 31.2±6.1 19.4 ± 14.8 34.4 ± 10.8
p- ialS 99.9 ± 153.3 64.0 + 92.1 64.5 ± 89.6 26.83 ± 29.3
Omp25-GST stimulation
Rev.1 ND 7.0±1.0 70.0 ± 71.7 F
p-omp25 6.5 ± 5.6 33.2 ± 23.1 13.7 ± 16.6 32.0±13.1
lalB stimulation
Rev.1
p-ialB 10.3±14.1
S1.0 pg/ml recorded in each sample
5.2 ± 9.37 s 1.0 2.8 ± 4.1
Net IL-12 p40 and [IL-12 p70] production (mean only) pg/ml
Brucellergene™ stimulation
Rev.1
p-omp25
34.4 [ S1.0]
33.8 [29.9]
35.0 [5.1]
44.9[9.1]
62.0 [6.9]
151.7 [S1.0]
53.8 (12.3]
68.5 [S1.0]
p-ialB S1.0 pg/ml recorded in each sample
Omp25-GST stimulation
Rev.1 ND
p-omp25 111.0 [ S1.0]
lalB stimulation
Rev.1
-ialB
62.9 (5.4]
51.5 [ s1.0]]
42.5 [12.0]
500 [7.5]
F
189.1 [17.0]
:51.0pg/ml recorded in each sample
Net IL-4 production (mean only) pg/ml
Brucellergene™ stimulation 1Omp25-GST stimulation IlalB stimulation
Rev.1
p-omp25
- ialB
s10.0 pg/ml recorded in each sample
Net IL-10 production (mean only) pg/ml
Brucellergene™ stimulation / Omp25-GST stimulation / lalB stimulation
Rev.1
p-omp25 S10.0 pg/ml recorded in each sample
-ialB
ND: not determined, F: failed assay, * significant quantity of IFN-ycompared to corresponding
antigen naiVe control (PBS or pcDNA3.1). Each data point was obtained from three mice per
group. Samples were assayed in duplicate.
184
TNF-a. production from vaccinated mice
As with IFN-y stimulation, TNF-a was found in all ConA stimulated samples,
except those from the failed Rev.1 assay at week 11 of the p-omp25 study. The
average concentration of net TNF-a in the ConA stimulated samples was
around 95.48 ± 70.66 pg/ml (Mean ± standard deviation). Significant differences
in the TNF-a concentration of different vaccine groups was not observed (p ~
0.05). The average concentration of TNF-a in the SNs from unstimulated cells
was 15.81 ± 7.69 pg/m!. Significant differences in the TNF-a concentration of
resting cultures (unstimulated) from each vaccine group was not observed (p ~
0.05).
The net concentration (Concentration of antigen stimulated TNF-a minus resting
concentration) of TNF-a produced in response to Brucellergene TM, recombinant
Omp25-GST or lalB stimulation was measured. TNF-a production was
detected. However, variation of TNF-u concentrations within groups (n = 3)
meant that overall the responses of the vaccinated mice were not significantly
different (Mann-Whitney U test, p ~ 0.05) to those observed from non-immune
PBS inoculated mice stimulated with the same antigen.
IL-12 production from vaccinated mice
IL-12 p40 and p70 were measured in the SNs of cultured splenocytes by
Biosource ELiSAs. For these assays group samples were pooled, such that
each test sample consisted of the pooled SN from a single group (n = 3) of mice
stimulated with a designated antigen at a designated time.
A low level of IL-12 p40 was detected intermittently in SNs of p-omp25 and
Rev.1 vaccinated mice following stimulation with Omp25-GST or
Bruceliergene™. The average IL-12 p40 concentration in the SNs of
unstimulated pooled splenocyte cultures from these mice was 53.46 ± 33.37
(Mean ± standard deviation) pg/ml, but an antigen specific effect on IL-12 p40
production was not observed. A similar pattern of IL-12 p70 production was
observed, although IL-12 p70 was not detected in unstimulated SNs and
concentrations observed in stimulated SN never exceeded 30 pg/m!. Notably,
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neither IL-12 p40 nor p70 were detected in the SNs from Rev.1 vaccinated mice
in response to stimulation with recombinant lalB. Furthermore, IL-12 p40 and
p70 were not determined following stimulation of p-ialB group splenocytes with
either Brucellergene TM or recombinant lalB.
IL-4 production from vaccinated mice
IL-4 was recorded intermittently, at concentrations of S10 pg/ml in the SNs from
unstimulated, lalB, Omp25 and Brucellergene™ stimulated samples. A
significant vaccine or stimulation specific effect on IL-4 concentration was not
detected (p > 0.05). IL-4 was consistently detected in the ConA stimulated SNs.
IL-10 production from vaccinated mice
SNs were tested for the presence of IL-10. Each sample contained between 1
and 10 pg/ml of IL-10. Neither antigen nor vaccine specific effects on IL-10
concentration were detected.
6.5: Discussion
The main aims of the investigations described in this chapter were to assess a
vaccine formulation based upon a mixture of the two omp25 constructs for
protective efficacy and also to measure the antigen specific immune responses
elicited by both p-omp25 and p-ialB vaccines.
The protective efficacy of the combined pCR3.1-omp25 and pTargeT-omp25
vaccine: p-omp25 was confirmed. Mice receiving the p-omp25 vaccine, given as
four intramuscular inoculations of 100 J.1gper dose at three week intervals, were
able to control Brucella replication in the spleen to a similar extent to those mice
vaccinated with the 'gold standard' live strain vaccine, B. melitensis Rev.1 (V4).
Similarly, the p-ialB vaccine resulted in an equivalent protective effect to the
Rev.1 (V4) vaccine. Both the p-omp25 and p-ialB vaccines effected a mean 2 -
3 log reduction of splenic Brucella compared to the PBS unprotected control
(3.42 or 2.15 protection units or ~ 99% reduction of actual numbers). This
represents a considerable improvement over the protective efficacy so far
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described for other Brucella specific DNA vaccines. In addition this represents
the first report of protection mediated by DNA vaccines against brucellosis
caused by B. melitensis. A DNA vaccine encoding the B. abortus GroEL was
found to be immunogenic but not protective against B. abortus 544 challenge
(LeClerq et aI, 2002). The immunodominant cytosolic P39 protein (AI-Mariri et
aI, 2001) resulted in only a modest reduction of B. abortus 544 at eight weeks
post-challenge (0.73 Log reduction in splenic Brucella compared to control
mice), and a statistically inSignificant reduction (0.15 Log) at an earlier sampling
time (4 weeks post-challenge). A more successful result was recorded from a
DNA vaccine based upon Brucella Lumazine synthetase, which afforded a 1.25-
1.65 log control of splenic Brucella following B. abortus 544 challenge
(Velikovsky et aI, 2002). Similarly, a DNA vaccine encoding Brucella Superoxide
dismutase (SOD) resulted in a 1.15 log protective effect through intramuscular
inoculation which was moderately improved (1.52) by delivery of the vaccine
directly to the spleen (Munoz-Montesino et aI, 2004). Thus far B. melitensis
specific DNA vaccines with demonstrable protective efficacy have not been
reported.
Importantly, the immune mediators of the protective effect were examined and
the induction of critical Th 1 biased effector responses were shown for the novel
p-omp25 and p-ialB vaccines. The presence of relatively high titre antibodies of
the IgG2a isotype in the sera of DNA and Rev.1 vaccinated mice, suggested the
involvement of IFN-y rather than IL-4 in the specific response to vaccination
(Snapper et ai, 1988). Antigen specific IFN-y secretion was directly measured
following specific antigen stimulation of splenocytes. Other Th 1 cytokines were
also measured in the SNs of stimulated splenocyte cultures: TNF-a and IL-12
p40 and p70 were produced in response to stimulation with Brucella antigens
although a consistent statistically significant antigen specific stimulation effect
could not be seen. Overall the cytokine analysis revealed a Th 1 dominated
immune response specific antigen stimulation in the DNA and Rev.1 vaccinated
mice. This response is expected to contribute to the protection of mice following
B. melitensis 16M challenge.
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The established method for estimating optimal protective efficacy of live
vaccines in the BALB/c infection model involves challenge at 30 days post-
vaccination (Bosseray et aI, 1991). This suggests that the most appropriate time
to measure corresponding immunological effectors of protection is around 30
days post-vaccination. Specific secretion of cytokines was measured from the
Rev.1 vaccinated mice at weeks 2, 3, 5, 8, and 11 post-vaccination during the
current experiments. Thus, the response measured between weeks two and
five of the study corresponded to the time when the mouse was optimally
protected against challenge. The data obtained in these studies indicated that
period of optimal protection from Rev.1 correlated well with the detection of
Brucella specific IFN-y and the first appearance of specific IgG2a. Thus
suggesting that these are significant effectors of the protective response. The
ability of the Rev.1 vaccinated mice to recognise the Omp25 and lalB antigens
was also measured.
The expected humoral immune response to Rev.1 was observed. IgG1 and
IgG2a specific antibodies were detected using the 16M ELISA. The Omp25-
GST ELISA confirmed the specific immunological recognition of the Omp25
antigen in Rev.1 vaccinated mice (Figure 6 e [c] and [d]), and the kinetics of the
response measured in the Omp25-GST ELISA was similar to those measured
in the 16M ELISA. The maximum titres achieved in the 16M ELISA were
considerably higher than in the Omp25-GST ELISA, reflecting the fact the
dominant serological response from Rev.1 vaccinated mice is directed against
the S-LPS present in 16M antigen. Additionally, possible structural differences
between the recombinant Omp25-GST and native Omp25 in the 16M antigen
that result from the absence of Omp25- LPS association in the recombinant
preparation and possible differences in protein folding may impact upon
availability of conformational epitopes. Therefore, the detection of responses
from Rev.1 vaccinated mice in the Omp25-GST ELISA was significant because
it indicated that the E. coli derived recombinant Omp25-GST preparation was
not prohibitive to the binding of anti-Omp25 antibodies raised against the native
protein delivered by the live Rev.1. Notably, the IgG2a Omp25-GST specific
antibodies were detected earlier than IgG1 Omp25-GST specific antibodies in
the Rev.1 vaccinated mice. This IgG2a dominance persisted for the duration of
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the experiment. Thus, indicating that although both IgG1 and IgG2a antibodies
are produced on exposure to Rev.1, the response directed against Omp25
antigen is IgG2a dominated. Thereby suggesting native Omp25 antigen
promotes a Th 1 type immune response in the context of protective vaccination.
In contrast, lalB specific antibody responses were not detected in Rev.1
vaccinated mice. Transcription of ia/S from the S. melitensis strain 16M was
confirmed through RT-PCR studies described in Chapter 3, and the expression
of protein from cultured 16M has been confirmed through the proteome studies
of Wagner et aI, (2002). Moreover, the same group directly compared the
cultured proteomes of S. melitensis 16M and Rev.1 demonstrating significant
differences in the expression of certain proteins, but differential expression of
lalB was not recorded (Eschenbrenner et aI, 2002). Together this data suggests
that lalB expression is a consistent and persistent phenomenon from cultured S.
melitensis strains, and therefore the antigen is expected to be accessible for
interaction with the immune system following Rev.1 vaccination. Notably, these
expression studies are restricted to measuring lalB expression under artificial
culture conditions and do not necessarily reflect the changing environment and
stimuli encountered in vivo. It is therefore possible that the lack of lalB specific
antibodies in the vaccinated mice reflects a lack of expression of this antigen
from Rev.1 in vivo.
Specific antibody responses were recorded from the mice that received
inoculation with the novel DNA vaccines. Relatively high titre IgG1 and IgG2a
specific responses were detected from the p-omp25 inoculated mice in both the
16M and Omp25-GST ELlSAs. The confirmation of specific antibody from the p-
omp25 group in the 16M ELISA proved that antibodies induced by this vaccine
were able to bind native Omp25. Furthermore, demonstration of p-omp25 16M
reactive antibodies supported a possible in vivo interaction between p-omp25
generated antibodies and viable B. melitensis 16M following challenge. The titre
of anti-Omp25 in the antisera from p-omp25 vaccinated mice exceeded that
recorded for the Rev.1 vaccinated mice, indicating an enhanced response to
this antigen elicited by the monospecific DNA construct compared to the
recommended live vaccine strain Rev.1. In addition, Omp25 specific serum
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antibodies were apparent after a single inoculation, suggesting that immunity
might be achieved from less than four inoculations of p-omp25.
High titre lalB specific antibodies were measured following vaccination with p-
ialB. In the 16M ELISA (expected to contain native Brucella lalB protein) the
response was not detected until the final sampling time (week eleven) of the
study. Due to differential sensitivities of the two ELiSAs, a response was
determined earlier in the recombinant lalB ELISA, with seropositive results
apparent from week eight of the study. These data suggest that at least three
inoculations were required to elicit detectable specific antibody, and that four
inoculations resulted in production of high titre antibody responses. Again, it is
significant that the reactivity is demonstrable in the 16M ELISA as this denotes
recognition of native lalB protein by antibodies raised through p-ialB
vaccination, and such reactivity would be essential for these antibodies to have
an impact on live Brucella challenge in vivo.
In the 16M ELISA the IgG1 titre from p-ialB exceeded that measured from the
Rev.1 vaccinated animals. Since the reactivity of Rev.1 group antisera in the
16M ELISA is polyclonal but antisera from DNA vaccinated mice is
monospecific, this result suggests that high affinity and avidity response
antibodies are induced by p-ialB vaccine. In contrast to the IgG2a biased
response to the Omp25 antigen from p-omp25 vaccinates, the balance of IgG1
and IgG2a in p-ialB antisera does not suggest a strong Th 1 bias.
In summary, both DNA vaccines (p-omp25 and p- ialB) promote development of
specific antibodies. IgG2a dominant Omp25 specific responses are achieved by
both Rev.1 and p-omp25 vaccination, whereas lalB specific antibodies are only
observed in p-ialB vaccinated mice: Rev. 1 vaccinated mice do not produce lalB
specific antibodies.
Historically antibodies have not been considered important for protection
against intracellular pathogens (for review see Casadevall, A., 2003). This view
is increasingly being challenged, and there is evidence for antibody mediated
protection against obligate intracellular pathogens such as Ehrlichia chaffensis
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(Winslow et aI, 2000), and Listeria monocytogenes (Edelson 1999 and 2001).
The role of antibodies in protection against brucellosis is ambiguous. Protection
has been described in mice following passive transfer of Brucella specific
antibodies (Montaraz et aI, 1986), but in a natural infection situation their impact
is difficult to determine. The detection of Brucella specific antibodies is more
often associated with diagnosis of active infection, rather than considered as an
indicator of immunity. Indeed, Duran-Ferrer et aI, (2004) noted a reduction in
magnitude and duration of antibody response in pregnant 'immune' Rev.1
vaccinated sheep following challenge with virulent Brucella in comparison to
previously naive sheep. Nevertheless, it is well known that opsonisation of
bacteria by specific antibody enhances the efficiency of phagocytic uptake, and
this has been documented for both virulent and attenuated Brucella strains in
cultures of both activated and quiescent phagocytic cells. Moreover,
opsonisation appears to decrease survival time and replication of internalised
Brucella (Harmon et aI, 1988., Caron et aI, 1994., Gross et aI, 1998), suggesting
that antibodies can affect the outcome of infection.
Protection has been observed in passive transfer studies using monoclonal
antibodies (Mabs) against Brucella LPS and a number of outer membrane
proteins (Montaraz et aI, 1986., Cloeckaert et aI, 1991, Bowden et a/, 1995).
However, to date the protection mediated by antibodies specific for proteins has
been difficult to demonstrate against smooth strain Brucella challenge and
significantly, protection mediated through Omp25 specific antibodies has been
repeatedly dismissed. For example, Montaraz (Montaraz et aI, 1986) was
unable to protect BALB/c mice against B. abortus challenge through passive
transfer of IgM raised against 'porins' from Brucella outer membrane fractions.
Furthermore, IgG2a Mab specific to the Omp25 protein (A59/05F01/C09) was
unable to provide significant protection against challenge with the naturally
rough B. avis (Bowden et aI, 2000) suggesting that even in the absence of
interference from LPS and peptidoglycan on the Brucella surface antibodies
against this protein as are not sufficient for protection. The role of lalB specific
antibodies in brucellosis immunity has not previously been assessed.
Significantly, over 70% of Brucella convalescent antisera were reactive to this
protein, suggesting widespread humoral recognition of this protein. It is possible
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that Omp25 and lalB specific antibodies contribute to protection through
increasing the efficiency of the phagocytosis and subsequent destruction of the
internalised Brucella. Alternatively, interaction of the specific antibody and
Brucella antigen may promote protection through neutralisation of an essential
virulence function. The data obtained in this study confirms that specific
antibodies capable of recognising and binding with native lalB and Omp25 are
generated by the DNA vaccines, but their relative contribution to the observed
protection remains undefined.
Irrespective of any direct role in protection, the demonstration of specific IgG2a
antibody is significant since immunoglobulin class switching to generate IgG2a
requires the involvement of the critical cytokine effector IFN-y. The actual
measurement of IFN-y and other cytokines was achieved through in vitro
restimulation of the splenocytes of vaccinated mice and measurement of
cytokine concentration in the 48 hour stimulated splenocyte cultures. For the
Rev.1 vaccination this data reflects the changes in IFN-y response occurring
with time post-vaccination. The Rev.1 vaccinated mice were shown to produce
IFN-y upon stimulation with the Omp25-GST or Brucellergene TM antigens, but
not upon stimulation with the lalB antigen. Apart from a modest and statistically
insignificant reduction in the quantity of IFN-y elicited following ConA stimulation
at weeks five and eight, there was no direct evidence for a disruption of IFN-y
production from Rev.1 vaccinated (infected) mice, which would correlate with
the observed IFN-y hiatus observed in BALB/c mice exposed to virulent Brucella
infection (Murphy et aI, 2001a).
Rev.1 vaccination resulted in a Th1 cytokine profile in which IFN-y was the
principal effector released upon encounter with Brucella specific antigens.
Importantly, IFN-y release was also observed when Rev.1 mice were stimulated
with recombinant Omp25-GST indicating that native Omp25 primes T cells
following Rev.1 vaccination. In contrast, IFN-y was not observed in the SNs of
lalB stimulated splenocytes from Rev.1 mice, suggesting that the lalB antigen is
not involved in Rev.1 mediated immunity.
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The measurement of antigen specific IFN-y is significant since IFN-y is
considered crucial to anti-Brucella immunity (Murphy et aI, 2001a/b). Cytokine
production following Omp25 stimulation was qualitatively similar in p-omp25 and
Rev.1 vaccinated mice. A rapid induction of IFN-y response was observed, with
considerable IFN-y evident following the second p-omp25 inoculation. At week
eight and week eleven (after the third and fourth p-omp25 vaccinations
respectively) the mean concentration of Omp25 specific IFN-y was elevated in
the SNs of p-omp25 inoculated mice, compared to those from other mice.
However, this was not considered statistically significant because of the high
degree of variability within the groups. Although desirable, statistical
significance in the assays cannot be taken as an absolute measure of success
or failure because of low sample numbers. Nonetheless, the data confirms
antigen speciflc induction of IFN-y in p-omp25 inoculated mice, which is evident
in SN from week five of the study after one booster inoculation.
TNF-a and IL-12 were also measured intermittently in the SN from Brucella
antigen stimulated splenocytes. However, the production of these cytokines in
vaccinated mice was never significantly different to that observed in the antigen
na"ive controls. TNF-a is a primary mediator of inflammatory responses and
important in the regulation of immune responses. It is expressed by a number of
activated cell types, including macrophages, neutrophils and NK cells of the
innate immune response as well as antigen specific T and B cells. Thus, a large
proportion of the TNF-a observed in these studies from any group of mice is a
result of innate response to bacterial antigen by the splenocyte populations, and
consequently innate TNF-a production may obscure measurement of antigen
specific effects.
Despite the absence of a convincing vaccine mediated augmentation of TNF-a
production, the demonstration of production of this cytokine from p-omp25 is
noteworthy because of the reported inhibitory effects of native Omp25 on TNF-a
production by cultured human macrophages (Jubier-Maurin et a', 2001). The
inhibition of this key mediator is known to be significant in the control of
Brucella, particularly early on in the infection (Zhan et a', 1996., Murphy et ai,
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2001) and thus Omp25 has an important immunomodulatory role that possible
contributes to the virulence or survival of the Brucella. The reported inhibition of
TNF-a by Omp25 has yet to be confirmed in vivo or indeed demonstrated from
cell cultures other than human THP-1 macrophages, but the possibility of such
effects naturally invites questions regarding the safety of an Omp25 based
vaccine. Judging from the fact that the p-omp25 vaccinated mice are capable of
TNF-a generation and that these mice are protected against challenge it would
appear that such immunomodulation does not feature in this particular model.
Nevertheless, because this is often cited as a host specific effect there remains
a concern TNF-a inhibition could occur in humans inoculated with this vaccine.
The investigation of this potential problem in humans is outside the scope of this
thesis but would need to be addressed before the application of this vaccine in
humans could be considered.
lalB specific IFN-y, TNF-a or IL-12 were not recorded in the splenocyte SNs
from either Rev.1 or p-ialB vaccinated mice. In the absence of demonstrable
lalB specific Th 1 cytokines, IL-10 and IL-4 production was assessed in order to
check for a possible mechanism of IL-12 inhibition, and the involvement of
regulatory T cells in the immune response to p-ialB vaccination or lalB
stimulation. IL-10 is known to inhibit the synthesis of Th 1 type cytokines, and
reduce activation of monocytes, macrophages and dendritic cells (For review
see de Waal Malefyt and Moore, 1998). However, no evidence of elevated IL-10
concentrations was detected in any of the groups. In addition, Brucella antigen
specific induction of IL-4 was not observed in any of the samples thus ruling out
the generation of a strongly Th 2 biased immune response.
Although the actual in vivo proportion of Brucella reactive cells was not
measured, ex vivo incubation with Brucellergene™, lalB, or Omp25-GST, and T
cell fractionation and ELISPOT methods were used to evaluate the number of
antigen specific primed and activated IFN-y secreting cells in the splenocyte
population of the mice post-vaccination. The ELISPOT data therefore provided
a snapshot of the effector cell population present in the vaccinated mice prior to
challenge.
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The phenotype of antigen specific IFN-y secreting cells was determined by
simple in vitro T cell depletion procedures. Both CD4+ and CD8+ T cell have
been shown to contribute to the control of Brucella growth in the BALB/c mouse
in adoptive transfer studies (Araya et aI, 1989). Additional studies involving in
vivo depletion strategies have indicated that the involvement of CD8+ cells is
crucial (Pavlov et aI, 1982., Mielke, 1991., Oliveira and Splitter 1995). However,
recently it has been suggested that whilst CD8+ T cells are important in the
control of live attenuated Brucella infections, they have a less significant role in
the control of virulent infections. Baldwin and Gorenka (2004) postulated that
CD8+ cells are effective at contrOlling primary infection with virulent B. abortus
2308 in C57BLl6 mice at three and six weeks post-infection but not at ten
weeks. The absence of a role for CD8+ cells in the later stages of infection with
virulent strains is postulated to relate to an as yet undefined virulence
mechanism which manipulates antigen presentation in the infected host in order
to avoid MHC class I peptide loading and thereby avoid induction and the
cytotoxic action of CD8+ T cells. Ultimately, this strategy would promote
establishment and persistence of the virulent Brucella infection in the mouse,
because once this virulence factor was operational infected cells would not
display antigen for recognition by CD8+ effector cells. Therefore, any protective
effect from CD8+ T cells is limited to the early stages of infection prior to the
activation of the virulence factors that reduce MHC class I peptide loading and
hide the virulent Brucella from activated cytotoxic T cells. This hypothesis
ultimately indicates that CD4+ T cells are crucial for the control of chronic
brucellosis.
For the Rev.1 (V4) mice the ELISPOT data showed that CD4+ cells were
largely responsible for the production of Brucellergene TM specific IFN-y. When
these splenocytes were stimulated with the Omp25-GST antigen rather than
Brucellergene TM a qualitatively similar CD4+ dominated response was
observed. Thus indicating that an Omp25 specific CD4+ effector cells
population is generated following exposure of the host to native Omp25 antigen
delivered by live Brucella. The relative contribution of the Omp25 specific
response to the overall protective effect of Rev.1 vaccination cannot be directly
determined in this experiment, but is clear that a significant number of effector
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cells are produced soon after exposure, suggesting that the immune response
against this antigen is important. In contrast, lalB specific IFN-y effector cells
were not detected from Rev.1 vaccinated mice. This finding correlates with the
humoral immune response and SN cytokine data, and supports the hypothesis
that lalB is not a significant antigen in Rev.1 mediated immunity.
Omp25 specific effector cells were also confirmed in p-omp25 vaccinated mice.
A significant number of Omp25-GST responsive cells were observed in the total
splenocyte population from these mice. In fact, a greater frequency of Spot
Forming Cells (SFC) was measured from these samples than observed in the
concurrent Bruceliergene™ stimulation of the Rev.1 (V4) derived splenocytes.
Since the Brucellergene ™ response of the Rev.1 (V4) vaccinated mice
indicates the magnitude of IFN-y priming achieved through a successful
protective vaccine in response to multipartite stimulus, the high number of
Omp25-GST specific SFC suggests observed following p-omp25 vaccination
suggests highly effective priming of biologically significant numbers of T cells.
Interestingly, the T cell subset depletion studies indicated that CD8+ T cells
were mainly responsible for the production of IFN-y following p-omp25
vaccination. Depletion of the CD8+ fraction of the splenocyte population
resulted in an 85% reduction in the number of detectable responsive cells,
whereas CD4+ depletion only caused a 44% reduction. This result contrasted
with that observed for the Rev.1 vaccine where CD4+ cells were responsible for
the majority of the Omp25 specific IFN-y production. Whether this difference is
significant in terms of the longevity of protective immunity or for the
extrapolation of findings to the target species is speculative.
Despite the absence of confirmed specific IFN-y in the SN of cultured stimulated
splenocytes, lalB specific effector cells were observed in p-ia/S vaccinates
using the ELiSPOT assay. Notably the total number of lalB specific SFC
detected in the ELISPOT for p-ialB vaccinated mice was not significantly
different to the number of Omp25 specific SFC demonstrated following p-omp25
vaccination despite differences in the quantity of this effector recorded in the SN
of each set of stimulated cells. This finding suggests that both the p-ia/S and p-
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omp25 vaccines result in quantitatively similar numbers of primed T cells, but
there is a difference in the capacity of the primed T cells to respond to stimulus
with cognate antigen. That is, lalB specific T cells secrete less IFN-y upon
ligation with cognate antigen than Omp25 specific T cells. Interestingly, the lalB
specific IFN-y secreting cells were shown to be mainly CD4+ cells. Depletion of
CD4+ cells resulted in an 85% reduction in the IFN-y secreting SFC per million
detected in ELiSPOT assay. CD8+ cells were also primed by this vaccine, as
depletion of this subset resulted in a 51% decrease in detected effector cells.
The priming of different T cell subsets is usually related to the mechanisms of
antigen presentation. DNA vaccines promote CD8+ T cell priming when antigen
is presented by APCs in the context of MHC class I. Direct transfection of APCs
results in endogenous production and processing of the encoded antigen to
produce strong CD8+ effector cells responses, whereas transfected myocytes
are thought to promote CD8+ T cell priming mainly through cross-presentation
mechanisms. The generation of CD4+ effector cells following DNA vaccination
is generally thought to occur following expression of the encoded gene in
bystander cells, and subsequent uptake and MHC class II restricted processing
of the exogenous antigen by APCs. However, autophagy occurring in dendritic
cells as part of normal cell homeostasis has also been shown to deliver
endogenous antigens into the phagolysomal complex and thus access the MHC
class II processing pathway (For review see Howarth and Elliot, 2004).
The differential priming of antigen specific CD4+ and CD8+ subsets by Rev.1,
p-ialB and p-omp25 vaccines may be related to differences in the antigen
presentation pathways targeted by the different vaccines. Rush et sI (2002)
have shown that cell effective priming of T cell subsets through DNA
vaccination is dependent upon both the quantity of presented antigen and the
cellular location of the expressed antigen, with cell associated antigen
accessing to MHC class I proceSSing routes delivering stronger CD8+ priming.
Omp25 specific CD4+ and CD8+ priming were observed from both p-omp25
and Rev.1 vaccines. However. the relative frequencies of CD4+ and CD8+ cells
suggests that class II presentation of Omp25 derived peptides is dominant
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following Rev.1 vaccination, whereas class I presentation is dominant following
DNA vaccination. From this observation it can be concluded that DNA derived
Omp25 is probably cell associated and effectively targeted to MHC class I
peptide loading through either direct or cross-presentation routes. In contrast,
the strong antibody response and CD4+ priming bias of p-ialB reflects
dominance of the MHC class II presentation of the antigen. During the
production of the recombinant lalB protein it was observed that the N terminal
signal sequence of the ialB gene was active in E. coli resulting in the export of
the nascent protein to the cell membrane and cleavage of the GST fusion tag
from the mature protein (Mahavir Singh, personal communication).
Furthermore, although it was not conclusively demonstrated, the IFA results
obtained in chapter 3 suggested that the secretion signal of the Brucella ialB
gene was also functional in eukaryotic cells. The signal is expected to result in
the export of the protein to the cell surface and potential secretion into the
extracellular environment. If such processing occurs in vivo following expression
of the p-ialB plasmid by transfected host cells, or following expression of the
ialB gene directly from Brucella during infection, the secreted protein will be
readily accessible for exogenous antigen processing via MHC class II restricted
mechanisms leading to CD4+ priming, thus accounting for the CD4+ bias in the
IFN-y producing cells. Secretion of the antigen also makes it accessible for
interaction with 8 cells and antibody binding, and thus explains the high
antibody titres observed following p-ialB vaccination.
Despite a difference in T cell priming this study does not reveal any discernable
difference between the ability of p- ialB, p-omp25 or Rev.1 vaccinated mice to
protect mice against B. melitensis 16M challenge.
In conclusion, current results have confirmed that protective vaccination with
Rev.1 results in the generation of a CD4+ dominated effector response and
negligible numbers of CD8+ effector cells. Similarly, the protective p-ialB
vaccine promotes a CD4+ dominated response, with a lower but significant
population of CD8+ effector cells. In contrast, p-omp25 vaccination results in a
CD8+ dominated response with a relatively low number of CD4+ cells. The
impact of these differences in T cell priming upon protective efficacy are not
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immediately apparent from this investigation as each vaccine promoted an
equivalent protective effect following challenge at 30 days post-vaccination.
Baldwin and Gorenka indicated that CD8+ T cells were still effective for the
control of B. abortus 2308 in the C57BLl6 mouse up to six weeks post-infection,
and therefore extrapolation of this finding to the current investigations suggests
that CD8+ cells would contribute to the control of infection observed at 15 days
post-challenge but may not be sufficient to control any residual Brucella
remaining after six weeks. In this case the CD4+ effector cells become essential
for the complete elimination of infection, and thus vaccines such as Rev.1 or p-
ialB which induce high frequency CD4+ priming are likely to be most effective
for long term control of infection. In contrast vaccines promoting CD8+ priming
have to induce suitably potent effectors to eradicate infection prior to the
subversion of antigen processing by virulent organisms. The absence of viable
Brucella recovery from 75% of the p-omp25 vaccinated mice suggests effective
deployment of anti-Brucella effectors, but sterile immunity in 100% of vaccinates
is not achieved. Consequently, although the CD8+ priming by the p-omp25
vaccine is significant, the demonstration of an appreciable Omp25 specific
CD4+ population is encouraging as this is likely to be essential for the clearance
of residual infection.
This investigation of p-omp25 represents the first report of protective immunity
against smooth strain Brucella challenge effected by Omp25 specific immune
responses. Other researchers have reported that the delivery of viable
recombinant E. coli expressing B. melitensis Omp25 on the surface was unable
to confer protection against B. melitensis 16M challenge in the BALBI mouse
model despite the generation of significant titres of specific IgG2a and a
doubling of antigen specific IFN-y compared to unmodified E. coli controls
(Bowden et aI, 1998). It is not realistic to directly compare the IFN-y response
described by Bowden et aI, with that generated through p-omp25 immunisation
as the influence of the E. coli specific response in the former study cannot
accurately be delimited and may obscure the antigen specific response. E. coli
LPS will undoubtedly account for a large proportion of the IFN-y induction
observed in this study. However, a comparison of the capacity of the E. coli
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Omp25 and p-omp25 vaccines to promote specific responses may provide
some insight into the differential protective efficacies. For instance, although the
E. coli Omp25 vaccine induces far greater quantities of IFN-y (in the ng/ml
range rather than pg/ml), there is a greater relative enhancement of antigen
specific IFN-y (a mean ten-fold increase) between the p-omp25 vaccine and it's
relevant vector control (E. coli pUC19 for the Bowden study and pcDNA3.1
vector control in this study). It is therefore possible, that Omp25 specific priming
may be more potent from the DNA vaccine than the live E. coli, and this
improved IFN-y response may be directly related to the enhanced protective
efficacy.
It is not possible to determine the impact of potential differences in the IFN-y
secreting cell phenotypes between the DNA and E. coli Omp25 vaccines as this
was not measured in the E. coli study. However, as the parent strain E. coli is
not normally considered to be an intracellular pathogen, delivery of the Omp25
antigen for MHC class I presentation and generation of CD8+ T cells is
anticipated to be less significant than seen with DNA vaccines. Thus, the potent
induction of Omp25 specific CD8+ cells may also contribute to the improved
efficacy of the p-omp25 vaccine.
The specific immune response to Brucella lalB antigen has not previously been
investigated, and this study represents the first report indicating this to be an
important protective antigen in brucellosis. The p-ialB vaccination resulted in an
equivalent protective effect to that observed from the Rev.1 or p-omp25
vaccines. Immune responses to p-ialB vaccination were characterised by strong
antibody responses and a CD4+ dominated IFN-y secreting effector population.
The Brucella lalB antigen is postulated to be involved in a specific receptor
defined interaction with host cells, which facilitates internalisation. This function
is well characterised for the homologous Bartonella ialB product (Mitchell and
Minnick 1995). In Brucella lalB is likely to be most important in cells such as
placental trophoblasts, as specific receptor mediated internalisation is a
redundant mechanism in professional phagocytes. However, lalB receptor
interaction may facilitate entry of the bacteria into phagocytes without the
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activation of bactericidal responses associated with Fc, complement or
fibronectin (Fn) mediated internalisation. Alternatively, the ialB gene product
may playa role in the subversion of pathways trafficking internalised bacteria to
the replicative niche. A major immunological output of p-ialB vaccination is
antibody. It is therefore hypothesised that the generation of high affinity anti-lalB
IgG may act to neutralise the function of the lalB protein. Moreover, the
secretion or surface location of the lalB protein allows antibodies to be effective
in a neutralising, complement fixing, or opsonising capacity. A thorough
investigation of the role of the ialB locus in Brucella pathogenesis is required.
The production of B. melitensis L\iaiBmutants and comparison of in vitro and in
vivo growth would be facilitate understanding of the role of this antigen in
pathogenesis and protective immunity. Importantly, lalB specific immune
responses were shown to be protective, despite their notable absence in Rev.1
mediated immunity.
In conclusion, the data generated in this investigation confirms that mice were
protected through vaccination with the p-omp25 or p-ialB DNA vaccines and
that the four-dose vaccination schedule resulted in the generation of antigen
specific IFN-y and serum antibodies of IgG1 and IgG2a isotype. The value of
Omp25 as a protective antigen is supported by the observation of significant
Omp25 antibody and IFN-y production in Rev.1 vaccinated mice. In contrast
lalB specific antibody and IFN-y were not detected from Rev.1 vaccinated mice
suggesting that this antigen is not contributory to protective immunity in Rev.1
vaccinated mice. The demonstration of p-omp25 and p-ialB protective efficacy
and characterisation of antigen specific responses in the BALB/c mouse is a
significant first step towards the development of a non-living vaccine that could
be applied to target species: small ruminants or man.
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Chapter 7: AN INVESTIGATION OF CATIONIC
LIPOSOME DELIVERY SYSTEMS TO IMPROVE
DNA VACCINE EFFICIENCY
7.1: Summary
The DNA vaccines p-omp25 and p-ialB had been shown to have equivalent
protective efficacy against B. melitensis 16M challenge when delivered as four
100)Jg doses at three week intervals (p-omp25 [X4] and p-ialS [X4]). In order to
reduce the amount of DNA and the number of inoculations needed for the
protective effect, modifications to the vaccination strategy were assessed. A
single dose ilm inoculation of either naked DNA vaccine (p-omp25 [X1] or p-ia/S
[X1]), or liposome adsorbed DNA (L-p-omp25 [X1] or L-p-ia/S ) was unable to
provide the same level of protection as the p-omp25 [X4] or p-ia/S [X4]
vaccination.
Differences were recorded in the specific immune responses elicited by the
different vaccine preparations. The specific antibody responses were greatest
following the multiple dose vaccinations with naked DNA (p-omp25 [X4] or p-
ia/S [X4]. Single dose naked DNA (p-omp25 [X1) or p-ia/S [X1}) vaccinations
produced only low titres or an absence of detectable antibodies, but delivery of
equivalent quantities of DNA surface adsorbed to cationic liposomes (L-p-
omp25 or L-p-ia/S ) resulted in improved titres. IFN-r secreting CD4+ or CD8+
effector cells were not demonstrable in either p-ialB [X1} or L-p-iaIB [X1}
vaccinated mice. However, an anamnestic IFN-r effector cells was detected
from L-p-ia/S [X1] vaccinated mice post-challenge, suggesting that modest
enhancement of T cell priming had occutred. Although significant, this
improvement was insufficient for protective immunity from a single dose of
vaccine, suggesting that antibody alone is insufficient and that CD4+ effectors
are required for protection. In contrast, fewer total IFN-r secreting cells were
observed for the L-p-omp25 [X1] vaccinated mice than in the p-omp25 [X1}
mice, and a reduction in the capacity for CD8+ T cell priming was observed in L-
p-omp25 [X1] vaccinates. The superior efficacy of the p-omp25 [X4] versus the
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p-omp25 [X1] strategy was also correlated with a modest increase in CD8+
effector cells. Together the data suggest that both cell subsets contribute to
protection but that the CD8+ cells are essential for clearance under the
conditions assessed in this experiment.
In conclusion, four doses of p-omp25 or p-ialB naked DNA vaccines are
protective. A single dose of these naked DNA vaccines is not sufficiently
immunogenic to be protective. Liposome delivery of these vaccines is effective
for promoting more rapid induction of antibody responses. However, a single
dose of liposome DNA vaccine does not promote appropriate cellular responses
for protection against Brucella challenge.
7.2: Introduction
In the previous chapters two novel DNA vaccines based upon the B. melitensis
16M genes ialB and omp25 have been shown to be protective in the BALB/c
mouse model of brucellosis. Through these studies it was concluded that p-
omp25 protection was effected through a Th 1 biased cell mediated response to
vaccination, characterised by the generation of antigen specific IFN-y secreting
CD8+ and CD4+ cells, with a simultaneous IgG2a dominated specific antibody
response. Furthermore, facets of this response (IFN-y and IgG2a) were
demonstrable after two inoculations of the p-omp25 plasmid, suggesting that it
may be possible to achieve protection from a reduced number of inoculations of
the vaccine. The p-ialB vaccine was also shown to have significant protective
efficacy in the mouse model, and evoked a high titre specific antibody
responses and CD4+ dominated effector responses.
Before these vaccines can be tested for efficacy in a small ruminant host,
further work is required to improve the efficiency of the vaccination protocol.
The present protective protocol requires four inoculations of 100 ~g of plasmid,
given at three week intervals. The extrapolation of this vaccination protocol to
the intended host is not necessarily simple and the quantities and frequency of
DNA inoculations required for effective vaccination of livestock need to be
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determined. Since increased quantities of DNA are perceived as necessary to
elicit immune reactions from larger animals in comparison to the mouse models,
this currently makes large scale DNA vaccination of livestock economically
untenable. For this reason methods to improve the efficiency of vaccination, in
terms of reducing the amount of DNA required to promote an effective immune
response are required before vaccine trials.
Secondly, in addition to a drastic reduction in the amount of DNA required, the
impracticality of booster vaccinations needs to be addressed. The need for
repeated booster vaccinations invokes a need for multiple farm visits by a
veterinarian for administration of the vaccine, or precise and regular direct
application of the licensed product by the stockowner. In the case of human
vaccination the current vaccination schedule would require patients to make
multiple follow-up visits to health care professionals. In both a veterinary and
medical setting this requirement not only increases the cost of vaccination but
also increases the opportunity and propensity for non-compliance with the
protective protocols. Therefore, in order to make DNA vaccination a useful
alternative to current strategies an efficacious vaccine consisting of a single
immunisation of a minimal amount of DNA is required. And thus in order to
progress with the development of p-ialB and p-omp25 for use in target species
demonstrable protective efficacy and defined immunological correlates of
protection in the BALB/c mouse model following a single inoculation of DNA
needs to be demonstrated. The principal aim of work undertaken in this study
was to assess the protective efficacy and immune response achieved following
a single inoculation of the selected DNA vaccines (p-omp25 and p-ialB ).
Unfortunately, naked DNA vaccination is an inefficient procedure. Indeed, to the
best of the authors knowledge, there are no convincing examples of a protective
effect demonstrable from subjects receiving only a single intramuscular
immunisation with a naked DNA vaccine. Methods for improving the efficiency
of DNA vaccination in livestock and non-human primates have been widely
investigated (van Drunen Littel-van den Hurk et aI, 2004., O'Hagan et aI, 2001.,
Singh and O'Hagan, 2003). Most of these concentrate on improving the
expression capacity of the plasmid or improving the delivery of the plasmid to
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the host cells. The capacity of a DNA vaccine to induce an immune response is
naturally dependent upon its capacity to express encoded antigen in-vivo.
Numerous studies have shown that engineering of vaccines in order to increase
the level of antigen expression through the inclusion of molecular adjuvants,
non-specific intron elements and Kozak signal sequences, along with promoter
and codon optimisation can all be useful in improving the level of expression of
encoded antigen from plasmids (For review see Garmory et aI, 2003). However,
the expression of antigen is only possible from appropriately transfected host
cells and therefore the effectiveness of the vaccination is ultimately restricted by
the efficiency with which the plasmid is delivered to the nucleus of the target
host cell.
From biodistribution studies aimed toward assessing the fate of parenterally
administered naked DNA it is estimated that as much as 99% of inoculated
plasmid is destroyed almost immediately by extracellular nucleases. Therefore,
the vast majority of DNA inoculated into the host is not appropriately
internalised by host cells and therefore cannot contribute to the induction of an
immune response in terms of generation and presentation of specific antigen.
This 'waste' DNA is not entirely redundant as it is thought to contribute to the
overall effect of DNA vaccination through CpG specific stimulation of innate
receptors such as TLRs, and thus functions as an inherent adjuvant in the
vaccine preparation (Klinman et ai, 2004). Nevertheless, parenteral delivery of
naked DNA is a very inefficient use of the plasmid preparations. One
consequence of this is that the success of this naked DNA vaccine approach in
both murine models and target species often appears to be somewhat dose
dependent. For any DNA vaccine there appears to be a critical threshold dose
of DNA below which the number of transfected cells is too low to result in
measurable immune reaction. Increasing the quantity of DNA above this
threshold does not always increase the effectiveness of the vaccine but
decreasing the quantities of DNA generally results in decline or indeed
abrogation of the response.
Numerous mechanical and formulation strategies have been investigated for
ability to increase in vivo transfection efficiencies. Among the widely reported
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mechanical strategies for improving the delivery of DNA vaccine plasmids to
host cells are ballistic devices referred to "Gene guns", and the increasingly
popular in-vivo electroporation strategies. In addition to the mechanical
strategies, the physical formulation of a vaccine can impact upon
immunogenicity and efficacy. The formulation of vaccines with classical
adjuvants such as alum, and oil and water emulsions are the most notable
examples of this. Both mechanical and formulation strategies have been
investigated for improving DNA vaccination in livestock species (For review see
van Drunen Little-van de Hurk et aI, 2004).
Studies of delivery strategies used with DNA vaccination are summarised in
table 7.1.
Table 7.1: A summary of some of the more widely investigated DNA
vaccine delivery strategies
Reference Detail
I: Classical adjuvants
Fischer et ai, (2003) The formulation of a Rabies DNA vaccine with Aluminiumphosphate results in a rapid high titre serological response.
Van Rooij et ai, (2002) Neutralising antibody production and reduced shedding of
Porcine Pseudorabies Virus (PPRV) in Pigs, following
administration of DNA vaccine formulated with DDA adjuvant.
II: Biological adjuvants
I
Sobol et ai, (2003)
Wong et et, (2002)
Somasundaram et ai,
(1999)
Min et ai, (2001)
Local mucosal immune responses achieved through DNA
vaccination with a plasmid encoding Influenza virus
Haemagglutinin antigen (HA) co-delivered with Cholera Toxin
(CT).
Improved efficacy of a Foot and Mouth Disease Virus DNA
vaccine in Pigs through co-administration of IL-2.
Improved efficacy of a PRV DNA vaccine, using porcine GM-
CSF as an adjuvant.
Asse.ssment of the adjuvant potential of cytoklnes on a DNA
vaccine for avian coccidiosis, caused b Eimeria acervuline.
Continued ....
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Table 7.1 continued ...
/1/: Mechanical delivery strategies
Braun et ai, (1999) Gene gun delivery of a DNA vaccine encoding the BovineHerpes Virus gO antigen shown to be protective in cattle
Lodmell et ai, (2002)
De Rose et ai, (2002)
Babiuk et ai, (2002),
Tollefsen et ai, (2003)
Babiuk et ai, (2003)
Gene gun delivery of Rabies DNA vaccines results in more
rapid induction of significant neutralising antibody titres in non-
human primates.
A review discussing various delivery routes for the
administration of DNA vaccines to sheep.
Intramuscular inoculation of plasmid DNA followed by in-vivo
electroporation improves the efficiency of plasmid uptake and
subsequent immune responses in ruminants.
DNA vaccine
Spanning the division between delivery strategy and classical adjuvant are
liposome and microparticle based approaches. Liposomes and microparticles
have proven efficacious for the mucosal delivery of drugs and proteinaceous
effectors, and more recently the adjuvant properties of these delivery systems
have been exploited in vaccine development. DNA or proteins encapsulated
within appropriate size liposomes or microparticulate formulations are readily
taken up by host cells thereby resulting in increased transfection efficiency for
DNA vaccines. Moreover, lipid formulation of DNA is frequently used to improve
transfection efficiencies in vitro. Appropriate particle design can also provide a
level of protection for the DNA plasmids against degradation by nucleases.
Studies comparing particle mediated DNA vaccination with naked DNA
vaccination show that lower quantities of DNA are required to elicit equivalent
immune responses when using the particle approach. Furthermore, particle
based formulation permits the investigation of alternate delivery routes, such as
oral inoculation or direct administration to mucosal surfaces, which otherwise
would not be applicable for naked DNA immunisation. The applicability of these
systems for mucosal delivery is particularly appealing in the context of
brucellosis vaccine development, as promoting local mucosal protective
responses is a potential strategy for preventing the establishment of infection.
Thus particle based delivery strategies offer a number of advantages over the
direct intramuscular inoculation of naked DNA vaccine.
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The use of microparticles based upon the variants of the polymer PLG for the
delivery of vaccines has been extensively reviewed (O'Hagan et ai, 2004.,
Singh et ai, 2004). Similarly, the use of phospholipid vesicles, or liposomes, for
the improved delivery of vaccines has been widely investigated (Felnerova et ai,
2004). Liposomal delivery of protein antigens has an adjuvant effect but unlike
many classical adjuvants does not induce local or systemic toxicity (Allison and
Gregordiadis, 1974., Alving, 1991., Gregoriadis, 1990), which is a distinct
advantage in a veterinary or clinical setting. Variations of liposome formulas
incorporating immunostimulatory compounds such as MPL, or Quil A
(ISCOMS), or viral membrane proteins (virosomes) have been investigated for
antigen delivery, and have shown usefulness in improvement of immune
responses in a number of model systems (Singh and 0' Hagan, 2002).
Neutrally charged non-ionic surfactant based liposomes, or niosomes, have
also been shown promote increased potency response to model antigens in
small animal models (Brewer et ai, 1998), and cationic cholesterol based
liposomes have proven to be an effective in augmenting the immune response
to an influenza vaccine (Guy et aI, 2001).
In the context of DNA vaccination, delivery of the plasmid directly to the APC is
the primary advantage of particle-based formulations. Lipid based transfection
agents have been proven highly effective at promoting DNA uptake by cells in
culture (Feigner, 1991), and in vivo (Gregoriadis, 1996). Gregoriadis et aI,
(1997) demonstrated Significant improvement of antibody and cytokine
responses from mice receiving DNA vaccines entrapped in cationic liposomes
compared to mice receiving equivalent quantities of naked DNA. In addition,
cationic llposome preparations have proven effective adjuvants for the mucosal
delivery of HIV-1 DNA vaccines in mice (Ishii et aI, 1997). In large animal
targets, llposome based DNA vaccines have proven effective for induction of
serological responses in ponies against rabies virus (Fischer et aI, 2003a), and
improving the protective efficacy of a DNA vaccine for canine distemper virus
(CDV) in dogs (Fischer et aI, 2003b).
The immunopotentiation effect of liposomes is believed to derive from both the
increased uptake of DNA into professional antigen presenting cells, and
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subsequent trafficking to the local draining lymph node for efficient T cell
priming. In support of this claim, liposome complexed DNA does not appear to
be taken up by muscle cells at the site of inoculation in significant quantities, but
is detectable at the draining lymph node presumably following phagocytosis by
APe (Velinova et aI, 1996). Following phagocytosis it is presumed that the
liposome fuses with the phagosomal membrane and releases the DNA into the
cytoplasm leading eventually to the expression of the encoding antigen, and
processing for immune recognition (Legendre, 1995).
Thus, the use of a liposome based delivery strategy with the p-omp25 and p-
ialB vaccines may be able to improve the immunogenicity of these vaccines.
Liposomes can protect the DNA from nuclease attack, whilst enhanced uptake
leads to more efficient induction of immune systemic immune responses in the
lymph node. Such an approach is hypothesised to improve the efficiency of the
DNA vaccination process such that a reduction of the quantity of DNA or the
number of inoculations required to generate the protective response may be
possible. The achievement of protective efficacy from a single inoculation of
vaccine would go some way toward promoting DNA vaccination as a practical
alternative to current live vaccines for brucellosis.
In summary, the investigations described in this chapter were devised to
investigate the immunogenicity and protective efficacy of a single shot of the
naked DNA vaccines p-omp25 and p-ialB . Since intramuscular naked DNA
vaccination is known to be a relatively ineffective method, an alternative delivery
strategy involving the passive adsorption of DNA to cationic Iiposomes was also
investigated as a means to improve vaccine efficacy.
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7.3: Experimental procedures and aims
The protective efficacy and immunogenicity of naked DNA and liposome
formulated DNA vaccination was assessed. As this investigation required the
comparison of protective efficacy and immunogenicity of a considerable number
of groups of mice, it was not possible to conduct all experiments concurrently.
Thus, the data presented in this chapter is the result of three separate in-vivo
investigations. The BALB/c mouse brucellosis model was used in all studies,
and appropriate control groups of unvaccinated mice, pcDNA3.1 inoculated
mice and Rev.1 vaccinated mice were included in each experiment. These
studies can be summarised as follows: -
1. p-omp25 [X1] vs p-ialB [X1]: A comparison of the protective efficacy of
single dose naked DNA vaccination with either p-omp25 or p-ialB .
2. L-p-omp25 [X1] vs p-omp25 [X4]: A comparison of the protective efficacy
of a single dose of liposome adsorbed p-omp25 (L-p-omp25 [X1] [X1])
with multiple dose naked p-omp25 (p-omp25 [X4]) vaccination.
3. L-p-iaIB vs p-ialB [X4]: A comparison of the protective efficacy of a single
dose of liposome adsorbed p-ialB (L-p-iaIB [X1]) with multiple dose
naked p-ialB [X4] vaccination.
The general experimental schedule is outlined in figure 7.1.
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Figure 7.1: Schematic representation of experiments to evaluate different
doses and vaccine formulations
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All details for materials and methods for each protocol within these experiments are described
in Chapter 2.
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For immunogenicity assessments antibody production was measured by ELISA
(16M antigen, recombinant Omp25-GST and recombinant laIB), and IFN-y
ELISPOT assays were used to assess the antigen specific immune response of
vaccinated mice both pre- and post-challenge.
In all of these studies commercially produced GMP grade plasmids, p-omp25 p-
ialB and pcDNA3.1 were used. Cationic liposome preparations were prepared
for this study by Dr James Brewer (University of Glasgow, Division of
Immunology and Immunopathology, Western Infirmary, Glasgow, UK). To
prepare liposome formulated DNA vaccines for inoculation, plasmid DNA was
directly mixed with liposome preparation and inoculated into mice within 1 hour
of preparation.
7.4: Results
The production of liposome based vaccines
The DNA binding efficiency of the liposome preparations was assessed.
Following mixing of the DNA and cationic liposome preparations, 50 ~I of SN
was removed from the mixture and analysed by agarose gel electrophoresis
and spectrophotometry. Neither method revealed the presence of plasmid DNA
in the SN indicating that binding to the liposomes had been effective.
7.4.1: The immunogenicity of the vaccine preparations
The capacity of vaccines to prime Brucella specific immune responses was
measured in terms of specific antibody titre and the frequency and phenotype of
antigen specific IFN-y secreting cells detectable prior to challenge.
Specific antibody production
The antibody titre following vaccination was measured from each group of mice
at two weeks post-vaccination. Single dose naked DNA and liposome
vaccination titres were compared with data obtained from previous assessment
of multiple dose naked DNA vaccinations. The data is summarised in table 7.1
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Table 7.2: A comparison of antibody responses following a single
immunisation with either naked DNA or liposome adsorbed DNA.
Titre of specific IgG1 and IgG2a antibodies in ELISA
ELISA
l Omp25-GST
i lalB 16MI I
I
Isotype IgG1 IgG2a IgG1 IgG2a IgG1 IgG2a
p-omp25 [x1] - 11320 NO NO - -
p-omp25 [X4] 11640 111280 NO NO 1/420 1/520
L-p-omp25 [X1]
i 1/320 1/1000 NO NO 11640 1/1280\
\
p-ialB [X1] I NO NO - - - -I
p-ialB [X4] NO NO 1/5210 115210 1/5210 1/5210
L-p-iaIB [X1] NO NO 11270 ( 1/30) 1/500 1/120
pcONA3.1 [X1] - - - - - -
pcONA3.1 [X4] - - - - - -
L-pcONA3.1 - - - - - -
Liposome only - - - - - -
Rev.1 @ 2 weeks - - - - - -
post-vaccination
Rev.1 @ 11 weeks 1/640 1/640 - - 1/2560 1/2560
post-vaccination
NO: Not tested. - : Negative sample (OD below assay cut off)
Data in Table 7.2 shows that a single intramuscular inoculation of naked p-ialB
plasmid was not sufficient to generate a detectable level of specific antibodies in
either the lalB recombinant antigen ELISA or the 16M antigen ELISA Whereas,
multiple inoculations of naked p-ialB elicited strong and equal magnitude
antibody titres of both IgG1 and IgG2a isotype. However, a single inoculation
with 100 Ilg of p-ialB surface adsorbed to cationic liposomes (L-p-iaIB ) was
able to generate detectable specific IgG1 and low titre IgG2a. The titre from L-p-
ialB group mice was low, and IgG1 isotype antibodies were the dominant class
of antibody whereas high titre balanced IgG1 and IgG2a responses were
detected following p-ialB [X4]. Overall, the use of liposome delivery for the p-
ialB plasmid resulted in detectable antibody responses after a single
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inoculation. which was not demonstrable from mice inoculated with an
equivalent quantity of naked DNA.
IgG1 and IgG2a Omp25 specific antibodies were detected following multiple
inoculations with p-omp25 vaccine (p-omp25 [X4]). IgG2a titres were in excess
of IgG1 titres. Notably. Omp25 specific IgG2a was recorded after a single
inoculation (p-omp25 [X1]). Specific antibody was also detected in the serum of
mice receiving liposome formulated L-p-omp25. A higher titre IgG2a response
was observed from L-p-omp25 [X1]vaccinated mice than naked p-omp25 [X1]
vaccinated mice. Furthermore. a detectable IgG1 response is achieved after a
single inoculation with L-p-omp25 [X1]but not p-omp25 [X1]. The antibody
response measured from L-p-omp25 [X1]p-omp25 [X1] and p-omp25 [X4] was
dominantly IgG2a isotype.
IFN-y production from vaccinated mice prior to challenge
For mice receiving the full course of four inoculations with plasmid DNA the
ELiSPOT assays have previously been described in Chapter 6. These results
are reiterated here for direct comparison against the results obtained for mice
inoculated with a single dose of naked DNA or liposome adsorbed DNA.
The results of the EllS POT investigations to determine the frequency and
phenotype of primed antigen specific IFN-y effector cells are summarised in
table 7.3.
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Table 7.3: A comparison of the frequency and phenotype of IFN-r
secreting cells from mice receiving various doses and formulations of
DNA vaccines. Lt IFN-r secreting cells per million in response to
stimulation with specific antigens
Vaccine Net responsive cells
Total cell
population
CD4+ depleted cell
population
CD8+ depleted cell
population
Stimulation with recombinant Omp25-GST [10 ~g/ ml]
Liposome [X1] 12.0 ± 2.21 0 0
pcDNA3.1 [X1] 0 0 0
pcDNA3,1 [X4] 0 0 0
L-pcDNA3.1 [X1] 0 0 0
p-omp25 [X1] 50.8 ± 24.9* 27,B ± 2.3 U45%} 11.3 ± 2.3U7B%}
p-omp25 [X4] 73.3 ± 20.3* 41.0 ± 5.2 U44%} 1O.B± 3,5 {tB5%}
L-p-omp25 [X1] 25.0.± 0.77* 2.8 ± 0.08 U89%} 13,0 ± 0.9 U4B%}
Stimulation with recombinant lalB [20 ~g/ml]
Liposome [X1] 10.25 ± 1.75 0 2.25 ± 1.77
pcDNA3.1 [X1] 17.25 ± 2.00 32.0 ± 17.58 11.25 ± 5.57
pcDNA3.1 [X4] 0 0 0
L-pcDNA3.1 [X1] 28.75 ± 19.12 7.05 ± 4,OS 0
p-ialB [X1] 12.75 ± 1.75 0 0
p-ialB [X4] 75.02 ± 18.37* 11.0 ± 4.B5 {tB5%} 3625 ± 2.92 US2%}
L-p-iaIB [X1] 23.25 ± 6.06 0 0
The number of IFN-y secreting antigen specific cells detected in splenocyte preparations from
vaccinated mice. Data is displayed as LI SFC / million, where LI SFC is derived by subtraction of
the background response of corresponding unstimulated cells. Data is displayed as mean
LI SFC /million ± Standard deviation.
* indicates SFC values Significantly different to the vector and liposome control groups (ANOVA
and Bonferroni's multiple comparison test, p >0.05).
{l percentage decrease or inhibition of responder cell frequency from total cells}
The effector response of Rev.1 vaccinated mice was also measured in these
investigations (see Chapter 6 for full discussion). Results showed that IFN-y is
mainly produced by CD4+ cells following vaccination with Rev.1.
The mean frequency of antigen specific IFN-y secreting cells in the splenocyte
populations of p-omp25 [X1] inoculated mice was modestly reduced in
comparison to that observed under identical stimulation conditions for the p-
omp25 [X1] vaccine: p-omp25 [4] mean 50 SFC per million compared with p-
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omp25 [X4] mean 73 SFC per million. A direct statistical comparison of the
number of SFC per well for the four replicate wells of each group sample
showed no significant difference between the data sets (Mann-Whitney U test, p
> 0.05), suggesting an equivalent effect for the two vaccine strategies. IFN-y
production from both p-omp25 [X1] and p-omp25 [X4] mice was dominated by
CD8+ T cells. Thus indicating that for this particular construct booster
vaccinations do not significantly increase the frequency of antigen specific
effector cells or alter the bias in CD4+: CD8+ priming.
For the L-p-omp25 [X1] vaccinated mice, IFN-y effector cells were detected at a
lower frequency than the p-omp25 [X1] vaccinated mice but this difference was
not determined to be statistically significant (Mann-Whitney U test, p > 0.05).
However, a statistically significant difference in the SFC from p-omp25 [X4] and
L-p-omp25 [X1] vaccinated mice was observed (Mann-Whitney U Test, p =
0.0286). Interestingly, T cell subset depletion assays revealed that the majority
of IFN-y secreting cells in the splenocyte population from L-p-omp25 [X1]
samples were CD4+ cells. This is in direct contrast to the data from the samples
obtained from mice inoculated with naked p-omp25 where both single and four
dose vaccination protocols elicited cells largely of the CD8+ phenotype.
For p-ialB vaccination the benefit of booster inoculations was more apparent.
The p-ialB [X1] was unable to elicit statistically significant numbers of lalB
specific SFC when compared to the SFC observed from pcDNA3.1 [X1]
inoculation (Mann-Whitney U test, p> 0.05). However, p-ialB [X4] group
produced approximately 75 SFC per million, and Mann-Whitney U test revealed
that this response was significantly different to that observed in both the
pcDNA3.1 and p-ialB [X1] groups (p = 0.0286).
The dominant phenotype of responder cells in p-ialB [X4] samples was shown
to be CD4+ cells. L-p-iaIB vaccination resulted in a low and statistically
insignificant total number of SFC, when compared to the response observed
from the control L-pcDNA3.1 group (p> 0.05), and a lower mean total SFC than
observed for p-ialB [X1]. Both CD4+ and CD8+ subset depletion eliminated the
detectable response from the p-ialB [X1] or L-p-iaIB samples.
216
7.4.2: The protective efficacy of the various vaccination
protocols
Due to the considerable numbers of mice involved in this investigation, it was
not possible to conduct a single efficacy trial to compare all the selected
vaccination strategies. Therefore, the protective efficacy of single dose naked
DNA vaccination, multiple dose naked DNA vaccination, or single dose
liposome formulated DNA vaccination was assessed in a number of separate
experiments, described on page 210.
The assessments of protective efficacy of liposome formulations of L-p-omp25
[X1]and L-p-iaIB (Experiments 2 and 3) were actually conducted concurrently
with the studies described in chapter 6. A direct comparison of the protective
efficacy of a single dose of the naked DNA vaccinations (p-iaIB and p-omp25)
was conducted in a separate study (Experiment 1). The data for protective
efficacy is summarised in table 7.4.
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Table 7.4: The protective effect of vaccination with naked DNA or
liposome formulated DNA.
Vaccine group Protection units
Brucella per spleen
as a % of challenge
dose
Brucella CFU per
spleen
Experiment 1: A comparison of single dose naked DNA vaccine efficacy
5.00 ± 0.05 114.8
4.56 ± 0.31 104.8
4.45±0.44 102.3
4.19 ± 0.42* 96.4
Experiment 2: p-omp25 [X4] compared with L-p-omp25 [X1]
Rev.1 (V1) 4.28 ± 0.21 96.8 0.55
Rev.1(V4) 1.47±0.82* 33.2 3.35*
o
0.02
3.42"
0.81
-0.03
PBS 4.83 ± 0.29 109.2
PcDNA3.1 [X4] 4.80 ± 0.21 108.5
p-omp25 [X4] 1.40 ± 0.69" 31.7
L-p-omp25 [X1] 4.01 ± 0.14 90.8
L-pcDNA3.1 4.86 ± 0.44 109.8
Experiment 3: p-ialB [X4] compared with L-p-iaiB
Rev.1 (V1) 2.2 ± 1.0* 51.2
Rev.1 (V4) 1.94 ± 0.77* 44.8
PBS [X4] 4.10 ± 0.68 93.6
PcDNA3.1 [X4] 3.75 ± 0.36 86.1
p-ialB [X4] 1.91 ± 0.93* 44.0
L-p-iaIB [X1] 3.07 ± 1.08 70.5
L-pcDNA3.1 3.37 ± 0.58 77.5
1.83*
2.12*
o
0.32
2.15*
1.00
0.70
Brucella CFU per spleen: Log Brucella CFU per spleen ± standard deviation.
Protection units = Log Brucella CFU per spleen of unvaccinated mice - Log Brucella CFU per
spleen of vaccinated mice. % Challenge dose: (Log CFU Brucella per spleen / Log CFU
challenge dose) X 100.
* indicates statistically significant reduction of Brucella CFU per spleen compared to PBS
controls (Mann Whitney U test, p < 0.05).
The data obtained in these investigations confirms a protective effect for Rev.1
(V4) vaccination in each experiment, and a protective effect from the four dose
vaccination protocols for p-omp25 or p-ialB (p < 0.05). Statistically significant
reduction of bacterial load is also observed for p-ialB [X1] vaccination (p <
0.05), in experiment 1. However, in terms of protection units this effect is slight
and does not compare favourably with the protective effect of the multiple dose
vaccines or the Rev.1 controls. Furthermore, the reduction is not significantly
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different (p > 0.05) when compared to that observed in the pcDNA3.1
vaccinated mice.
In experiment 2, L-p-omp25 [X1]vaccination provided a 0.88 protection unit
effect. Although a reduction in splenic Brucella was apparent this was not found
to be statistically significant (p > 0.05) in comparison to the unprotected
controls.
L-p-iaIB vaccination provided 1.0 unit of protection in experiment 3, although
this effect was not significant compared to the PBS, L-p-iaIB [X1] or vector
(pcDNA3.1) controls.
The relationship between protective efficacy and vaccine primed
antigen specific immune responses
To permit comparison of protective efficacy between experiments the Brucella
load post-challenge for each vaccine group was presented as the percentage of
the challenge dose. The mean log Brucella per spleen was calculated from the
combined data from all three experiments. These values for protective effect
were directly compared against the vaccine specific immune effectors
measured during the investigations. These comparisons of protection against
humoral immune responses and protection against IFN-y secreting cells are
presented in figures 7.2 and 7.3.
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Figure 7.2: The relationship between the protective efficacy of vaccination
and the generation of antigen specific IFN-r secreting effector cells
L-pcDNA3.1
L-p-iaiB
*p-iaiB [X4]
*p-iaiB
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Liposome only
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Graphical representation of the data from protection trials and analysis of IFN-y producing
antigen specific cells detected in mice two weeks prior to challenge
Bacterial load represented as a percentage of the challenge dose in each study. Groups
marked with· were shown to have a statistically significant protective effect.
CD4+ cells = [Total SFC - CD4+ depleted SFC], CD8+ cells = [Total SFC - CD8+ depleted
SFC).
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Figure 7.3: The relationship between the protective efficacy of vaccination
and the generation of specific antibodies
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Graphical representation of the data from protection trials and analysis of specific antibody
production detected in mice two weeks prior to challenge. Bacteria//oad represented as a
percentage of the challenge dose in each study. Groups marked with· were shown to have a
statistically significant protective effect.lgG1 and IgG2a titres measured.
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Figures 7.2 and 7.3 show the immune responses alongside the observed
protective effect of vaccination. The data shows that antigen specific immune
effectors, either IFN-y secreting effector cells or specific antibody, are present in
the protected animals prior to challenge.
Immune responses specific to the lalB antigen are characterised by strong
antibody responses and the priming of IFN-y secretion from CD4+ T cells. A
direct comparison of the total number of lalB specific effector cells and
protective effect of vaccination revealed a statistically significant correlation
(Pearson correlation method, p = 0.0066 (two-tailed), 95% confidence limits, ~
= 0.7344), showing a direct relationship between the number of lalB primed
effector cells and the reduction of Brucella load in that group of mice. Antibody
responses were also directly correlated with protective effect: Pearson analysis
to compare antibody titre against protective effect revealed p = 0.0024, ~ =
0.8076, and p = 0.0035, ~ = 0.7836, for IgG1 and IgG2a respectively.
Omp25 specific responses were characterised by the priming of both CD8+ and
CD4+ Tem responses, and production of relatively low titre antibody responses.
Each of the omp25 based DNA vaccine formulations assessed were shown to
have some level of protective activity in this model. A direct comparison of the
total number of Omp25 specific cells and protective effect of vaccination
revealed a statistically significant correlation (Pearson correlation method, p =
0.0087 (two-tailed), 95% confidence limits, ~ = 0.7095), showing a direct
relationship between the number of Omp25 primed effector cells and the
reduction of Brucella load in that group of mice. This relationship was preserved
when the CD4+ depleted cell population response (l.e.: the relative number of
CD8+ T cells) was directly compared against the protective effect: p = 0.0099, ~
= 0.6793, but not when CD8+ depleted cell population (l.e.: the relative number
of CD4+ T cells) was compared against the protective effect (p > 0.05).
Antibody responses were also directly correlated with protective effect: Pearson
analysis to compare antibody titre against protective effect revealed p = 0.0015,
~ = 0.8345, and p = 0.0139, ~ = 0.6631, for IgG1 and IgG2a respectively.
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7.4.3: IFN-r production from vaccinated mice post-challenge
IFN-y ELISPOT was conducted on splenocyte samples harvested during each
of the protective efficacy bacterial enumeration studies. The aim of this
investigation was to determine whether prior exposure to the candidate antigens
resulted in measurably different responses to Brucella challenge. The results
are summarised in table 7.4.
Table 7.4: A comparison of the frequency of IFN-y secreting cells from
vaccinated mice that had been challenged with -1 X1ct CFU B.melitensis
16M. LiIFN-y secreting cells per million in response to stimulation with
specific antigens
Vaccine group Omp25 stimulation lalB stimulation
Rev.1 60.00 ± 10.68 9.50 ± 11.50
PBS 146.75 ± 18.23 5.25 ± 2.73
Uposome [X1] 27.25 ± 8.99 1.00 ± 3.00
pcONA3.1 [X1] 89.00 ± 6.69 0
pcONA3.1 [X4] >500 0
L-pcONA3.1 [X1] >500 0
p-omp25 [X1] 3.75±1.77* NO
p-omp25 [X4] >500 NO
L-p-omp25 [X1] 46.25 ± 12.87 NO
p-iaiB [X1] NO 6.00 ± 0.62
p-iaiB [X4] NO >500
L-p-iaiB [X1] NO 43.50 ± 3.97
The number of IFN-y secreting antigen specific cells detected in splenocyte preparations from
vaccinated mice. Data is displayed as L1 SFC I million, where L1 SFC is derived by subtraction of
the background response of corresponding unstimulated cells. Data is displayed as mean L1
SFC Imillion ± Standard deviation.
NO: Not determined. > 500 indicates saturated colour development in the wells. * sub-optimal
assay: <200 SFC recorded following ConA stimulation for this group.
Table 7.4 shows the results of IFN-y ELiSPOT assays performed post-
challenge. Splenocytes used in this assay were harvested and stimulated
concurrently to the assays for enumeration of bacterial load. These data were
directly compared against the protection data. This comparison in depicted in
Figure 7.4.
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Figure 7.4: The relationship between the protective efficacy of vaccination
and the number of antigen specific effector cells detected post-challenge
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Graphical representation of the data from protection trials and analysis of total number of
specific IFNyproducing cells detected in mice at 15 ±1 days post- challenge. Bars represent
mean values and error bars on protection data reflect standard deviation.
Groups marked with* were shown to have a statistically significant protective effect. " indicates
assay with sub-optimal positive control (ConA) responses « 50 SFC per well) in IFNy EL/Spot.
Detection limits of assay are 500 SFC per well.
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Figure 7.4 shows the mean total IFNy secreting cells for each group compared
to the bacterial load recovered from challenged mice. Omp25-GST reactive
cells are detected regardless of vaccination status, and there is not a significant
correlation between prior exposure to the Omp25 antigen and the production of
Omp25 specific effector cells post-challenge. A Pearson correlation analysis of
total effector cells compared to protective effect (in terms of % challenge dose)
confirmed the absence of a measurable correlation (p = 0.1136, r2 = 0.3620).
The result for p-omp25 [X1] is possibly not reflective of the actual Omp25
responsive cells in this sample: the mitogen control stimulation for this group
also failed to reveal expected numbers of SFC, suggesting poor viability of this
splenocyte preparation. However, even if these data are removed from the
correlation analysis, a significant relationship between the number of IFNy
secreting cells detected post-challenge and the protective effect cannot be
measured.
Considerable numbers of lalB specific effector cells were only detected in
groups that had previously been exposed to the lalB antigen, i.e.: p-ialB [X4]
and L-p-iaIB [X1]. Very few lalB primed IFNy secreting cells were detected in the
Rev.1, PBS, and pcDNA3.1 groups. However, a significant correlation could not
be demonstrated between the total number of lalB specific effector cells and
protection (Pearson correlation analysis, p = 0.0785, ~ = 0.4277).
7.5: Discussion
The main aim of this study was to re-evaluate the immunogenicity and
protective efficacy of the p-ialB and p-omp25 DNA vaccines, when administered
as a single 100 J.1gintramuscular inoculation. Furthermore, it was hoped that the
formulation of these vaccines surface absorbed onto cationic liposomes would
improve the effectiveness of a single dose of 100 J.1gnaked DNA.
For both the p-omp25 and p-ialB vaccines a multiple booster protocol consisting
of four 100 J.1gdoses of plasmid at three week intervals was the most successful
approach in terms of protective efficacy. A slight reduction in bacterial load was
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observed for the p-omp25 vaccine in a single dose protocol when the plasmid
was delivered as either naked DNA (p-omp25 [X1]) or liposome adsorbed (L-p-
omp25), although these were not considered statistically signficant. A slight
protective effect (deemed statistically significant) was observed for the p-;aIB
[X1] vaccination, but protection was not indicated for the L-p-iaIB vaccination.
Overall, the data showed that single doses of vaccine given either as naked
DNA or as liposome adsorbed DNA was unable to provide equivalent protective
efficacy to that observed following multiple inoculations. ELiSPOT and ELISA
techniques were used to analyse the capacity of the different vaccination
strategies to prime IFN-y secreting T cells and antibody production respectively,
in the hope of explaining the qualitative differences in protection.
p-omp25 specific immunity
Single versus multiple dose naked DNA vaccination
Antibody responses were demonstrable following a single 100 ~g dose of naked
p-omp25 vaccine. Further booster inoculations served to increase the titre of the
specific response. Antibody responses were persistently dominated by high titre
IgG2a, suggesting a strong Th 1 bias to the immune response. However,
analysis of cellular effectors indicated that multiple booster vaccinations with
naked p-omp25 (p-omp25 [X4]) did not result in significantly more antigen
specific effector cells compared to the response elicited following a single
vaccination (p-omp25 [X1]) (Mann Whitney U test p > 0.05). Thus suggesting
that the increased protective effect of the multiple dose strategy is not achieved
through generation of a greater magnitude of cellular response. Furthermore,
both the multiple and single dose formulations of vaccine resulted in
predominantly CD8+ IFN-y responses. Depletion of the CD8+ subset resulted in
a 77% and 85% reduction in the detected effector response for p-omp25 [X1]
and p-omp25 [X4] respectively, suggesting a modest but statistically
insignificant increase in the priming of CD8+ cells from the protective four dose
p-omp25 [X4] protocol. Similarly, depletion of CD4+ cells resulted in a 44%
decrease in the total number of cells for the p-omp25 [X4] vaccination, and a
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45% decrease for the p-omp25 [X1), implying no difference in the ability of the
two vaccines to prime CD4+ T cells. Since statistically significant differences in
immune responses are not seen between p-omp25 [X1) and p-omp25 [X4) it is
not possible to determine which subset of cells has the greatest impact upon
the protective effect.
Liposome versus naked DNA vaccination
Liposome adsorption of the p-omp25 vaccine notably increased the antibody
titre observed after a single inoculation, suggesting a considerable
immunopotentiating effect from the liposome delivery. Notably, liposome
delivery did not alter the bias of the IgG2a dominated response to this antigen.
Similarly enhanced specific antibody responses following liposomal delivery of a
luciferase encoding plasmid were recorded by Norman et aI, (2000). In contrast,
the frequency of Omp25 specific IFN-y secreting cells was not improved by
liposome delivery of the vaccines, but differences in responsive T cell subsets
were recorded. Non specific IFN-y secreting cells were detected by ELISPOT
from mice that had received inoculation with uncomplexed (without DNA)
liposomes, suggesting an enhancement of non-specific IFN-y production
presumably triggered by activation of macrophages upon phagocytosis of the
liposome particles. In this way the Iiposomes are anticipated to act as adjuvants
as well as delivery vehicles for the DNA. However, this non-specific effect was
not reflected in an increase of IFN-y secreting cells for the L-p-omp25 [X1)
vaccinated mice compared to the equivalent quantity of DNA delivered as
naked DNA (p-omp25 [X1]): comparable frequencies of total antigen speCific
effector cells were detected from p-omp25 [X1] or L-p-omp25 [X1) groups.
Although similar frequencies of total effector cells were recorded in both groups,
there were significant differences in the T cell subsets responding to p-omp25
[X1) and L-p-omp25 [X1] vaccination. Whereas CD8+ cells were the dominant
type recorded from the splenocytes of p-omp25 [X1] vaccinated mice, CD4+ T
cells were the dominant cell subset recorded from L-p-omp25 [X1] vaccinated
mice. From these data it is not possible to determine whether this difference in
227
phenotype of primed effector cells had any significant impact upon the
development and maintenance of protective immunity, as both of these single
dose preparations induced equivalent non-protective effects (weak reduction in
bacterial load) despite the involvement of distinct T cell subsets.
Other researchers have shown that entrapment of DNA vaccines within cationic
liposomes can augment both Th 1 and Th 2 type cytokine production in
comparison to that achieved through naked DNA vaccination (Gregoriadis et aI,
1997). It is possible that the enhanced antibody responses observed following
L-p-omp25 [X1] vaccination were a result of increased priming of Th 2 type
immune responses rather than the protective Th1 cellular responses. IL-4
producing CD4+ cells were not measured in this investigation, and thus this
hypothesis cannot be validated. However, measurable levels of antigen speciflc
IL-4 could not be demonstrated in the omp25 vaccine studies in any of the
groups (data not shown), suggesting that any induction of Th 2 cytokine
production is small. Furthermore, the Omp25 and 16M specific antibody
response measured from L-p-omp25 [X1] vaccinated mice is IgG2a dominated,
supporting the absence of IL-4 in the specific response.
The CD4+ and CD8+ effector cells generated by naked p-omp25 vaccination
are likely to be the result of myocyte transfection and antigen production,
followed by antigen uptake by a professional APC and processing via
conventional MHC class " pathways and cross presentation to access MHC
class I pathways. Intramuscular delivery of naked DNA is not considered an
efficient way to delivery DNA directly to APCs (O'Hagan et ai, 2004), and much
evidence suggests that cross-presentation is the dominant route of CD8+
priming in this situation (Ulmer et a/, 1996., Corr et a/, 1999). The relative
abundance of the CD8+ T cell subset demonstrated in this study suggests that
the naked DNA derived Omp25 antigen readily accesses the MHC class I
processing pathways, either because of effective direct transfection of
professional APCs, or because of intrinsic properties of the protein which target
it to the cytosol of APes.
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DNA vaccines were surface adsorbed onto cationic liposomes to promote
efficient uptake of DNA into cells. Direct uptake of liposomes by professional
APCs was also expected to enhance immune induction in the draining lymph
nodes, and increased potential for MHC class I restricted presentation of
endogenously produced DNA encoded antigens and direct priming of CD8+ T
cells. However, the L-p-omp25 [X1]vaccine was not able to produce the total
numbers of effector cells achieved by either the protective p-omp25 [X4]
vaccination or the uneffective p-omp25 [X1] vaccination. Depletion studies
indicated that CD4+ T cells are the dominant responders to the L-p-omp25 [X1]
vaccine. Moreover, the actual frequency of antigen specific CD4+ T cells
elicited by p-omp25 [X1], p-omp25 [X4], or L-p-omp25 [X1]was not significantly
different (p > 0.05), suggesting that the principal difference between the
vaccines was that liposome formulation was less effective than naked DNA for
presenting antigen in association with MHC class I for priming CD8+ T cells. A
clear reason for the apparent reduction in CD8+ cell priming for L-p-omp25
[X1]compared with p-omp25 [X1] is not apparent.
Post-challenge ELiSPOT investigations revealed that all mice contained Omp25
specific effector cells post-exposure to live Brucella. In most cases the
frequency of cells was above the analytical capacity of the assay, and resulted
in saturated readings (> 500 SFC I 106), suggesting that native Omp25 is a
prominent and significant immunogen in live B. melitensis 16M infections. A
significant difference in IFN-y generation between groups that had been primed
by vaccination compared to that from pre-challenge antigen natve mice was not
observed. An investigation of effector cells at an earlier interval post-challenge
may have revealed an anamnestic response from the Omp25 responsive mice.
However, at 15 days post-challenge it appears that the strong primary Omp25
specific response observed in natve mice may mask this effect.
Although an explanation for specific abrogation of CD8+ priming by liposome
vaccination is not apparent, these data clearly indicate that the CD8+ effector
cells are important contributors to the protective effect of the omp25 based
vaccines. A clear relationship between the number of CD8+ effector cells (Total
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SFC - CD8+ depleted SFC) and protective effect is evident. In contrast, a clear
correlation between CD4+ effector cells and protection is not observed. Overall,
these results suggest that CD8+ T cells are the main effectors of the protective
response of p-omp25 vaccination. Furthermore. these data indicate that the
liposome 'single inoculation' delivery strategy is not useful as a mechanism
through which to achieve increased uptake and immunogenicity, and protective
efficacy of the p-omp25 vaccine.
p-ialB specific immunity
Single versus multiple dose naked DNA vaccination
Studies with the p-ialB vaccine showed that multiple inoculations of the naked
DNA vaccine (p-iaIB [X4]) was the most immunogenic and efficacious strategy.
In this respect this data concurs with that from the p-omp25 studies. However
there were several differences in the data from the p-ialB studies compared to
the p-omp25 studies suggesting a different mode of action for these two
equivalently protective vaccines.
Antibody production was the most striking output of the immune response
following p-ialB [X4] vaccination: high titre equally balanced IgG1 and IgG2a
responses were detected. A single dose of naked DNA (p-iaIB [X1]) was unable
to induce detectable levels of antibody. Similarly, significant IFN-y secreting
cells were only observed from the p-ialB [x4] protective vaccination regime. IFN-
t secretion was mainly attributed to CD4+ cells, with the bias toward MHC class
II primed immune responses resulting from secretion of the endogenously
manufactured protein and hence supplying antigen for exogenous uptake.
Antigen secretion also increases the availability of the lalB protein for interaction
with B cells, thus promoting strong antibody responses. In general, it was
shown that that the protective effect of p-ialB [X4] vaccination correlated to the
induction of high titre speCific antibody and a CD4+ dominated cellular
response.
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Unlike the single dose p-omp25 [X1] DNA vaccine the p-ialB [X1] vaccine did
not induce measurable antigen specific IFN-y production (detected as IFNg
secreting effector celis). Since the quantity of DNA delivered in these
experiments was, as near as practicable, equivalent, the discrepancy in
immunogenicity suggests that the lalB antigen may be inherently less
immunogenic than the Omp25 antigen. Indirect evidence suggesting that lalB is
a comparatively weak immunogen can be found through measurement of the
lalB specific response of Rev.1 and 16M infected mice. It is notable that lalB
specific effector cells or antibodies are not detected from mice that have been
vaccinated with Rev.1 or from lalB natve mice that have been challenged with
B. melitensis 16M. This suggests that the native antigen is either poorly
expressed or poorly immunogenic, and indicates that lalB specific immune
responses are not essential for the development of Rev.1 mediated protection.
Differences in plasmid structure between p-omp25 and p-ialB may account for
slight differences in immunogenicity. It has previously been demonstrated that
the presence of an intron element (such as included in the pTargeT vector) can
promote an increase in the expression of the encoded gene in-vivo (Chapman
et aI, 1991., Hartikka, et aI, 1996). Enhanced expression from pTargeT-omp25
may account for the more rapid induction of Omp25 specific responses that are
detected after a single inoculation. This modest improvement in immunogenicity
is only observed as a more rapid induction of specific response and does not
the impact on the overall magnitude of the specific response. Interestingly,
when pTargeT-omp25 (with intron element) and pCR3.1-omp25 (without intron
element) were directly compared (in chapter 5) differences in the magnitude or
rapidity of the Omp25 specific response of mice treated with the different
vaccines was not observed.
Nevertheless, this perceived poor immunogenicity is overcome by multiple
inoculations of p-ia/B since lalB specific CD4+ and antibodies generated by p-
ia/B [X4] vaccination are highly effective for the control of B. melitensis in the
murine host.
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Liposome versus naked DNA vaccination
lalB specific antibody was detected following a single dose of L-p-iaIB
compared to three doses of naked p-ialB , indicating that liposome formulation
of the p-ialB vaccine prompted more rapid induction of immune responses
compared to naked DNA vaccination. This effect is presumably due to a more
effective uptake of L-p-iaIB by APCs, resulting in a faster delivery of antigen to
the LNs and other sites of immune induction. Unfortunately, despite this
improvement in antibody production, antigen specific effector cells were not
apparent in the L-p-iaIB vaccinated mice prior to challenge. It was interesting
therefore that the post-challenge ELiSPOT data from the p-ialB investigations
indicated that only p-ialB [X4] and L-p-iaIB vaccinated mice had measurable
lalB specific IFN-y production post-exposure to virulent B. melitensis 16M,
suggesting an anamnestic response from these animals. In the post-challenge
studies the number of antigen specific effector cells observed from L-p-iaIB
inoculated mice was considerably increased to that observed in p-ialB [X 1]
inoculated mice thereby providing further evidence of enhanced immunogenicity
of the liposome formulation.
Conclusion
Overall, it was shown that the liposome strategy was effective for generating
antigen specific immune responses from a reduced dose of DNA. However, the
necessary improvements in cellular immune responses, (and in particular the
antcipated increased generation of CD8+ T cells), were not observed. Thus,
whilst this strategy was effective in one sense (antibody enhancement), it does
not appear to be wholly appropriate for use against intracellular pathogens such
as Brucella which are controlled by cellular responses and in particular by IFNy
production. Furthermore, this investigation has concluded that a single dose of
these naked DNA vaccines is unable to provide effective control of Brucella. For
p-omp25 [X1] the reduction in protective effect (compared to p-omp25 [X4]) was
related to a relatively reduced level of CD8+ T cell priming. For the L-p-omp25
[X1] vaccination the lack of protection was directly linked to the lack of
production of CD8+ T cells, which therefore appear to be the crucial effectors of
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p-omp25 specific immunity. These data suggest that a CD8+ effector response
is effective in the control of B. melitensis infection via recognition of the Omp25
antigen, despite the fact that Omp25 specific CD8+ effectors were not observed
from Rev.1 vaccinated mice.
In contrast, protection afforded by the p-ialB based vaccines is achieved
through the action of high titre antibodies and CD4+ IFN-y secreting cells. For
the p-ialB [X1] vaccination the immune stimulus was simply not sufficient for the
generation of a significant antigen specific response. lalB specific antibody
production was augmented by liposome delivery of the p-ialB vaccine but T cell
effector generation was not detectably enhanced. These data suggest that
although antibodies may be significant in protection they are insufficient to
control B. melitensis challenge: lalB specific CD4+ IFN-y secreting cells are
needed for protective efficacy. Nevertheless, despite the absence of detectable
lalB specific IFN-y secreting cells prior to challenge, L-p-iaIB vaccination
resulted in an anamnestic response post-challenge. Thus, liposome delivery of
this vaccine modestly improved the immunogenicity of a single 100 ~g dose of
DNA. This result is promising suggesting that, with further modifications, L-p-
ialB may become an effective vaccine.
In conclusion, attempts to improve the efficiency of the single dose vaccination
by targeting DNA delivery directly to APCs were partially successful. For both
vaccines (omp25 and ialB based) liposome adsorbed formulations of the
vaccines were able to promote a stronger antibody responses than equivalent
quantities of naked DNA, indicating that liposome delivery could enhance
humoral immunity. Unfortunately, significant enhancement of cellular immune
responses was not measured. Since cell mediated immunity against
intracellular pathogens is essential (Mackaness 1971), and IFN-y in particular is
essential for the control of Brucella (Murphy et ai, 2001a) future investigations
into these vaccines may be best directed toward alternative strategies with
proven potential for the enhancement of cell-mediated immunity.
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Chapter 8: CONCLUSIONS AND FUTURE
PERSPECTIVES
Summary of project findings
Following the selection of five candidate genes from the B. melitensis 16M
genome and the construction and evaluation of eukaryotic expression plasmids
encoding these antigens, two protective DNA vaccines were identified. These
vaccines, p-ialB and p-omp25 , encoded the putative invasion protein B (lalB)
and 25 kDa outer membrane protein (Omp25) respectively. Although, the
Omp25 antigen has previously been studied in terms of Brucella virulence,
serodiagnosis and as a protective antigen (for review see Viscaino et aI, 2002),
this study represents the first report of a significant protective effect achieved
against B. melitensis 16M challenge using the Omp25 antigen in a subunit
vaccine approach. The ialB candidate was selected based upon its' putative
function as an invasion protein which was assigned due to shared identity with
the invasion protein B (iaIB) of Bartonella bacilliformis. This candidate has not
previously been investigated with regard to Brucella virulence or pathogenesis.
This study is the first to identify the Brucella invasion protein B (laIB) as a novel
protective antigen in brucellosis.
Naked DNA vaccination with either p-omp25 or p-ialB , (with a total of four
inoculations per mouse, at 100 J.1gDNA per inoculation, given at three week
intervals) provided equivalent protection to the live vaccine B. melitensis Rev.1
under the model conditions used in these investigations. Immunogenicity
assessment revealed the production of antigen specific IFN-y and specific
antibodies following vaccination. Attempts to reduce the number of inoculations
required for successful vaccination were partially successful, with cationic
liposome adsorbed formulations of DNA able to promote rapid antibody
responses, suggesting a faster induction of candidate specific immune
responses. Unfortunately, protective cell mediated responses were not
enhanced by liposome formulation of the vaccine and consequently there was
not significant improvement in protective efficacy compared to single dose
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naked DNA. This work indicated that alternative approaches may be necessary
to improve the efficiency or practicality of these vaccines before progression to
assessment in target species can be considered.
Future perspectives
During the lifetime of this project, the B. melitensis 16M was sequenced. Early
access to the incomplete genome data (with kind permission of Dr Vito
DelVecchio, IMBM, University of Scranton, PA. USA), facilitated selection of
four of the five candidate antigens investigated in this study. Prior to genome
availability candidate selection was a more restricted process, reliant upon prior
knowledge of the candidate and it's suggested role in Brucella virulence and
pathogenicity. Whilst this approach is valuable, the availability of the genome
sequence has significantly increased the potential choice of antigens for study.
Genome sequences for the most significant pathogenic species of Brucella: B.
melitensis, B. suis and B. abortus, are now available and sequencing of the
naturally rough strain B. ovis is reported to be underway (Halling et ai, 2004).
With an ever expanding list of sequenced pathogen genomes and rapidly
evolving progress in genomic comparisons and characterisation, the pool of
data that can be mined for antigen selection is constantly increasing. For this
study in silico selection was based upon putative assigned functions and
identity with known immunogenic and protective antigens in other pathogens.
Four novel candidates: BMEI1584 (iaIB), BMEII0105 ('rpB), BMEII0150 (me),
and BMEII0681 (virJ / acvB) were chosen using this approach. The BMEI1249
(omp25) candidate was selected as a known immunogenic protein important for
the maintenance of the Brucella outer membrane structure and function.
Targeting immune responses to these antigens was hypothesised to interfere
with important aspects of Brucella virulence. This panel of candidates was
chosen to highlight different aspects of pathogenesis and virulence. The
putative invasion protein 8 (laIB) was selected as an example of a Brucella
antigen hypothesised to be involved in the establishment of infection or
establishment of a replicative niche. Similarly, BMEII0150 (fliC) and BMEII0681
(virJ) were selected as examples of putative structural components of type III
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and putative effectors of type IV secretion systems, respectively. Finally,
candidate BMEII0105, (rpB was selected to represent antigens involved in the
acquisition or transport of essential nutrients.
This initial breadth of antigen selection, and subsequent data describing their
protective efficacy indicated that the surface expressed candidates Omp25 and
FrpB, and the hypothetically exported protein lalB were the most useful
antigens for subunit vaccine development. Importantly, these antigens were
also shown to be the most consistently expressed candidate genes during
targeted transcription studies. The success of these vaccines being linked to the
availability of the native antigen during Brucella infection for interaction with the
immune system. Future work to identify similar candidates will be greatly
facilitated by high throughput whole genome technologies such as microarrays
and proteomics, which will increase the rate at which antigens expressed under
certain infection conditions can be identified and hence selected for
investigation. For each of the types of candidate targeted in this study, further
representatives exist in the Brucella genomes for exploitation in future vaccine
development projects. Based upon the results described in this thesis,
focussing on candidates which are constitutively expressed, surface located or
secreted, appears to be a sensible approach for selection of antigens useful as
subunit vaccines.
The protective efficacy of the p-omp25 and p-ialB vaccines was shown to be
equivalent to that provided by the live vaccine strain Rev.1 in these
investigations. Notably, this is the first study to evaluate DNA vaccine efficacy
against B. melitensis challenge, and the first to directly compare efficacy against
that achieved by the live strain Rev.1. These are promising results for Brucella
DNA vaccines, and in terms of the ability to control splenic Brucella infections
the results show an improvement from other Brucella specific DNA vaccines
reported in literature to date. However, it is important to note that standardised
methods were not adopted for the assessment of each different vaccine
reported in literature and thus direct comparison is not entirely applicable. Most
notably, the interval between vaccination and challenge and between challenge
and bacterial enumeration varies between studies. A standard model for
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assessing vaccine immunogenicity and residual virulence of live strains has
been described by Bosseray et aI, (1990), although only limited adherence to
standardised practices is reflected in the literature. Numerous adaptations of the
model have been employed in order to emphasise certain aspects of Brucella
control and Brucella: host interaction.
In previous work at VLA (Mansour 2003) the kinetics of Brucella elimination in
vaccinated and challenged mice was measured. This experiment was
anticipated to allow a more thorough assessment of vaccine effects than can be
inferred from a snapshot assessment of bacterial load at a single defined time
post-challenge. However, the results indicated the expected pattern for Brucella
replication and control in protected (B. abortus S19) and naive (PBS) BALB/c
mice and confirmed that protection was most accurately determined through
measurement of Brucella load at 15 days post-challenge. Nevertheless, early
assessment of protective efficacy revealed a delay in the onset of detectable
infection in pCDNA-62 vaccinated mice, that would not have been observed in
the single assessment of efficacy at 15 days post-challenge. Now that
protective efficacy for p-omp25 and p-iaiB in this model has been established at
15 days post-infection, it would be useful to determine the kinetics of Brucella
elimination post-challenge, and more importantly to determine the limits and
duration of immunity through challenge with different quantities and different
strains of Brucella and at longer intervals post-vaccination. Furthermore, the
current protection assays in murine models concentrate on the detection of
bacterial load in the spleen. It would be advisable to also consider the effects of
vaccination on dissemination of the bacteria to the other organs of the body, in
particular to pathologically significant sites such as reproductive tissues. Whilst
these studies are best performed in target species, preliminary data from small
animal models could indicate whether the lalB protein is involved in invasion of
a particular cell or tissue type.
A significant facet of this study was the measurement of immune responses
induced in vaccinated mice. The investigation of the p-ialB and p-omp25
vaccines revealed the generation of CD4+ and CD8+ IFNy secreting cells, and
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production of antigen specific immunoglobulins. Comparison of responses
induced by the p-omp25 and p-ialB vaccines and the live vaccine Rev.1 were
useful for determining common immunological correlates of protection. In all
vaccinated mice the absence of IFNy production was associated with an
absence of protective efficacy. Although, as for other pathogens, the presence
of IFNy is not always sufficient for control of Brucella. To gain a more thorough
picture of protective immunity other Th 1 cytokines were measured, although an
antigen specific effect was not observed in these investigations. Technologies
for cytokine measurement and quantification are continually advancing, and it is
probable that the use of more sensitive assays, assays for additional cytokines,
or alternative and multiplexed techniques for cytokine detection (e.g.:
microarray, xMApTM Luminex® technology, and FACS) could be of value in
determining a more comprehensive picture of the cytokine profile of immune
mice or target species. A number of recent publications have indicated the
upregulation of IL-6 and IL-8 during natural brucellosis (Refik et al 2005), or the
relevance of IL-18 and IL-23 in the control of intramacrophagic Brucella
(Paranavitana et al 2005., and Fernandez-Lago et al 2005). It would be
pertinent in future experiments to assess a wider range of immunological
responses so as to mirror the complexity of the immune response in the living
host.
In this study IFNy production was assumed to be the principal effector of the
protective immune response. The production of IFNy was studied in terms of the
principal responding T cell subsets (CD4+ and CD8+ only) from the splenocyte
population. From Rev.1 vaccinated mice stimulation with Omp25 and
Brucellergene TM resulted in IFNy production from mainly CD4+ cells (CD4+
effector cells), whereas it was noted that DNA vaccines primed a greater
number of antigen specific CD8+ effector cells. For p-omp25 [X1] and [X4]
vaccination a slight (not statistically significant) increase in total effector cells
was associated with increasing numbers of inoculations and significant
improvement in protective efficacy. For p-ialB [X1] vaccination, IFN-y secreting
cells were not detected, but four inoculations with this vaccine (p-iaIB [X4])
generated significant numbers of effector cells. In terms of responsive cell type,
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Omp25 specific responses from p-omp25 vaccinated mice were dominated by
CDS+ cells, whereas Omp25 specific responses from Rev.1 vaccinated mice
were dominated by C04+ cells. lalB specific IFNy production was dominated by
CD4+ cells. Furthermore, despite demonstrable protective efficacy from the p-
ialS vaccine, an lal8 specific response was not demonstrable from Rev.1
vaccinated mice, suggesting that this antigen was not involved in the protective
immune response attributed to the live vaccine. Now that production of antigen
specific effector cells has been established, It would be of value to study of the
contribution of the different Omp25 and lal8 specific T cell subsets in control of
brucellosis, through the use of CD4"/" and COS"'"mice, and through adoptive
transfer studies. Such experiments would help to determine whether the
reduction of CDS+ involvement in L-p-omp25 compared to p-omp25 (X4)
vaccinated mice was significant, or whether the reduced efficacy is due to an
overall quantitative reduction in IFNy levels, or additional parameters that have
not been monitored in this study. Furthermore, further characterisation of the
phenotype of responsive cells would be useful in defining immunological
correlates of protection for extrapolating data to target species. A role for CD4+
and CDS+ T cells in control of Brucella has previously been established
(Oliveira et a/1995) and is supported by this study. However, looking at these
cells in isolation may not be sufficient to elucidate their role in protection; other
possible contributors should be assessed. A role for natural killer cells in control
of brucellosis has been disputed (Golding et al 2001). Proliferation of yBT cells
early in infection has been reported in humans (Dornand et al 2004, Bertotto et
al 1993), and the relatively high frequency of yB T cells in ruminants may be
significant in the pathology of brucellosis in these animals. Recently, CD4"/CDS"
cells have been shown to contribute to the control of important intracellular
pathogens such as Mycobacterium tuberculosis and Francisella tularensis
(Cowley et al 2005). Therefore, in addition to evaluating the role of CD4+ and
CDS+ cells, the involvement of yo, NKT1.1 and CD4"/CDS" cells in p-omp25 and
p-ialB vaccine induced responses should also be investigated for a fuller picture
of cellular immunity.
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Notably the study described in this thesis measured the generation of the
effector cell population. With further surface antigen characterisation these cells
could be categorised as effector memory T cells (Tern),although at present it is
only possible to class them as effector cells. Whilst the effector cells (potentially
Tem)are representative of the immediate response following in vivo encounter
with specific antigen (viable Brucella), it has been noted that generation of
antigen specific central memory T cells (Tem)is more closely associated with
DNA vaccine mediated protection for some chronic disease conditions such as
HIV (Seaman et al 2004). The presence of Temwas not established was not
established in this study, although a cultured ELISPOT assay could indicate
whether or not delayed effector responses indicative of activation of Temwere
generated following vaccination. Assessment of Ternand Temlevels induced by
the Brucella vaccines, as well as adoptive transfer studies with antigen specific
T cells, would also provide further information on the mediators of the protective
responses induced by the p-ialB and p-omp25 vaccines.
It is important to remember that demonstration of efficacy and immunogenicity
for different DNA vaccines relies not only on appropriate selection of antigens
but also on the construction of functional plasmid constructs and an appropriate
delivery strategy. Notably, delivery of the p-ialB and p-omp25 vaccines surface
adsorbed to cationic liposomes promoted a more rapid evolution of detectable
specific antibodies, and for the L-p-omp25 vaccine promoted a qualitatively
distinct IFNy response compared to delivery via naked DNA. L-p-omp25 [X1]
vaccination resulted in a lower frequency of total responsive cells and a CD4+
dominated response, which was not protective. The attempts to enhance
efficacy of the p-ialB vaccine through surface adsorption to cationic Iiposomes
was partially successful with L-p-iaIB [X1] vaccination resulting in measurable
levels of lalB specific antibody and a notable anamnestic response. However,
these effects were not sufficient to promote Significant protection. Thus whilst
the antibody promoting effect of liposome delivery could potentially be exploited
for the generation of monospecific and monoclonal reagents, this is not an
appropriate method for vaccine enhancement in this study.
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Although liposomal delivery was not successful in this study, alterations to the
liposome formulation may alter this outcome. One possible approach would be
to encapsulate the DNA within the liposome rather than adsorbed to the
surface. This has been a successful approach for a number of DNA vaccines
Another approach would be to modify the composition of the liposomes. Recent
work by Murillo and colleagues (2004) has indicated a difference in the
protective effect of Brucella vaccines based upon protein antigen preparations
which was attributable to difference in the design of the microparticulate delivery
system used: PLG based microspheres are better than PLGA. Thus confirming
that the carrier has a profound influence on the outcome of vaccination.
Encapsulation or conjugation with protein antigens, cytokines, mannose, or
even Brucella LPS are other possibilities. Furthermore, combining the p-omp25
and p-ialB vaccines for delivery as a multivalent vaccine may also improve
efficacy. Additional protective antigens could also be incorporated into these
vaccines.
Alternatively, there are a multitude of other approaches for vaccine delivery,
e.g.: in vivo electroporation (Tollesfsen et al 2003 ), PLG based microparticle
generation (O'Hagan, 2004), delivery via live attenuated bacterial vehicle (AI-
Mariri et al 2002., Garmory et al 2003b), or construction, e.g.: inclusion of
specific targeting sequences (Kim et al 2005), intron elements, further CpG
motifs, and codon optimised antigen sequences that could be investigated in
future for improving the p-ialB and p-omp25 vaccine efficiency.
Notably, rational vaccine development in the field of brucellosis has recently
been weighted toward investigation of attenuated mutant strains and has
focussed on identification of genes which contribute to the establishment of
intracellular infection and maintenance of the chronic infection state. Targeted
mutagenesis of genes to create auxotrophic mutants, egg: aromatic llaroA
mutants (Foulongne et aI, 2001), stress response (AdnaK) mutants (Kohler et
aI, 2002), LPS defective mutants (llwboA) (Winter et ai, 1996) have resulted in
attenuated strains which were considered promising vaccine candidates. Whole
genome mutagenesis studies have invariably identified genes associated with
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IV secretion systems, LPS biogenesis, and the maintenance of metabolism and
acquisition of essential nutrients (Kohler et a', 2002) as essential in the
pathogenesis of brucellosis. Such studies have resulted in identification of a
number of promising candidates for attenuated vaccine development. For a
number of reasons mutagenesis studies have so far failed to identify candidates
associated directly with the initial invasion of the host cell, with the notable
exception of the Brucella LPS. For this reason the approach taken in this thesis
has been valuable for identifying important Brucella antigens (egg: lalB) that
have been missed in mutagenesis screens to date, and as such represents a
complementary approach for the identification of potentially protective antigens
and candidate genes for targeted deletion. During the lifetime of this project,
Edmonds et a', (2002) have developed and characterised omp25 deletion
mutant strains of Brucella, and reported attenuation and protective efficacy in
both the murine model and target species. To date there are no reports
describing the effects of ialB deletion on Brucella virulence, or the attenuation
and protective efficacy of such strains. In light of the success of the p-ialB
vaccine, it is important to develop defined ialB mutant strains in order to
facilitate characterisation of this newly identified protective antigen, and
elucidate the role of the antigen in Brucella infections. Furthermore, although
only weakly effective as a subunit vaccine, the 'rpB candidate may yet prove to
be of value when this gene is deleted from virulent Brucella. A libhuA mutant
strain of B. abortus 2308, in which the 'rpB gene (alternatively named as the
bhuA gene: for Brucella heme uptake A), is deleted is reportedly unable to
utilise heme as an iron source in the presence of chelating agents. Further
studies are reported to be underway to characterise the role of 'rpS or bhuA in
Brucella virulence (Roop et ai, 2004).
Importantly, the use of live Brucella strains as vaccines relies of the balance
between attenuation and persistence: the vaccine strains must persist within the
host for a period of time in order to promote appropriate immune reactions. With
this caveat comes concerns over possible reversion to virulence and potential
for shedding of the strain into the environment, and each of the currently
licensed live vaccines is beset by problems associated with residual virulence.
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Furthermore, despite considerable research effort and widespread application
to livestock, there are not any live strain Brucella vaccines considered safe for
use in humans (For review see Hoover et aI, 2004). Therefore, the development
of an efficacious non-living vaccine may offer an alternative strategy for
prophylaxis of human populations, as well as improving the practicalities of
livestock vaccination. Underlying the current preference for live attenuated
vaccine development is the paucity of information identifying protective antigens
and the unchallenged superiority of live strains as promoters of protective
responses against intracellular pathogens. These caveats are not immutable.
The approach taken in this thesis highlights the value of the genome sequences
for identifying novel protective antigens, and can readily be extended to assess
further putative antigens. Furthermore, considerable advances are being made
in the fields of immunology, vaccine delivery and adjuvant design which can be
applied to improve the efficacy of subunit vaccines.
In conclusion, approaches used in this investigation have facilitated
identification of a novel protective antigen (laIB) in brucellosis, and indicated
that DNA vaccination possibly improves protective efficacy of the Omp25
antigen compared with the protein delivery based approaches attempted by
previous researchers. The study has utilised genomic information to rapidly and
simply establish whether hypothetical proteins in the Brucella genome are
significant as protective antigens. This approach can readily be applied to other
putative antigens and, unlike work to create defined mutant strains, vaccine
constructs can be created safely and relatively rapidly at containment level 2.
Thus minimising the risk of infection to researcher and vaccine user. Whilst the
p-ialB and p-omp25 vaccines offer comparable protective efficacy to the live
vaccine Rev.1 in these studies, further investigations are necessary to confirm
and validate these effects. Work to improve vaccine delivery efficiency was not
successful in terms of promoting a rapid or significant protective effect but the
results of the investigations did suggest a possible use for the cationic liposome
formulation of DNA in promoting high titre antibody responses that could be
exploited for reagent development.
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Live vaccines remain the most popular type of Brucella vaccine in the world
today, although it is notable that attempts to reduce the virulence of existing
vaccines have resulted in poorer protective efficacy, and the most effective
vaccines retain a level of virulence that makes them unacceptable for use in
humans. Therefore, as a strategy to generate safer Brucella vaccines the
subunit or non-living vaccine approach is Significant. There is still plenty of work
to be done to unravel the complexities of Brucella virulence, pathogenesis and
immunity, but as this knowledge expands the possibility of developing an
effective non-living vaccine also increases. The p-ialB and p-omp25 vaccines
constructed and evaluated in this thesis have shown promising control of
Brucella in the murine infection model and further study is now necessary to
further elucidate protective immunity, establish the duration of this immunity,
and assess efficacy in target species. A number of avenues have been
highlighted for further investigation.
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APPENDIX 1: PLASMID MAPS
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APPENDIX 2: RECOMBINANT PROTEIN
PRODUCTION - FURTHER DETAILS
For this study, GST or His Tagged constructs were created from sub-cloning
from the eukaryotic expression constructs. Briefly, each candidate gene was
excised from the relevant eukayotic expression construct by specific restriction
at the sites encoded into the cloning primers, and combined with an
appropriately restricted vector. Different E.eo/; host cells are recommended for
maintenance of plasmid or expression of protein. For both pRSET and pGEX
constructs E.eoli TOP10 cells were used for maintenance and E.eoli BL21 DE3
(pLys) S cells were used for expression of recombinant proteins.
Sequence fidelity, orientation and reading frame of the recombinant plasmids
was determined by restriction mapping and sequencing as described
previously.
Expression induction was optimised and crude cell lysate were used in ELlSAs
described in Chapter 3. Purification of recombinant Omp25 and lalB antigen
from supernantant or lysate was subcontracted to Lionex GmbH (Germany).
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APPENDIX 3:SUPPLIERS AND REAGENTS USED
IN THIS THESIS
Product Manufactu rers
General rade chemicals
Suphuric acid
Tris
Urea
Acetone HPLC grade water
Bovine Serum Albumen Hydrochloric acid
Bromophenol Blue Imidazole
CAPS Isopropanol
Chloroform Methanol
Citric acid Nickel chloride
Copper sulphate Parafomaldehyde
Di-Sodium hydrogen phosphate Potassium chloride
D'Tf Sodium azide
EDTA Sodium carbonate
Ethanol Sodium chloride
Formaldehyde Sodium di-hydrogen phosphate
General purpose agarose Sodium hydrogen carbonate
Glacial acetic acid Sterile D-PBS
Glycerol Sucrose
Sigma Aldrich UK
(World Headquarters:
3050 Spruce SI.
St Louis
MO 63103
USA)
BDH/VWR
International: Merck
House
Poole
Dorset
BH151TD
England
Fisher Scientific UK Ltd
Bishop Meadow Road,
Loughborough,
Leicestershire
L0115RG
Molecular biology reagents
1 kB ladder
Accuprime™ SuperMix 1
LipofectamineTM_Plus™
Low melting point (Nusieve) agarose
One-Shot™ competent cells, TOP10F', TOP10, BL21 DE3 (pLyS)
pcDNA3.1™
pCR3.PM
pRSEpM
Tri-reagent TM
Invitrogen ™ Life
Technologies
Invitrogen BV
PO Box 2312
9704 CH Groningen
The Netherlands
DEPC treated water
DNA-free™ kit
M-MLV-RT
Nuclease-free™ water
Oligo dTTM
Random decamers™
RetroscriptTMRT-PCR kit
Ambion Inc J Ambion (Europe)
Ltd
2130 Woodward SI
Austin
Texas 78744-1832
USA
Spltf1reClose
Ermine Business Park
Huntingdon
Cambridgeshire
PE296XY
UK
1 Kb DNA ladder
dNTPs
JM109 competant cells
pTargeT ™
Restriction endonucleases
T41igase
Promega Corporation
2800 Woods Hollow Road
Madison
WI 53711-5399
USA
Limulus Amoebacyte Lysate (L.A.L) E-Toxate kit Sigma Aldrich UK
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Pyrochrome endotoxin assay
Cape Cod Inc. (ACC)
124 Bernard E. Saint Jean
Drive
East Falmouth, MA 02536-
4445, USA
Gel extraction kit
Plasmid purification kits (Mini-prep - Giga prep)
Qiagen Ltd
Boundary Court
Gatwick Road
Crawley
West Sussex
RH 109 AA
UK
Custom services
Oligo production
Plasmid and PCR product sequencing
Plasmid purification
Recombinant protein purification
Oswel Sequencing Services
Oswel
University of Southampton
Boldrewood,
Southampton
UK.
PlasmidFactory GmbH & Co.
KG
Meisenstr. 96
0-33 607 Bielefeld
Germany
Lionex GMBH
12 Mascheroder Weg
Braunschweig
German
Culture media
DMEM
Non-essential amino acids
Myoclone™ Plus Foetal Bovine serum
50mM 2-Mercaptoethanol
Antibiotic antimycotic solution (X100)
Hanks Balanced Salt Solution (HBSS)
SOC
Albimi broth
LB-Agar
LB-broth
MEM
SDA + 10% horse serum
TSA
TSA + Penicillin
Penbrithin (Ampicillin)
Sigma Aldrich UK
Invitroge n™ Life Tech nologles
VLA Biotechnology Dept
Veterinary Laboratories
Agency, Weybridge
Woodham Lane
New Haw
Addlestone
Surrey
KT 153 NB, UK
SmlthKllne Beecham
Pharamceuticals
Welwyn Garden City,
Hertfordshire AL7 1EY UK.
Protein Science Reagents
BCAklt
Dialysis cassettes (3kDa and 10 kDa CO)
Pierce Endogen Perbio
Century House
High St.
Tattenhall
Cheshire
CH39RJ
UK
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Excel Gel system
Protein silver staining kit
Rainbow markers
0.451lM Nitrocellulose membrane
Coomassie Blue Safe stain
Protean II gel tanks and equipment
OTT Novex Gels
SOS-PAGE sample buffer (X2)
See-Blue 2 markers
Amersham BioSciences UK.
Pollards Wood
Nightingales lane
Chalfont St Giles
Bucks, HP8 4SP, UK
Bio-Rad laboratories Inc.
Bio-Rad house
Maylands Avenue
Hemel Hempstead
Herts, HP2 7TO. UK
InvitrogenTM Life Technologies
Immunological reagents
Streptavidin-Horse raddish perxoidase
Streptavidin-alkaline phosphatase
Goat Anti-Mouse IgG 1 Horse raddish peroxidase (STAR81 P)
Goat Anti-mouse IgG2a Horse raddish peroxidase (STAR82P)
Anti-mouse Ig FITC
Anti-Rabbit Ig FITC
Anti-Sheep IgG FITC
Anti-sheep/goat IgG - horse raddish peroxidase
Anti-sheep IgG alkaline phosphatase
Anti-mouse Ig Fab' binding -alkaline phosphatase
Anti-Rabbit IgG horse raddish peroxidase
BCIP-NBT FastTabs™
1-Chloro-1-napthol (1C 1N) tablets
AN18 Anti-mouse iFN-y
RC Biotinylated anti-mouse IFN-y
Anti-mouse C04 (l3T4) conjugated beads
Anti-mouse C08+ (Ly-2) conjugated beads
Midi-Macs Magnets
Midi-Macs lS columns
96 well PVOF filter plates
FACSFlow FACS sheath fluid
100ilM mesh cell sieves
80llM mesh cell sieves
Amersham Biosciences UK
Serotec Ltd
22 Bankside
Station Approach
Kidlington
Oxford OX5 1JE UK
Nordic Immunologieals
Tilburg
The Netherlands
Sigma UK
Mabtech AB
Stockholm
Sweden
Mlltenyl Blotec ltd.
Almac House
Church lane, Blsley
Surrey GU24 90R
Miliipore (U.K.) Limited
Units 3&5 The Courtyards
Hatters lane
Watford, WD18 8YH
BD Biosclences
Erembodegem·Dorp 86
B·9320 Erembodegem,
Belgium
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